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To all children
Look for happiness, everyday, continuously.
We always have to think about happiness,
And even if sometimes it forgets about us, 
We must not ever forget about it,
Till the last day of our life!
Roberto Benigni, 2014
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1.1.  CY TOMEG ALOVIRUS INFEC TION: FROM GLOBAL 
INFECTION TO NEGLECTED PUBLIC HE ALTH CONCERN
Cytomegalovirus (CMV) infection is without a doubt a global and endemic infection. In the USA, 
Australia and Europe the CMV seroprevalence varies between 36% and 77%, while in developing 
countries this percentage often reaches 100% (Fig. 1) (1). In countries with low to moderate 
seroprevalence, age is a predictor of seropositivity since the chance of exposure to CMV 
continues throughout life. As a rule of thumb, the socioeconomic status may be a reflection of 
factors that contribute to the exposure to CMV, such as crowded living conditions or numerous 
infants. Although in a considerable proportion of immunocompetent individuals CMV infection 
is subclinical, it can still cause a variety of clinical manifestation among which the mononucleosis 
like syndrome in young individuals is the best characterized (2). CMV has also been suggested 
as a co-factor in the pathogenesis of inflammatory, autoimmune and vascular disease, such as 
atherosclerotic coronary artery disease (3-6), as well as a risk-factor for all-cause mortality in large 
population-based cohorts in the USA and Europe (7, 8). However, the severe morbidity caused by 
CMV in immunocompromised individuals and neonates, and the following long-term disability in 
children, accounts for the true burden of disease of CMV infections.
Despite the considerable knowledge of the contribution of CMV to mortality and morbidity in 
immunocompromised individuals, the disease burden of congenital CMV infection (cCMV)  is less 
often acknowledged (9). One of the reasons of this discrepancy may lie in the epidemiology of 
congenital infection, which altered the dogma of pre-existing immunity to CMV in pregnant women 
protecting against vertical transmission. Indeed, the rate of cCMV is higher in highly seropositive 
countries, i.e. developing countries, where CMV is acquired very early in life. At 3 months of age two 
third of the infants are estimated to be infected, and 85% by the first year of life (10, 11). Here, fewer 
women of child-bearing age are seronegative compared to developed countries, and the rate of 
cCMV ranges from 1% to 5%, or even higher (11-13). In developed countries, ~50% of child-bearing 
age women is seronegative with a lower rate of cCMV, between 0.6% and 0.7% of live births (14-17) 
(Fig. 2). This discrepancy is most likely due to the fact that the seroprevalence reflects the size for 
the viral reservoirs in a population, though the characteristics of CMV infection make the modes 
of transmission and acquisition difficult to determine (see “The ancient virus” paragraph) (9). In 
general, when a seronegative mother gets infected during pregnancy the vertical transmission rate 
is 30-35%, whereas in seropositive mothers this rate is estimated to be 1.2% (18-20). Although recent 
observations highlighted the fact that this may be higher due to re-infections with a new viral strain 
(21). However, the main contributor to the worldwide number of cCMV cases is represented by 
seropositive mothers. 
Among congenitally infected children, 12.7% are estimated to be symptomatic at birth, with 
the most common symptoms being petechiae, jaundice, hepatosplenomegaly, thrombocytopenia, 
chorioretinitis, and microcephaly. An estimated 40-58% of these symptomatic children will 
develop permanent sequelae, such as hearing loss, mental retardation, and developmental 
delay. Importantly, of the 87.3% neonates that are asymptomatic at birth, ~13.5% will also develop 














Figure 1. Worldwide CMV seroprevalence rates in adults. Reprinted with permission from (1).
Figure 2. Worldwide CMV seroprevalence rates among women of reproductive age, and birth prevalence 
of congenital CMV infection. Shades represent CMV seroprevalence in women of child-bearing age, circles 
represent congenital CMV birth prevalence. Reprinted with permission from (9).
been shown in mothers with primary infection and in mothers with secondary infection (being 
either reactivation or reinfection) (12, 22, 23), as well as similar severity of symptoms (12, 24, 25). 
Overall, a quite high percentage of congenitally infected neonates, estimated to be 17%, will have 














Figure 3. Estimates of the prevalence of congenital CMV infection and sequelae. Reprinted with permission 
from (9).
is asymptomatic at birth. In this group there are no clinical signs that would point towards a CMV 
infection in the neonate, therefore the infection may easily remain unnoticed, and the late onset of 
sequelae makes a retrospective diagnosis rather challenging.
To conclude, CMV is the most common cause of congenital infection worldwide, a much less 
exotic infection than newly emerging infections such as Zika virus infections, but overall a much 
greater global problem (16, 17).
1. 2 .  THE ANCIENT VIRUS 
Cytomegalovirus (Fig. 4) is the largest and structurally most complex member of the family of 
human herpesviridae, which includes several DNA viruses whose hallmark is latency. The pathogenic 
herpesviridae for humans are divided into three subfamilies based on structural and replicative 
properties. CMV belongs to the sub-family of β-herpesvirinae, which share a common long replicative 
cycle (~36-48 hours in permissive cells). The common ancestor of α-, β- and γ-herpesvirinae is 
believed to date 400 million years ago (Mya) while the β-herpesvirinae made their appearance only 
50 Mya thereafter (350 Mya) (26). Importantly, the typical large inclusion-bearing cells produced 
by CMV were first reported in 1881 in a kidney of a stillborn infant with congenital syphilis (27), 
considerably later than their first appearance. CMV is 200 nm of diameter and has four distinct 
morphologic units: the core which contains 230 kilobase pairs of linear double-stranded DNA; 














which contains several viral proteins and RNA (29), and a double-stranded lipidic layer called 
envelope, where viral glycoproteins are embedded. The massive size of the genome is accompanied 
by a complex genomic organization and post-transcriptional modifications. The tegument is 
the most heterogeneous structure in CMV, and exerts several functions for viral replication, e.g. 
blocking of the cellular response that degrades entering DNA, and enhancing IE (immediate early) 
gene transcription (30-32). It also contains the immunodominant target of T cells and Abs, pp65 
(33-36). Several glycoproteins have been described, and the pentameric complex gH/gL/gUL128-131 
has been shown to elicit neutralizing Abs against several CMV strains (37-40). The initial binding 
between CMV and the target cell occurs via viral glycoproteins and cellular proteoglycans, followed 
by binding with more specific receptors and fusion/endocytosis (41-43). CMV has a broad tropism 
as it can be detected in fibroblasts, endothelial cells, epithelial cells, monocytes/macrophages, 
smooth muscle cells, stromal cells, neuronal cells, neutrophils, and hepatocytes (44-46). This 
suggests that the cellular receptors may be multiple, even though the primary targets are epithelial 
cells and monocytes. After these first events, the nucleocapsid is transported to the nucleus where 
the IE genes are expressed. IE1 (or pp72) is a phosphoprotein used as a target for detection of CMV 
infected cells, while IE2 is a transactivating protein responsible for activation of other viral genes 
(24). Next, the early, or β-genes, are expressed, which mainly contain viral proteins necessary for 
the viral genome synthesis, such as the viral DNA polymerase (24). Finally the late, or ϒ genes, are 
expressed and these mainly encode structural proteins. The viral DNA is produced in the nucleus as 
concatemers, and during the packaging is cleaved and incorporated into the nucleocapsid. Though 
the mechanism is not completely understood, the nucleocapsid leaves the nucleus and reaches 
the cytoplasm as a partially tegumented viral particle. The final maturation occurs in a specialized 
cytoplasmatic compartment called assembly compartment (100). The virus egression is believed 
to occur via cell lysis in certain cell subtypes, e.g. fibroblasts, or via a non-completely understood 
mechanism of exocytosis. Latency is accomplished through viral genome circularization in 
the cellular nucleus, forming a so-called episome (108), and is mainly established in monocytes, 
CD34+ progenitors and endothelial cells. Consequently, in the host there might be a low level of 
productive infection with recurrent viral secretion, and several pro-inflammatory signals can induce 
such reactivation (106-109). This finding distinguishes acute from chronic infection. Acute infection 
A B
Figure 4. Human Cytomegalovirus. A) Three-dimensional reconstruction of icosahedrally portion of human 















is characterized by an intense viral replication and shedding that lasts months, while the chronic 
infection is characterized by alternating replications and concomitant shedding.
1. 3.  TR ANSMISSION OF CY TOMEG ALOVIRUS
By definition the infectivity of CMV is much lower than of other viruses that have an airborne 
transmission (48). Therefore a close contact between a susceptible person with infected secretions 
is necessary for an efficient transmission. The transmission can occur via direct person-to-person 
or indirect contact, and sources of virus include oropharyngeal secretions, cervical and vaginal 
excretions, semen, breast milk, tears, urine, feces, and blood (49). CMV can therefore be transmitted 
horizontally through saliva, sexual contact, transplantation or breast-feeding, and vertically 
through the placenta. Despite the necessity of a close contact, the high seroprevalence in several 
countries suggests that CMV keeps spreading within a population, causing frequent infections. One 
of the most important contributing factors may be the high and chronic viral shedding of certain 
subgroups, such as congenitally and perinatally infected children, that can shed the virus for years, 
whereas in children and adults with primary infection this lasts ~6 months (50, 51). In addition, CMV 
can irregularly, and unpredictably, contribute to this frequent infection via secondary infections. 
In developed countries, where ~50% of women of child bearing age are seronegative, the most 
important source of infection is young children, possibly through their urine and saliva (52). 
Susceptible children are mainly infected through breast-feeding or other contacts with infected 
mothers and children, and only a small percentage via contact with the maternal cervical excretion 
during delivery (53). If infection occurs through breast-feeding, the presence of CMV in breast milk 
tends to be a bit later than immediately after birth, and CMV becomes detectable in the child only 
6-8 weeks after the first exposure to CMV in the breast milk (54-56). Approximately 37-59% of infants 
breast-fed by a seropositive mother are eventually infected (54, 57).
1.4.  C MV IM MUNE RE SP ONSE 
The clinical impact of cCMV is the result of the interplay between virus and host in a stepwise 
process that starts in the mother, reaches the placenta and the fetus to then continue in the children 
throughout their childhood. In the following paragraphs these compartments will be discussed 
separately, although the processes within one mother-child pair are obviously non-separable. 
The general CMV immune response will be discussed first as it helps understanding the changes 
occurring during pregnancy, and in the fetus. 
1.4.1. General CMV immune response
Following binding of CMV to the target cell, an alteration of the host gene expression occurs 
(58-60), with a rapid activation of the innate defence, possibly through TLR-2 and gB, that leads 
to a pro-inflammatory environment, co-stimulatory molecules, DC maturation, and IFN-α/β 
production  (59, 61). The primary aim of such a response is to control the infection, while modulating 
the adaptive immune response. After an initial local replication, CMV spread and dissemination is 














circulating monocytes enter host tissues, they differentiate into macrophages that can sustain viral r 
eplication (62).  
Upon acute primary CMV infection, a high pool of CD8+ T cells with a broad non-selective 
repertoire against several CMV Ags is produced. In healthy individuals, CMV DNAemia has a peak 
at 2-3 weeks after primary infection, and it decreases in 4-5 weeks after the primary infection (63). 
Cytotoxic T cells, with polyclonal TCRs, appear 2-3 weeks post-infection, and at ~5-8 weeks post-
infection only a few sub-populations will reach the memory pool (63). This time approximately 
coincides with the resolution of primary infection. The memory compartment produced upon 
CMV infection is much bigger than that produced in response to other viruses, and it increases 
with age reaching 5% of all peripheral CD8+ T cells for a single CMV epitope (64). This phenomenon 
is called memory inflation and it may be attributable to the intermittent virus reactivation, and/or 
reinfection, that boost the T cell response.
Unfortunately, data on the CD4+ T cell response during primary CMV infection in 
immunocompetent individuals is not available as the majority of studies focused on latent 
infection. In latency the frequency of CD4+ T cells specific for CMV in healthy donors was 
1-2% of all peripheral CD4+ T cells (65). However, some important conclusions drawn from 
transplantation studies may apply to the general population; though one should keep in mind that 
the immunosuppressive therapy might slightly change the kinetics of infection. In seronegative 
individuals that received a renal transplant from seropositive donors, viremia was detected ~25 days 
after transplantation, and CD4+ T cells appeared ~7 days after the first detection of viremia to then 
reach ~2.5% of the total of peripheral CD4+ T cells and again decrease to low level in the following 
~2-3 months (65). Additionally, even though the detection of CMV DNA was similar, the peak 
viral load and the duration of viremia was higher and longer in those who had symptoms (66). 
Interestingly, in immunocompetent children an impaired CD4 response was associated with longer 
viral shedding in both urine and saliva (67). 
Although it is commonly recognised that Abs have an important role during CMV infection, 
the majority of studies focused on the T cell response, and very little is known on the B cell 
compartment, and its kinetics during CMV infection. The protective effect of high Abs titers has 
been shown in several target populations (68-72). E.g. in immunocompetent individuals, a primary 
CMV infection induced an early and remarkable Abs response regardless of the clinical outcome, 
however, in those individuals with a more severe manifestation a deficient neutralizing Ab response 
was observed (69). Unfortunately, the real mechanism through which these Abs act in vivo still 
needs to be elucidated.
This remarkable CMV-specific immune response has an important feature, which is T and B 
cell exhaustion, though most studies focused on T cell exhaustion (73). T and B cell exhaustion is 
a state of dysfunction induced by chronic infections and prolonged exposure to high viral loads 
(73-75), and it is characterised by poor effector functions, expression of inhibitory molecules and 
specific transcriptional state (76). However, a certain degree of reversibility of this state has been 
shown through e.g. block of PD-1 (77). Importantly, exhaustion is a different concept than anergy or 














first encounter with the Ag. Whereas, senescence is considered to be the terminal differentiation of 
a cell that loses the proliferative potential, and is typical of a latent infection.
1.4.2. Maternal CMV immune response 
During pregnancy, the need to maintain the balance between fetal tolerance and antiviral 
immunity complicates the aforementioned immune response to CMV. Pregnancy does not seem 
to considerably alter the CMV-specific cell-mediated immune response compared to that of 
immunocompetent non-pregnant women (78, 79). However, in pregnant women who transmitted 
CMV to their fetus (transmitter), the lymphoproliferative response to CMV was lower and delayed 
(78, 79). Additionally, the duration of viremia was similar between transmitter and non-transmitter 
women (79). For what concerns the humoral response, Abs against gB were found to be higher during 
delivery in transmitter mothers, though the level of neutralizing Abs was lower (68). Additionally, 
primary CMV infection increased the expansion of activated and atypical memory B cells, enriched 
for CMV-specific cells, compared to the chronic infection. In the latter, the frequencies were 
similar to those of healthy adults, suggesting that the expansion does not last long (73), though 
the presence of memory B cells ensures a quick Abs production upon reactivation/reinfection.
1.4.3. Placental CMV immune response
The maternal immune system at the decidua level is mainly characterized by decidual natural killer 
cells (dNK), around 10% of leukocytes are T cells, both αβ and γδ subsets, while the frequency 
of B cells is low (80-82). At the maternal-fetal interface the majority of trophoblast cells are in 
direct contact with maternal cells, and fetus-specific maternal immune cells have been shown both 
locally and peripherally (83, 84). In normal conditions it does not damage pregnancy as several 
mechanisms are in place to prevent rejection of the fetal semi-allograft. Extravillous trophoblast 
cells do not express HLA-A, -B, -DR, -DQ and –DP (85), but they do express HLA-C and the non-
classical HLA-E and HLA–G. HLA-C and HLA-E prevent maternal NK cell-mediated cytotoxicity 
through binding with killer cell immunoglobulin-like receptors (KIRs) expressed on dNK. Whereas, 
HLA-G modulates the response of different cellular subsets including dNK, antigen-presenting 
cell (APC), T cells, and B cells (86, 87). The complex local maternal-fetal immune cross-talk differs 
from the peripheral immune system of both mother and child (88). Indeed, immune cells can be 
generated locally with a different function than the one acquired at the periphery. For example, 
CD8+ T cells express significantly lower levels of perforin and granzyme-B, dendritic cell (DC) are 
arrested in a tolerogenic state, and dNK cells can be generated locally (88, 89). Viral infections may 
increase the levels of pro-inflammatory cytokines, chemokines, and the influx of T cells in decidual 
tissues (90, 91). In this situation, the regulatory mechanisms might not be able to efficiently inhibit 
the allogeneic lymphocytes (89), which could damage the placenta. CMV replication occurs in 
the decidua, endothelial cells and endovascular cytotrophoblast (92-94). Even though maternal 
macrophages and NK cells may limit the viral replication in the uterine wall (93), once CMV infects 
the cytotrophoblasts there is an extensive change in molecule expression that hampers their 














thicker placentas than women with asymptomatic foetuses; additionally the latter placentas were 
thicker than those of women with secondary infection (99). Furthermore, the infected placentas are 
characterized by an hypoxic-like environment that attempts to induce compensatory mechanism 
by increasing the area of the fetal part of the placenta in order to increase the oxygen influx, and this 
may contribute to the thickening as well (100, 101). However, more data are needed on the impact 
of cCMV on the placental immune cross-talk and on the decidual tissues in relation to outcome.
1.4.4. Fetal and neonatal CMV immune response
How CMV reaches the fetus from the placenta is largely unknown, but maternal Abs affinity 
probably plays a role in the chance of fetal infection. In case of high avidity IgG, viral replication in 
the cytotrophoblast is limited and therefore the virus spreads less to the other layers of the placenta 
(93, 102-104); with low avidity IgG the viral infection is not prevented and therefore viral transport is 
facilitated. The placental alterations mentioned in the previous paragraph clearly induce a placental 
dysfunction that could hamper fetal development, and in turn contribute to the development of 
symptoms at birth. Upon fetal infection, the induction of a CMV-specific immune response has been 
shown. The majority of available data refer to αβ T cells. In congenitally infected children, there is 
a strong response of CD8+ T cells (10, 67, 105-110), during which they acquire a late differentiation 
phenotype (10, 105, 106, 111), and a restricted number of clones is generated (105). CMV-specific 
CD8+ T cells have been detected as early as 22-28 weeks of gestation (105, 108). During the first year 
of life, the number of CMV-specific IFNγ-producing CD8+ T cells increases, as well as the repertoire 
of CMV peptides against which they react (10, 110). Expansion of CD4+ T cells, as well as of γϒ T 
cells (112), has also been described in the context of cCMV (113). γϒ T cells with antiviral activity 
have been detected as early as 21 weeks of gestation (112). These might have a more important 
role in early life as they develop earlier than αβ T cells (114). Despite the oligoclonal expansion of 
fetal CD4+ and CD8+ T cells, similar to that in adults, their functionality and cytokines response 
was lower, and they showed a typical exhaustion phenotype (74). This is similar to what happens in 
adults after primary or chronic infection, but the magnitude of this phenomenon is more intense 
during fetal life (114), most likely because of the higher viral loads the foetuses are exposed to (63). 
This exhaustion of T cells in the foetuses may be responsible for the prolonged CMV viral excretion 
in these children which can last up to 5 years (50, 74). In general, also after postnatal CMV infection 
the viral excretion is longer, ~2 years, than in immunocompetent adults, and this suggests a limited 
control of the infection in early life (50, 51, 67, 114). Unfortunately, little information is available on 
fetal B cell immunity during cCMV. IgM positive B cells have shown to emerge in the peripheral 
circulation as early as 12 weeks of gestation (115), and CMV infected foetuses can produce IgM (116-
118), but the antiviral activity and the role in CMV disease control have not been evaluated yet (119). 
The evidence of NK cell activation in the context of cCMV is scarce. An expansion of NKG2C+ NK 














1. 5.  PROGNOSTIC M ARKER S FOR cC MV CLINIC AL 
OUTCOME
One of the main problem with cCMV is that, despite the extensive knowledge on the clinical 
outcome and despite being the most common congenital infection leading to a variety of permanent 
disabilities, the question whether a child will be symptomatic at birth or will develop LTI remains 
largely unanswered. This is just because cCMV pathogenesis is largely unknown. A prognostic 
marker for clinical outcome would help identifying subgroups of patients that would benefit from 
certain clinical interventions, as well as giving more insights into cCMV pathogenesis.
In the following paragraphs, the available prognostic markers are classified into different 
subgroups according to the main goals of prediction: vertical transmission of CMV, symptoms at 
birth and LTI development, and whether these measurements were performed in the mother, in 
the fetus or in the neonate. Whereas, the first paragraph is focused on what is known on the viral 
genomic variability in relation to clinical outcome.
1.5.1. CMV genomic variability
Several viral proteins have the capacity to modulate the host immune response 
(listed below). Therefore, the first attempt was to predict outcome by means of these 
immunomodulatory molecules. 
•	 UL144: non-functional truncated TNF-α-like receptor gene;
•	 US28: functional β-chemokine receptor which binds and sequesters 
extracellular chemokines;
•	 Envelope glycoproteins: gB (UL55), gN (UL73), gH (UL75) have been associated with 
polymorphisms that may contribute escaping the immune response;
•	 UL146, UL147: α-chemokines, vCXCL-1 and vCXCL-2.
Some studies have related UL144 (121, 122), UL55 (gB) (121, 123-125), UL73 (gN) (123, 126, 127), UL146 
(vCXCL-1) and UL147 (vCXCL-2) (128, 129) to outcome, whereas others have not. For US28 (121, 122) 
and UL75 (gH) (130, 131), there  seems to be no clear association with cCMV outcome. Additionally, 
infection with multiple strains have been demonstrated in several populations: at the maternal-
fetal interface (94), in congenitally infected newborns (132, 133), in immunocompetent and 
immunocompromised adults and young infants (134-138). Few studies have evaluated mixed 
infection in relation to clinical outcome, with some contradicting results (121, 130). However, in 
murine studies, and in immunocompromised patients, the mixed infection has been associated 
to enhanced pathogenicity (139-141). And unique genotypes are found in different compartments 
(133). How a mixed infection occurs in the fetus is largely unknown as it may occur as a single event 
with multiple strains, as multiple transmission moments or both mechanisms. To conclude, there 
are no strong evidence for either genomic variability nor for multiple strain infection in relation to 















1.5.2.1. Predicting vertical transmission of CMV
Pregnant women who transmitted CMV to their fetus showed a lower and delayed lymphoproliferative 
response to CMV (78, 79). In these cohorts, the primary maternal infection occurred in different 
trimesters of gestation. The trimester of maternal primary infection is a determinant for vertical 
transmission, and the risk of transmission increases with the month of gestation (142, 143). In cases 
of infection in the first trimester, IgG avidity may be considered a prognostic marker for vertical 
transmission. A low avidity IgG (suggesting recent infection) is associated with 36% transmission, 
whereas intermediate avidity (timing of infection unclear) with 6% transmission (144). Contradicting 
results have been shown for maternal IgM, as it is used in different definitions of primary maternal 
infection. Indeed, when used as a marker for primary maternal infection the vertical transmission 
occurred only when IgM were present (145), while in another study of congenitally infected foetuses 
IgM could be detected only in 56% of mothers most likely because the group of mothers was 
characterized by both primary and secondary infection (though not stated clearly) (146). Overall, 
maternal seropositivity may be considered a marker for transmission. When a seronegative mother 
gets infected during pregnancy the vertical transmission rate is 30-35%, whereas in seropositive 
mothers this rate is lower (18-20). Concerning the virus, though very high viral load, evaluated by 
means of DNA quantification in AF, gave 100% of vertical transmission, very low or negative viral 
load, did not exclude it (145, 147). Different gB genotypes did not seem to correlate with transmission 
(148). Importantly, if the ultimate goal was to predict vertical transmission, all the mothers would 
need to be screened. 
1.5.2.2. Predicting symptoms at birth
The gestational age at the onset of maternal primary infection is perhaps the most recognised 
factor related to cCMV outcome. If cCMV occurs in the first trimester the outcome is more severe, 
e.g. with neurological involvement, whereas if it occurs in the third trimester the symptoms, if any, 
are mild (149). Additionally, CMV DNA in AF was assessed in relation to maternal primary infection. 
Even though it seems that higher viral loads are related to a worse outcome at birth (145, 150-152), 
some studies have highlighted the importance of stratifying for onset of maternal primary infection. 
The CMV DNA in AF was significantly correlated to a worse outcome at birth if the maternal infection 
occurred relatively early (145, 149), whereas others have not found a correlation (153). Only few 
studies have evaluated the role of CMV DNA in AF of a group of mothers with both primary and 
secondary infection, and no correlation was found (147, 148). These findings may be due to different 
factors. First of all, primary maternal infection may result in higher AF viral load than secondary 
infection, as the maternal CMV-specific immune response is still developing and may not be able 
to control viral replication as efficiently as when a previous infection occurred. Second of all, 
a correlation between AF viral load and gestational age at the time of sampling has been shown (147, 
148, 151), therefore when maternal primary infections occur early in gestation there might be an 














1.5.2.3. Predicting LTI development
This has not been extensively explored, as after birth the immune system of the child may have 
a more important role in controlling CMV infection and disease. However, a trend towards higher 
risk of LTI development was shown for those infected neonates born from mothers with primary 
infection occurring in the first trimester of gestation (followed-up annually till 6 years of age) (149). 
This may be because earlier maternal primary infection infections are associated with symptoms at 
birth, and symptoms at birth are associated with LTI development. Whereas, CMV DNA in AF did not 
seem to correlate with LTI (149). 
1.5.3. Fetus
1.5.3.1. Predicting symptoms at birth
Several markers, mainly  quantified in cord blood, have been explored with the goal to predict clinical 
outcome, and these can be divided into different categories (virological, immunological, metabolic 
and imaging). In the majority of the cases, these markers have been quantified in the context of 
maternal primary infection. In case of secondary maternal infection this was specified.
Virological (markers related to viral components)
•	 Antigenemia (detection of viral proteins in blood): viral proteins are more indicative of 
a productive infection compared to DNA quantification, therefore they are associated with 
symptoms at birth (149, 152);
•	 DNAemia (detection of viral DNA in blood): the results are not conclusive in predicting 
symptoms at birth as some have found an association while others have not (149, 152, 154);
•	 Viremia (detection of virus in blood): the results are not conclusive in predicting symptoms 
at birth as some have found an association while others have not (149, 152).
Immunological (marker related to the host immune system)
•	 Platelet counts: lower platelet count has been consistently associated with symptomatic 
disease at birth (152, 154), and when combined with fetal ultrasound seemed to predict 
better (154);
•	 IgM: shown to be related to symptomatic disease at birth (149, 152); 
•	 White blood cells count: higher levels were found in symptomatic (152); 
•	 % lymphocytes: higher in the CMV+ foetuses and in those who were symptomatic at 
birth (152);
•	 β-2 microglobulin: higher in CMV+ foetuses and in those who were symptomatic at 
birth (152);
•	 CD4+/CD8+: even though the ratio is higher in CMV- no correlation was found in those 
CMV+ with symptoms at birth (152);
•	 % CD3+HLADR+: though higher in CMV+ there was no correlation with those who developed 














Metabolic (markers related to the host metabolism)
•	 Plasma aminotransferase: aspartate aminotransferase (AST) increased in the symptomatic, 
whereas this was not observed for alanine aminotransferase (ALT) (152, 154, 155);
•	 Gamma-glutamyl-transpeptidase (GGT): no correlation was found in any of the studies, 
even though it was found higher in CMV+ foetuses (152, 154, 155).
Imaging
•	 Ultrasound: if fetal infection is not established, ultrasound may predict symptoms, whereas, if 
fetal infection is diagnosed, ultrasound imaging may be associated with a poor outcome (154, 
156). In the absence of ultrasound abnormalities, a minority of neonates were symptomatic 
(154). The absence of abnormal ultrasound does not exclude the presence of abnormalities 
because some of them may appear later than when the ultrasound is performed; 
•	 MRI (Magnetic Resonance Imaging): no correlation was found between MRI findings and 
symptoms in the first 11 months of life (157). This technique is more accurate and can show 
secondary lesions, even in the absence of ultrasounds abnormalities. Type of maternal 
infection not clear.
1.5.3.2. Predicting long-term impairment
The study of markers in fetus in relation to LTI development did not show any meaningful findings, 
though only few markers have been explored: CMV DNA, viremia, IgM, and ultrasound/MRI (149, 
157). In particular, for imaging the main conclusion was that a normal ultrasound or MRI correlates 
with a normal development (157). 
1.5.4. Neonate
1.5.4.1. Predicting symptoms at birth
Measuring markers at birth may have advantages over measuring them in the fetus because 
the material is more accessible and still reflects the situation during pregnancy, at least in 
the last phase of pregnancy. Therefore, a big overlap between markers evaluated in the fetus and 
in the neonates was observed, and a similar categorization is presented (virological, immunological 
and metabolic). In the majority of the cases, these markers were quantified in the context of 
maternal primary infection. In case of secondary maternal infection this is specified.
Virological
•	 Antigenemia: as in the fetus, higher levels are associated with symptomatic 
disease (158, 159);
•	 DNAemia: as in the fetus, contradicting results were shown (149, 158-161). In general, in all 














high viral load in both groups, and very low only in the asymptomatic. Therefore, what could 
be reliably concluded from these data is the lower risk of symptomatic disease in very low 
viral load (160). Interestingly, in a study of CMV DNA quantified in DBS, with an unknown 
type of maternal infection, higher viral loads correlated with a higher risk of SNHL (162). 
Importantly, the relationship between CMV DNA and symptoms is not linear, and this has 
been demonstrated not only in DBS (161-163), suggesting that the damage is evident after 
a certain accumulation of viruses;
•	 CMV DNA in cerebrospinal fluid (CSF): only found in symptomatic neonates (164);
•	 CMV DNA in urine: no correlation was found even though the viral load is usually higher in 
urine compared to blood (10^5 vs 10^3), and persist longer (164).
•	 Viremia: associated with symptoms at birth (159);
•	 Virus clearance (urine or blood): the role of viral clearance in the clinical outcome remains 
not completely understood. Indeed, no difference in clearance from blood or urine was 
found between symptomatic and asymptomatic (161, 165). And there are some evidence 
of a shorter duration of excretion of CMV in urine in those neonates that had SNHL and 
progressive SNHL (165).
Immunological
•	 IgM: the results are discordant as some have not found a correlation (149, 159), whereas 
some have (166, 167); 
•	 β2-microglobulin and proteins: found increased in symptomatic that developed LTI (168) 
(type of maternal infection not clear).
Metabolic
•	 Platelet count + ALT: with maternal infection not clear, if platelet count <100000/mm3 + high 
ALT >80 UI/ml association with symptoms at birth (hearing loss) (169).
1.5.4.2. Predicting LTI development 
In the majority of the cases, these markers were quantified in the context of maternal primary 
infection. In case of secondary maternal infection this was specified.
Virological
•	 Antigenemia: no correlation was found with respect to long-term outcome (149);
•	 DNAemia: the results are contradicting as some studies have not found a relation between 
load at birth in the neonatal blood and long-term outcome (149), whereas others have 
(170). A correlation between high loads in asymptomatic developing LTI compared to 















•	 IgM: no correlation was found between IgM in neonatal blood and LTI development (149);
•	 β2-microglobulin and proteins: higher in the CSF of symptomatic that developed LTI (168). 
Clinical
•	 Severe symptoms at birth (central nervous system (CNS) involvement): are associated 
with higher risk of SNHL and cognitive deficits in a follow-up of ~4 years (maternal 
infection was not taken into consideration) (171). Clinical predictors are only available for 
symptomatic children;
•	 Symptoms at birth: studies have shown that even in case of not so severe symptoms at birth, 
symptomatic neonates have higher risk of developing LTI (17).
Imaging
•	 CT (Computed Tomography): abnormalities in symptomatic infected neonates are 
predictive for a worse long-term outcome (172), and in association with the presence of 
microcephaly at birth is predictive of cognitive LTI (173). In the latter, where all individuals 
were symptomatic, the absence of microcephaly in presence of CT abnormalities was 
associated with an intermediate outcome, whereas in absence of microcephaly and CT 
abnormalities with a good outcome. 
•	 MRI: even though the spectrum of MRI abnormalities is extremely broad, there are certain 
abnormalities associated with a poor long-term outcome (age at MRI ~2 years and follow-up 
~5 years) (174).
To conclude the section on prognostic markers for cCMV clinical outcome, there is no clear evidence 
of a biomarker that could potentially be used to define subgroups of patients that would benefit 
from certain clinical interventions. Several factors may have contributed to these discrepancies. 
First of all, the clinical definitions used for symptomatic neonates, or LTI development, are extremely 
diverse across studies. Different immunopathologies may underlie different outcomes. Second of 
all, in the majority of the cases a maternal primary infection was considered, therefore what happens 
in mothers with secondary infection is largely unknown. Third, it is almost impossible to determine 
the gestational age at vertical transmission.
1.6.  CLINIC AL STR ATEGIE S 
Finally, even if we had “The Biomarker” allowing the identification of such subgroups, what, how, 
and to whom we offer certain clinical interventions that would solve/improve short- and long-term 
disabilities remain an open question. Such complex problem needs stratification according to 
the goals of the clinical intervention and to the target population of such an intervention. As 
a primary prevention, we would like to prevent maternal infection as cCMV would not occur at 














like to prevent vertical transmission for the same aforementioned reason. However, there is no 
currently effective vaccine registered (175, 176), and there is no effective treatment that reduces 
vertical transmission, either antiviral or hyperimmunoglobuline (177, 178). As a tertiary prevention, 
we would like to prevent, or at least positively affect, the short- and/or long-term impairments. 
Provided that all infected neonates have been identified, e.g. through maternal and/or neonatal 
screening. Some studies have shown a certain degree of beneficial effect of a prenatal treatment 
with hyperimmunoglobuline or valacyclovir, however further studies are necessary (100, 179-182). 
Some other studies have focused on postnatal treatment of symptomatic neonates with (val)
ganciclovir, and have shown an improvement of the hearing, language/receptive components (183-
185). However, it still needs to be evaluated whether such treatment is beneficial for mildly affected 
or asymptomatic neonates who can still develop permanent impairments.
Importantly, several observations would need to be taken into consideration for the use of 
a future vaccine in the cCMV settings. Additionally to the mothers, infants and adolescents could 
be potential targets as well, depending on our goals. If given to infants it would prevent females 
to get infected and transmit the virus to the future foetuses. If given to toddlers we would reduce 
the transmission to mothers, though this would not be complete as the transmission from adults 
to adults may still occur. If given to adolescent girls we would prevent transmission to the fetus, 
similarly to when we give it to women, but with a different vaccine duration needed. The vaccine 
may as well be used in seropositive setting in order to boost pre-existing immunity.
As the way to a licensed vaccine seems to be long, the tertiary prevention sounds like a good 
compromise. However, in order this system to work a maternal/neonatal screening is necessary. 
The neonatal screening can be selective or universal. In the first case, CMV screening is reserved to 
those neonates that failed the hearing screening, or for those who have a specific clinical picture at 
birth. Therefore, all asymptomatic would be missed, as well as some symptomatic whose clinical signs 
are rather general and difficult to attribute to cCMV. In the second case, CMV screening is meant 
for all newborns, and is defined as “The systematic application of a test to identify asymptomatic 
individuals at risk of a specific disorder in order to prompt further investigation or preventative 
action. Benefits must outweigh harms.” cCMV meets many criteria of the universal screening. 
However, the universal screening would identify those asymptomatic for whom no clear beneficial 
intervention plan is available. This would increase parental stress, alter the familiar dynamics (186), 
force treatments whose benefits are not established yet, and induce unnecessary medical exams 
(187). This problem would be considerably resized if predictors for clinical outcome were available. 
Concluding, understanding the pathogenesis of cCMV would allow to figure out why certain 
children develop LTI and others do not. In turn, this would provide the necessary biomarkers to 
predict outcome and stratify patients according to the risk. On one hand we could define who 
benefits most from certain clinical interventions; and on the other hand we could define correlates 














1.7.  OUTLINE ON THE THE SIS 
The aim of this thesis was to determine potential prognostic markers for short- and long-term 
clinical outcome, and to determine potential correlates of protection. The first would allow 
the identification of subgroups of children that would benefit from certain clinical interventions; 
whereas the latter could be useful for future vaccine development. These goals were achieved by 
using samples from a large retrospective nationwide cohort of children, with (n=125) and without 
(n=263) cCMV, born in The Netherlands in 2008 and their mothers.
In Chapter 2 the immune system of the neonates, with and without cCMV, is assessed by means 
of quantification of several immunological markers extracted from dried blood spots (DBS) and 
correlated to the presence of cCMV, short- and long-term clinical outcome, and CMV viral load in 
DBS. These immunological markers refer to the number of γδ T cells, αβ T cells and B cells, with 
particular attention to B cell replication.
In Chapter 3 the metabolism of the neonates, with and without cCMV, is assessed in relation to 
the presence of cCMV, short- and long-term clinical outcome, and CMV viral load. This is achieved 
by the analysis of the metabolic markers normally extracted from DBS after birth for the screening 
of the rare genetic metabolic disorders. The metabolic markers included are essential amino acids, 
hormones, carnitines and enzymes.
In Chapter 4 the gene expression profile of the neonates, with and without cCMV, is assessed 
in relation to long-term clinical outcome, and CMV viral load. The RNA is extracted from DBS and 
sequenced by using the Illumina platform. Data analysis is performed with particular attention to 
the neonatal immune system.
In Chapter 5 data on maternal and child HLA that are expressed at the placenta are presented. 
HLA-C, HLA-E, and HLA-G are determined from 96 mother–child pairs with cCMV in relation to 
short- and long-term clinical outcome, and CMV viral load. The mothers are additionally typed 
for killer cell immunoglobulin-like receptors (KIRs) to get more insights into NK cells response. 
The typing is performed on DNA extracted from buccal swabs from children and their mothers.
In Chapter 6 data on maternal and child HLA that are not expressed at the placenta are 
presented. HLA-A, HLA-B, HLA-DR and HLA-DQ are determined from 96 mother-child pairs with 
cCMV in relation to a control group of 5604 Dutch blood donors and in relation to CMV viral load. 
The typing is performed on DNA extracted from buccal swabs from children and their mothers.
In Chapter 7 a brief summary of the findings of each chapter is presented first, with particular 
attention to the mechanisms of cCMV pathogenesis and its clinical implications. Second, the main 
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Congenital cytomegalovirus infection (cCMV) is the most common congenital infection which can 
cause long-term impairment (LTI). The pathogenesis of LTI is not completely understood. Fetal 
immunity may play a role in controlling the infection and preventing LTI, though immune activation 
may also contribute to fetal immunopathology. In this study we analyzed various molecular markers 
of T and B cell numbers in neonatal Dried Blood Spots (DBS) of 99 children with cCMV and 54 
children without cCMV: δRec-ψJα signal joints on T cell receptor excision circles, intronRSS-Kde 
signal joints on Igκ-deleting recombination excision circles, genomic intronRSS-Kde coding joint, 
genomic Vδ1-Jδ1 and Vδ2-Jδ1 rearrangements. Of this cohort clinical symptoms at birth and LTI at 
6 y of age were recorded. Neonates with cCMV had less TRECs in their blood than non-infected 
controls. Furthermore, cCMV infection was associated with increased numbers of γδ T cells and B 
cells, and these numbers were positively correlated with CMV viral load in the DBS. Infected children 
with a better long-term outcome had higher numbers of B cells at birth than those who developed 
LTI; no differences in B cell replication were observed. The potential protective role of B cells in 
controlling cCMV-related disease and the clinical value of this marker as a predictor of long-term 
outcome merit further evaluation.
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2 .1.  INTRODUCTION
Human cytomegalovirus (CMV) is the most common cause of congenital infections worldwide with 
an overall birth prevalence in industrialized countries between 0.6-0.7% (1, 2). Among congenitally 
infected children, 12.7% are estimated to be symptomatic at birth with the most common 
symptoms being petechiae, jaundice, hepatosplenomegaly, thrombocytopenia, chorioretinitis, and 
microcephaly (1, 2). An estimated 40-58% of these symptomatic children will develop permanent 
sequelae, such as hearing loss, mental retardation, and developmental delay (1). Importantly, out of 
the 87.3% of neonates that are asymptomatic at birth, approximately 13.5% will develop permanent 
sequelae as well (1). Defining markers that may help to predict whether a neonate will develop 
long-term impairment (LTI) will have profound impact on postnatal policy.
The pathogenesis of fetal damage during congenital infection is still poorly understood due to 
the complex interplay between viral, maternal, placental and fetal factors. It has been shown that 
infections occurring predominantly in the first half of pregnancy are associated with sequelae (3, 4). 
The developing fetal immune system may play a role in controlling the infection later in pregnancy, 
thereby preventing the development of long-term sequelae (5). There is evidence of fetal and 
neonatal immune system activation in the context of congenital CMV infection (cCMV). Previous 
studies have shown expansions of fetal γδ T cells (6), CD8+ T cells (7, 8) and CD4+ T cells (7, 9) in 
cCMV. Upon congenital infection similar types of effector CD4+ and CD8+ T cells as in adults are 
generated (10-12) but they appear to be functionally impaired (7), the CD4+ T cell response being 
more impaired than the CD8+ T cells (8, 13). Despite the fetal capacity to generate IgM against CMV 
(14), the fetal B cell response has not been extensively studied in cCMV. Previous studies on cellular 
and humoral immunity in cCMV have not related their findings to either symptoms at birth or LTI.
In recent years, molecular markers for T and B cells have been used to address several clinical 
questions. These markers specifically involve the circular excision products produced upon the most 
common TCR and Ig gene rearrangements during T and B progenitor cell generation in thymus 
and bone marrow, respectively. δRec-ΨJα signal joints on TCR excision circles (TRECs) are used in 
newborn screening on dried blood spots (DBS) for primary immunodeficiency such as SCID (15, 16) 
because they can be readily detected by quantitative PCR (17-19). Furthermore, studies have been 
carried out to implement screening for agammaglobulinemia (20), using quantitative PCR on DBS for 
Igκ-deleting recombination excision circles (KRECs). In addition, measurement of TRECs has been 
used in HIV patients to monitor the cellular recovery after initiation of highly active antiretroviral 
therapy (21), and in stem cell transplantation patients with primary immunodeficiency, TRECs and 
KRECs were used to monitor the thymic T cell and bone marrow B cell neogenesis (22, 23). Finally, 
the replication history of isolated B cell subsets has been used to improve the characterization of 
immunological disease with aberrant B lymphoid maturation (24-26).
For this study, neonatal DBS from a large cohort of children with cCMV and from non-infected 
controls were analyzed for molecular markers of T and B cells and the results were related to clinical 
data from birth until 6 y of age. Using quantitative real time PCR on DNA isolated from DBS, TCR 
and Ig gene rearrangements were detected. δRec-ΨJα signal joints on TRECs were detected as 
























in the genome as a measure of circulating γδ T cells. Furthermore, intronRSS-Kde coding joints 
(cj intronRSS-Kde) in the genome and intronRSS-Kde signal joints on KRECs were quantified as 
a measure of circulating B cells and newly-derived bone marrow B cells, respectively. KRECs were 
additionally used to determine the B cell replication history (27). 
In the present study, the quantification of TRECs and KRECs, as well as molecular markers for 
γδ T cells, was applied to provide new insights into the immune regulation of cCMV and to identify 
early markers to predict LTI at 6 y of age, such as neurodevelopmental impairment. 
2 . 2 .  M ATERIAL S AND METHODS
2.2.1. Study population and clinical data
A previously described, nationwide, retrospective cohort was used in this study. This cohort 
was derived from a total group of 31,484 children, born in 2008 in the Netherlands, that was 
retrospectively tested for cCMV infection by PCR for CMV DNA in neonatal DBS at 5 y of age 
(28). After approval by the Medical Ethics Committee of the Leiden University Medical Center, 
the parents of 125 congenitally CMV infected children and of 263 non-infected children were asked 
to participate. Parents of 99 congenitally infected children gave informed consent for the use of 
DBS and the use of clinical data for this study. In addition, 54 controls without cCMV were randomly 
sampled from a control group matched for gender-, month-of-birth and region. Children were 
defined as symptomatic at birth if they had one or more of the following signs or symptoms in 
the neonatal period: prematurity, being small for gestational age, microcephaly, hepato- or 
splenomegaly, generalized petechiae or purpura, hypotonia, abnormal laboratory findings 
(elevated liver transaminases, hyperbilirubinemia, neutropenia or thrombocytopenia), cerebral 
ultrasound abnormalities, ophthalmologic abnormalities or neonatal hearing impairment. LTI was 
defined as the presence of impairment in one or more domain (hearing, visual, neurological, motor, 
cognitive and speech-language). Additionally, the severity of the LTI was assessed by accumulating 
the number of domains affected and indicated as the presence of LTI in two or more domains. 
The same definitions were used for children with and without cCMV. Finally, in this cohort maternal 
seroimmunity to CMV before birth was unknown, therefore it was assumed that cCMV infection 
could have resulted from either maternal primary or secondary infection.
2.2.2. DNA extraction from DBS and quantitative PCR for CMV
After a first initial CMV PCR screening performed at the National Institute for Public Health and 
the Environment, a second confirmatory PCR was performed at the Leiden University Medical 
Center (28). For this purpose, DNA was extracted from DBS by using the QIAamp DNA minikit 
according to the previously described protocol (29). For each test one full DBS was punched by 
using an automated DBS puncher (1296-071, Perkin Elmer-Wallac, Zaventem, Belgium). CMV DNA 
amplification of a 126-bp fragment from the immediate-early antigen region was performed using 
an internally controlled quantitative real-time PCR as described previously (30, 31) on a CFX96 
Real-Time PCR Detection System (BioRad, Veenendaal, The Netherlands). The PCR was performed 
























2.2.3. Quantification of TCR and Ig gene rearrangements
To study the numbers of T and B cells in neonatal DBS, the most frequently formed TCR and Ig gene 
rearrangements were quantified by TaqMan-based quantitative PCR. The δRec-ΨJα rearrangement 
occurs in 70-80% of TCRD alleles in mature αβ T lymphocytes, resulting in TRECs in nearly all newly 
formed αβ T cells (32). Vδ1-Jδ1 and Vδ2-Jδ1 rearrangements are collectively present in nearly all 
mature γδ T cells in neonates, but absent in αβ T cells (6, 33). The intronRSS-Kde rearrangement 
occurs in ~30% of Igκ+ and in almost all Igλ+ mature B lymphocytes (27).
These rearrangements as well as the β-globin housekeeping gene were quantified in triplicate 
from each sample using two multiplex real-time PCR assays (Table 1). Each multiplex assay consisted 
of 5 µl of DNA extract and 20 µl reaction mixture containing 3.5 mM of MgCl
2
, 0.04 mg/ml of BSA 
and 12.5 µl HotStar Master mix (QIAGEN, Hilden, Germany). Both mixtures were optimized by primer 
limitation, and for probe and MgCl
2
 concentration with primers and probes specific for TREC, 
KREC, cj intronRSS-Kde, Vδ1-Jδ1, Vδ2-Jδ1 and β-globin to ensure equal amplification efficiencies. 
The Phocine Herpes Virus (PhHV) amplification was used to check for inhibition of the PCR and 
β-globin amplification was used to control for the number of nucleated cells. The following PCR 
mixes were used: the first mix contained 300 nM primers with 200 nM probe for cj intronRSS-Kde, 
Vδ1-Jδ1 and 500 nM primers with 200nM probe for β-globin. The second mix contained 300 nM 
KREC, Vδ2-δ1 and PhHV primers, 900 nM TREC primers, 200 nM KREC, TREC and Vδ2-δ1 probes, 50 
nM PhHV probe.
Quantification was performed using dilution series of DNA from the following cell lines: DB01+T, 
a modification of the previously published U698 DB01 cell line (27) that contains one TREC, one 
KREC and one cj intronRSS-Kde rearrangement copy per genome; Peer (34), a T lymphoid cell 
line, containing one Vδ1-Jδ1 rearrangement copy per genome and T-ALL T032 (34), a T-acute 
lymphoblastic leukemia cell line, containing one Vδ1-Jδ1 rearrangement construct per genome. For 
TRECs two positive controls (cord blood with two different levels of TRECs spotted on filter paper) 
and a negative control (leukocyte-reduced adult blood produced by filtration and spotted on filter 
paper) were included in each run. These materials were kindly provided by the Centers for Disease 
Control and Prevention, Atlanta. The real-time PCR was performed on a CFX96 Real-Time PCR 
Detection System (BioRad, Veenendaal, The Netherlands) in a 96-well plate using a thermocycling 
profile as follows: 15 min 95°C followed by 45 cycles of 95°C (30 s), 55°C (30 s) and 72°C (30 s). Data 
were analyzed with CFX Manager 3.1 software. 
The percentage of cells that contained the rearrangement in relation to the total amount of 
nucleated cells in blood was calculated using the ΔΔCt method with the formula as previously 
described (35): 2^((CTβ-globin – CTtarget)sample – (CTβ-globin – CTtarget)cell line)*100%. The housekeeping gene 
β-globin was quantified in both the sample and cell line used as standard.
The average number of B cell divisions, B cell replication history, was calculated with the formula 













The copies/µl of whole blood were calculated based on the theoretical recovery of 1 µg DNA 




























































































































































































































































































































































































































































































































































































































































































































































































2.2.4. Sensitivity and efficiency of the quantitative PCR assays
Ten-fold serial dilutions of DNA from the various control cell lines carrying the target rearrangements 
were used to determine the assay sensitivity. The analytical sensitivity, expressed as the lower limit 
of detection, was assessed by testing the dilutions in triplicate. Quantification of β-globin levels was 
possible with 0.05 ng total DNA with fewer than 36 PCR cycles in DB01+T, Peer and T-ALL 032 cell 
lines. Quantification of TREC and KREC levels was possible with 0.05 ng total DNA with fewer than 37 
PCR cycles. Quantification of cj intronRSS-Kde, Vδ1-Jδ1 and Vδ2-Jδ1 levels was possible with 0.05 ng 
total DNA with < 36 PCR cycles. 
The similar efficiency between each target and the β-globin is required to use the ΔCt method 
for correct quantification of normalized targets levels (37-39). The amplification efficiency, 
determined from the slope of the log-linear portion of the calibration curve, was assessed by 
testing the dilutions in triplicate. The efficiencies of the assays were very similar: 0.99 ± 0.02 for cj 
intronRSS-Kde, 0.98 ± 0.01 for KREC, 0.96 ± 0.02 for TREC and 0.99 ± 0.01 for β-globin in DB01+T cell 
line; 1.04 ± 0.01 for Vδ1-Jδ1 and 1.03 ± 0.03 for β-globin in Peer cell line; 1.06 ± 0.03 for Vδ2-Jδ1 and 
0.98 ± 0.01 for β-globin in T-ALL 032 cell line; all R2 ≥ 0.98.
2.2.5. Statistics
The differences in the levels of immunological markers between the different categories - CMV 
status, viral load, symptoms at birth and LTI - were assessed by using a linear mixed model with 
random effects in order to account for the repeated measurements on the same patient. A Pearson’s 
correlation analysis between viral loads, log(IU/ml), and the different immunological markers 
was carried out. P-values <0.05 were considered statistically significant. Due to the exploratory 
nature of this study the correction for multiple comparison was not applied for multiple statistical 
testing. Data were analyzed by using the Statistical Package for Social Sciences (SPSS, version 23, 
Chicago, IL).
2 . 3.  RE SULTS
2.3.1. Study population and clinical data
DBS of 99 children with cCMV were tested for using two multiplex real-time PCR assays (Table 1), as 
were 54 controls. The study population and the presence of symptoms at birth and LTI are shown 
in Table 2. In the control group, seven (12.9%) children showed symptoms at birth and five (9%) had 
LTI. In the children with cCMV, 16 (16%) children were symptomatic at birth and 22 (22%) had LTI.
2.3.2. TCR and Ig gene rearrangements in DBS of children with cCMV versus controls
First, the effect of cCMV was assessed by quantifying TCR and Ig gene rearrangements on DNA 
from DBS using real time PCR and comparing children with cCMV (cCMV+) and children without 
cCMV (cCMV-). Supplemental Table 1 shows the estimated means for the markers in our cohort. 
























the TREC rearrangement normalized for the presence of β-globin (p = 0.073) (Fig. 1A). In accordance 
with this finding, the number of TRECs per µl of whole blood was lower than the control group 
(p = 0.043) (Fig. 1B).
It has been shown that prematurity, defined as birth before 37 wk gestational age, is related 
to a lower amount of TRECs (15, 40) and that intra-uterine growth retardation, or dysmaturity, is 
associated with a small thymus (41). To exclude their influence on the differences in TRECs’ levels, an 
additional sensitivity analysis was performed by first excluding the group of premature newborns, 10 
(10%) with cCMV and 4 (7.4 %) in the control group, and then by excluding the group of dysmature 
Table 2. Long-term impairments in the group with cCMV and controls.
Long term impairment










Hearing impairmentc 1 1 0 0 0 0
Visual impairmentd 2 2 0 0 0 0
Neurological impairmente 4 2 2 4 4 0
Motor impairmentf 10 7 3 1 1 0
Cognitive impairmentg 4 2 2 2 2 0
Speech/language problemh 15 9 6 3 3 0
One or more impairmenti 22 14 8 5 5 0
More than one impairmentlj 7 5 2 3 3 0
a Asymptomatic (Asympt.) at birth; b Symptomatic (Sympt.) at birth; c Sensorineural hearing loss; d Optic nerve atrophy, 
cortical visual impairment, congenital cataract; e Cerebral palsy, epilepsy, microcephaly, ADHD, autism; f Motor impairment 
(fine, gross or balance) based on test or diagnosis or sensory processing disorder or developmental coordination disorder; 
g Cognitive impairment based on test or diagnosis; h Language impairment based on test or diagnosis, speech-impairment, 
oral motor skill difficulties or auditory processing disorder; i Any long-term impairment, in one or more domains; j Impairment 



















































































Figure 1. TRECs in DBS of CMV infected children and uninfected controls. (A) Frequency of TREC rearrangements 
in the group with cCMV (CMV+) and controls (CMV-).  p = 0.073. (B) Absolute TREC numbers per µl of whole 
























newborns, 2 (2%) with cCMV and 2 (3.7%) in the control group. No differences were found in 
the estimates and significance compared to the whole cohort (data not shown). Therefore, our data 
suggest that the reduction in the amount of TRECs is not confounded by prematurity or by being 
small for gestational age.
The percentage of γδ T cells that contained the Vδ1-Jδ1 rearrangement was significantly higher 
in the cCMV+ group (p = 0.019). To exclude the possibility that this higher percentage of Vδ1-Jδ1 
rearrangements was the results of fewer αβ T cells, we determined the absolute number of Vδ1-Jδ1 
per microliter of whole blood. Indeed, significantly more Vδ1-Jδ1 copies per µl of whole blood were 
present in the infected group (p = 0.038). No statistically significant difference between the groups 
was observed for the percentage of cells with the Vδ2-Jδ1 rearrangement nor for the Vδ2-Jδ1 copies 
per µl of whole blood.
In the cCMV+ group, the percentage of cells that contained the cj intronRSS-Kde rearrangement 
was higher than in the cCMV- group (p = 0.055). As the cj intronRSS-Kde copies per µl of whole 
blood were slightly higher in the cCMV+ group, but not statistically significant, the small increase in 
percentage might be due to a decrease in αβ T cells. The KREC copies and the percentage of cells 
that carried a KREC were not different between the cCMV+ and cCMV- groups (p = 0.297, p = 0.139 
respectively) even though the same trend of higher numbers in the cCMV+ group was observed. 
Consequently, the B cell replication history was not significantly different between cCMV+ 
and controls.
2.3.3. TCR and Ig gene rearrangements in DBS of children with cCMV in relation to 
CMV viral load
To study the relation between T and B cell numbers with CMV viral load, the cCMV+ group was 
divided into three by taking two cut-points at the first and third quartile of the viral load in DBS, 
resulting in a low (n=24), medium (n=50) and high (n=25) viral loads groups. The mean viral loads for 
each group were 254, 2907 and 27121 IU/ml, and the estimated means for the molecular T and B cell 
markers according to these groups are shown in Table 3.
The high viral load group did not show statistically significant differences compared with 
the low and medium viral load groups for the TRECs copies per µl whole blood or the percentage of 
cells that contained the TREC rearrangement. 
DBS from neonates with high CMV viral loads showed a significantly higher percentage of cells 
containing Vδ1-Jδ1 rearrangements than the low viral load group (p = 0.022), and slightly higher 
than the medium viral load group (p = 0.124) (Fig. 2A). In addition, the Vδ1- Jδ1 copies per µl of whole 
blood were significantly higher in this group than in the low and medium viral load groups (p = 
0.033, p = 0.041, respectively) (Fig. 2B). Furthermore, a Pearson’s r data analysis suggested a positive 
correlation between Vδ1- Jδ1 percentage as well as Vδ1- Jδ1 copies per microliter, and viral loads (p < 
0.001, r = 0.25, and r = 0.23, respectively). No statistically significant differences between the groups 
were observed for the percentage of cells that carried Vδ2-Jδ1 rearrangements nor in the copies 
























The percentage of cells that contained KRECs (Fig. 2C) and the KREC copies per microliter 
(Fig. 2D) were significantly higher in the high viral load group than in the low and medium viral 
load groups (p = 0.002, p = 0.001, and p<0.001, respectively). A Pearson’s r data analysis suggested 
a positive correlation between percentage of KREC, as well as KREC copies per microliter, and 
viral load (p < 0.001, r = 0.33, and r=0.41, respectively). Additionally, in the high viral load group, 
the percentage of cells that contained the cj intronRSS-Kde rearrangement was significantly higher 
than the low viral load group (p = 0.024), and trend significantly higher than the medium viral load 
group (p = 0.068) (Fig. 2E). These differences were even more significant for the cj intronRSS-Kde 
copies per µl of whole blood (p = 0.001, p = 0.004, respectively) (Fig. 2F). A Pearson’s r data analysis 
suggested a positive correlation between percentage cj intronRSS-Kde, as well as cj intronRSS-Kde 
copies per microliter, and viral loads (p < 0.01, r = 0.26, and r=0.37, respectively). No differences in 
the B cell replication history were observed between the viral load groups.
2.3.4. TCR and Ig gene rearrangements in DBS of children in relation to symptoms at 
birth
Next, TCR and Ig gene rearrangements were studied in relation to symptoms at birth to evaluate 
whether they reflected differences in symptoms (Supplemental Table 1). The comparison of T and 
B cell markers between asymptomatic cCMV+ and symptomatic cCMV+ individuals did not show 
statistical differences for any of the markers. Additionally, when comparing the asymptomatic 
cCMV+ with asymptomatic cCMV- groups a similar trend was observed in the same markers as 
Table 3. Estimated means and SEs of all immunological markers in viral load.
Estimated means (SE)








TREC (%) 5.2 (0.5) 5.3 (0.3) 5.0 (0.4)
TREC copies/µl 79 (9) 81 (6) 83 (8)
Vδ1-Jδ1 (%) 0.42 (0.08) 0.53 (0.05) 0.68 (0.08)
Vδ1-Jδ1  copies/µl 10 (2) 12 (1) 17 (2)
Vδ2- Jδ1 (%) 0.6 (0.08) 0.71 (0.06) 0.71 (0.08)
Vδ2-Jδ1  copies/µl 19 (2) 20 (2) 22 (2)
β-glob copies/µl 2307 (141) 2304 (98) 2439 (138)
B cell markers
KREC (%) 2.6 (0.3) 2.7 (0.2) 4.0 (0.3)
KREC copies/µl 34 (5) 38 (3) 65 (5)
cj int-Kde (%) 2.06 (0.31) 2.37 (0.21) 3.06 (0.3)
cj int-Kde  copies/µl 27 (4) 32 (3) 48 (4)
B rep. history -0.39 (0.09) -0.23 (0.06) -0.4 (0.09)
























shown in the overall comparison between cCMV+ and cCMV- children (data not shown). Finally, no 
significant differences in viral loads were found between symptomatic and asymptomatic subjects.
2.3.5. TCR and Ig gene rearrangements in DBS of children in relation to long-term 
impairment
Next, the TCR and Ig gene rearrangements were correlated with LTI (Supplemental Table 1). First, 
we evaluated the immunological markers in relation to the development of any disorder in one 
or more of the following domains of impairment: hearing, visual, neurological, motor, cognitive 
and speech-language. When comparing the group of children with cCMV infection that develop 
any LTI to those who do not, a significantly lower percentage of cells that contain the KREC 
rearrangement was observed (p = 0.008) (Fig. 3A). Also the KRECs copies per µl of whole blood 
were significantly lower in the patients with LTI (p = 0.005) (Fig. 3B). A similar trend, although not 























































































































































































































































Figure 2. Vδ1-Jδ1, sj KREC int-Kde, and cj intronRSS-Kde in DBS of CMV infected children with different viral 
loads. (A) Frequency of Vδ1-Jδ1 rearrangements in the infected group (CMV+) with low, medium and high 
viral load on DBS. *p = 0.022. (B) Absolute Vδ1-Jδ1 numbers per microliter of whole blood in the infected 
group (CMV+) with low, medium and high viral load on DBS. *p = 0.041, **p = 0.033. (C) Frequency of sj KREC 
int-Kde rearrangements in the infected group (CMV+) with low, median and high viral load on DBS. *p = 0.001, 
**p = 0.002. (D) Absolute sj KREC int-Kde numbers per µl of whole blood in the infected group (CMV+) with 
low, median and high viral load on DBS, both p < 0.001. (E) Frequency of cj intronRSS-Kde rearrangements in 
the infected group (CMV+) with low, median and high viral load on DBS. *p = 0.024. (F) Absolute cj intronRSS-
Kde numbers per µl of whole blood. *p = 0.004, **p = 0.001. The estimated means from each group of 
























rearrangement as well as cj intronRSS-Kde copies per µl of whole blood (p = 0.137, p=0.073). Second, 
TCR and Ig gene rearrangements were assessed in relation to the development of more extensive 
impairments, defined as LTI in two or more domains. Similar trends were observed when children 
with more extensive impairments were compared to children without any LTI. Lower percentages 
and numbers of KRECs (p = 0.04, p = 0.02, respectively) and slightly lower percentages and numbers 
of cells containing cj intronRSS-Kde rearrangements were detected in cCMV+ children with more 
extensive LTI than in cCMV+ children without any LTI. No differences in B cell replication history and 
TCR rearrangements were observed in relation to LTI. 
Next, we evaluated if the same markers that were significant in the overall cCMV+ and cCMV- 
comparison were still present in absence of any LTI. Indeed, a similar trend was observed in the same 
markers, TREC and Vδ1-Jδ1 (data not shown). In addition, the cCMV+ group had a significant increase 
in the percentage of cells that contains the KREC rearrangement (p = 0.021) and KREC copies 
(p = 0.044) as well as percentage of cells that contains the cj intronRSS-Kde rearrangement 
(p = 0.017) and slightly higher cj intronRSS-Kde copies per microliter of whole blood (p = 0.075).
Finally, no significant differences in viral loads were found between congenitally infected 
children with and without any LTI.
2 .4.  DISCUSSION
The analysis of molecular markers for T and B cells from DBS in this large cohort of children shows 
that cCMV resulted in reduced thymic production of αβ T cells, increased numbers of γδ T cells and 
a trend towards increased numbers of B cells. Children with cCMV and LTI did show lower number of 
B cells. The observed trend of B cells number increase in the infected group was further emphasized 

















































































Figure 3. B cells and long-term impairments in cCMV infected children. (A) Frequency of sj int-Kde KREC 
rearrangement on DBS in the cCMV+ group without and with any long term impairment (LTI). *p = 0.008. (B) 
Absolute sj KREC int-Kde numbers per microliter of whole blood on DBS in the cCMV+ group without and with 
























The reduced number of TRECs in the DBS from children with cCMV suggests that intrauterine 
infection leads to reduced thymic production of T cells. Indeed, the sensitivity analysis indicated 
that the reduction in the amount of TRECs in our cohort is not confounded by prematurity or 
by being small for gestational age. CMV infection is known to induce a shift from naïve towards 
more differentiated αβ T cells with a reduction in the pool of naïve T cells, as has been shown in 
immunosuppressed individuals and in elderly (42, 43) as well as in pregnant CMV IgG-seropositive 
women (44). However, these all concern adults in whom the reduction of the pool of naïve T cells 
might result from a process that takes place over a longer period of time than the gestational period 
and where the longevity of naïve T cells might also play a role in masking differences in thymic 
output, with the reduced output being visible only after several years (45). Therefore, this process 
is unlikely to be the cause of the reduced amount of TREC in our cohort. Interestingly, in vitro CMV 
has been shown to be capable of infecting thymic epithelial cells that play a central role in T cell 
development and maturation, both during gestation and early stage of life (46, 47). Moreover, in 
newborn infants with cCMV, hypoplastic thymuses have been described and both in guinea pig and 
mouse models pathologic changes of the thymus have been shown (48-50). Although the TREC 
numbers were only moderately lowered, the effect of cCMV on thymopoiesis certainly deserves 
further study.
In our study we did not find an increase in Vδ2 T cells in the cCMV infected group, however, we 
looked at Vδ2-Jδ1 so a role of γδ T cells with other Vδ-Jδ rearrangements, as reported previously, 
cannot be excluded (6). Our observation of increased percentages of Vδ1 T cells in children with 
cCMV is in accordance with a previous study that showed a γδ T cell response upon cCMV after 
primary maternal CMV infection. These fetal γδ T cells, detected as early as 21 wk of gestation, 
were shown to be activated, to undergo cell division and to become differentiated with highly 
restricted repertoires (6). Moreover, γδ clones derived from cCMV-infected newborns showed 
antiviral activity when incubated with CMV-infected cells (6) suggesting a role in controlling viral 
replication (51). These unconventional cells, react rapidly upon activation (52) and develop earlier 
than αβ T cells during immune ontogeny. Therefore, they might have an important role in early 
life (51) and, possibly, in a context where the αβ T-cell response is impaired, they might be more 
efficient in controlling the early phases of cCMV. In the mouse model, when adaptive mechanisms 
are impaired or absent, γδ T cells can provide effective control over CMV infection (53, 54). To 
further support this, γδ T cell expansion in solid organ transplanted patients in response to CMV 
was associated with the resolution of infection and less symptomatic CMV disease, whereas late γδ 
T cell expansion correlated with a more intense and durable CMV infection (55). In our cohort, this 
was not associated with fewer symptoms at birth or LTI. However, the symptoms that define CMV 
disease in solid organ-transplanted patients are different to the clinical signs in the cCMV setting 
and  the ability of γδ T cells to control long-term CMV disease, has not been elucidated (52). 
CMV viral load in DBS was not correlated to symptoms at birth or to LTI in our cohort. Some 
previous studies have demonstrated a relation between CMV viral load with clinical outcome (56, 
57), whereas others have not (58-60). The predictive role of CMV viral load in blood for congenital 
CMV disease may differ depending on the timing of infection and whether there was primary 
























it is impossible to establish the trimester of infection or if a maternal primary infection occurred. 
Interestingly, none of our tested molecular B and T cell markers were associated with symptoms 
at birth in cCMV infected children. cCMV infected children with LTI did show significantly lower 
absolute and relative numbers of KRECs as well as slightly decreased, though not statistically 
significant, absolute and relative numbers of cj intronRSS-Kde, compared with cCMV infected 
children without LTI. However, there were no differences in B cell replication. The same trend was 
observed when considering more severe LTI. These findings suggest that cCMV infection does not 
induce a notable intrauterine B cell proliferation and possibly no considerable Ab production, but 
rather hint to an increase in B cell production. Unfortunately, little information is available on fetal B 
cell immunity in relation to cCMV. IgM positive B cells have been shown to emerge in the peripheral 
circulation as early as 12 wk of gestation (61) and CMV infected fetuses can produce IgM (62-64), but 
the antiviral activity and the role in CMV disease control have not yet been evaluated (5). Whether 
the different numbers of B cells are associated with postnatal differences in the capacity to generate 
long-lived plasma cells, memory B cells or support effector functions of immune cells remains to 
be elucidated. The potential protective role of Ab can be illustrated by the fact that primary CMV 
infection in pregnancy is associated with a vertical transmission rate of 30-40% and that this risk is 
at least 10-fold-lower in seropositive pregnant women (2). Although it is uncertain whether Abs are 
capable of influencing an ongoing CMV infection, a possible better initial B cell response might be 
beneficial in controlling the progressive tissue damage responsible for LTI development, possibly 
due to a sustained viral replication and spread. A positive correlation between B cells number and 
viral load was observed. In a group of pregnant women with primary infection, an expansion of 
a large pool of activated memory B cells enriched for CMV specificity and higher in viremic women 
was shown, further supporting a causal relationship between high viral loads and cells activation 
(65). On the other hand, the difference in B cell numbers that we observed at birth between 
infected children with and without LTI may also be related to a different timing of infection, with 
earlier infections leading to a more extensive cCMV and inflammation influencing the early B cell 
lymphopoiesis in the fetal liver. 
To our knowledge, this is the first study on molecular markers for T and B cells in neonatal DBS of 
cCMV infected children in relation to long-term outcome. A reliable marker for long-term outcome 
could provide the means to introduce the long debated (66) newborn screening program for CMV 
in DBS by defining subgroups that would benefit from clinical, audiological follow-up and possibly 
antiviral treatment. Whether KREC, that was related to LTI, has enough discriminative power 
needs to be assessed in other CMV cohorts. Finally, this study on molecular markers generates 
new hypotheses on the effects of CMV infection on fetal, and possibly child, immunity and on 
the potential protective role of B cells in cCMV infection.
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Congenital Cytomegalovirus infection (cCMV) is the most common cause of congenital infections 
worldwide that can cause long-term impairment (LTI). The metabolic alterations due to cCMV are 
largely unknown. This study aims to assess the metabolites included in the neonatal screening in 
relation to cCMV and cCMV outcome, allowing the identification of prognostic markers for clinical 
outcome. Essential amino acids, hormones, carnitines and enzymes from dried blood spots (DBS) 
were analyzed of 102 children with cCMV and 179 children without cCMV, and they were related 
to symptoms at birth and LTI at 6 years of age. In this cohort, the neonatal screening parameters 
did not change in relation to cCMV, nor to symptoms at birth or LTI. However, metabolic changes 
were observed in children born preterm, with lower concentrations of essential amino acids in 
premature infants with cCMV compared to premature controls. Finally, a higher concentration 
of palmytoilcarnitine (C16) in the group with higher viral load was observed. Though these data 
demonstrate limitations in the use of neonatal screening data as predictors for long-term cCMV 
outcome, the metabolism of preterm neonates with cCMV merits further evaluation.
1.  












































Cytomegalovirus (CMV) infection is a common infection with a seroprevalence of almost 50% 
in the general Dutch population (1). CMV is the most common cause of congenital infections 
worldwide with an overall birth prevalence of 0.6-0.7% in industrialized countries (2, 3). A significant 
part of children with congenital CMV infection (cCMV) will have long-term permanent neurological 
sequelae. Among congenitally CMV-infected children, 12.7% is estimated to be symptomatic 
at birth with the most common symptoms being petechiae, jaundice, hepatosplenomegaly, 
thrombocytopenia, chorioretinitis, and microcephaly (2, 3). An estimated 40-58% of these 
symptomatic children will develop permanent sequelae, such as hearing loss, mental retardation, 
and developmental delay (3). Approximately 13.5% of the asymptomatic children will develop 
permanent sequelae as well (3).
cCMV outcome is the result of a complex interplay between viral, maternal, fetal, and child 
factors. In vitro, CMV has been shown to influence different cellular metabolic pathways. The fatty 
acid biosynthetic pathway of infected cells is highly upregulated in order to sustain the viral envelope 
production (4-6). In infected cells, the increased glucose uptake and glycolytic activity provide 
the necessary carbon atoms used for fatty acid biosynthesis (4, 6, 7). The cellular energy requirement 
is then insured by the increase of glutaminolysis in order to allow the tricarboxylic acid cycle (TCA) 
to function (8). In vivo, few studies have evaluated the metabolic changes occurring in children with 
cCMV. A recent metabolomics analysis on amniotic fluid (AF) showed that primary CMV infection 
during pregnancy, irrespective of fetal infection, resulted in the activation of  glutamine-glutamate 
and pyrimidine metabolic pathways and, when comparing asymptomatic CMV-infected newborns 
to symptomatic CMV-infected newborns, a possible shift in fatty acid biosynthesis was observed 
(9). Moreover, in a group of congenitally infected children a metabolic fingerprint was identified in 
urine samples compared to uninfected controls. An increase of ketone bodies (3-hydroxybutyrate 
and 3-aminoisobutyrate) was observed in the CMV-infected group in an attempt to compensate 
a general reduced level of ATP (10). 
The aim of this study was to assess the metabolites included in the neonatal screening, which is 
performed in Dried Blood Spots (DBS), in relation to cCMV and cCMV outcome. Importantly, several 
considerations should be taken into account with respect to the neonatal screening, specifically 
designed to diagnose rare genetic metabolic disorders. First of all, excluding the metabolic 
disorders, changes in these metabolites have only been reported in critically ill children. A decrease 
in thyroid hormones in septic neonates with poor outcome was observed and premature critically 
ill neonates showed different amino acids profiles, usually with higher concentrations, compared to 
the healthy controls (11, 12). The majority of newborns with cCMV do not have symptoms at birth or 
only have mild disease, and the clinical signs of symptoms and LTI included in this cohort are diverse. 
Therefore, if any changes in metabolites are found,  these will most  likely be subtle. Second, several 
factors have been described influencing the analytes measured on DBS, such as fetal blood volume, 
hematocrit, gestational age, birth weight, maternal factors and storage conditions (13-19). However, 
despite these potential limitations, this exploratory study was undertaken to study  biomarkers in 










































for long term outcome of cCMV with a profound impact on parental counselling, postnatal 
interventions and the potential introduction of neonatal screening for cCMV. For this purpose, 
the neonatal screening data of a large nation-wide cohort of children with and without cCMV was 
evaluated in relation to long-term impairment (LTI) at the age of six years.
3. 2 .  M ATERIAL S AND METHODS
3.2.1. Study population and clinical data
A previously described, nationwide, retrospective cohort was used for this study. A group of 31,484 
children born in 2008 in the Netherlands was retrospectively tested for cCMV by PCR for CMV DNA 
in neonatal DBS at 5 years of age (20). cCMV was diagnosed in 156 children and informed consent for 
retrieval of medical data was given by parents of 133 children with cCMV and 274 matched controls. 
After approval by the Medical Ethics Committee of the Leiden University Medical Center, the parents 
of 102 congenitally CMV-infected children and 197 children without cCMV gave informed consent to 
retrieve the neonatal screening data of their child. The controls without cCMV are from a gender-, 
month-of-birth and region-matched control group. Children were defined as symptomatic at birth 
if they had one or more of the following signs or symptoms in the neonatal period: prematurity, 
being small for gestational age, microcephaly, hepato- or splenomegaly, generalized petechiae or 
pupura, hypotonia, abnormal laboratory findings (elevated liver transaminases, hyperbilirubinemia, 
neutropenia or thrombocytopenia), cerebral ultrasound abnormalities, ophthalmologic 
abnormalities or neonatal hearing impairment. LTI was defined as the presence of impairment in one 
or more domain (hearing, visual, neurological, motor, cognitive and speech-language). Because in 
this cohort maternal seroimmunity to CMV before birth was unknown, it was assumed that cCMV 
infection could have resulted from either maternal primary or recurrent infection.
3.2.2. DNA extraction from DBS and qPCR of CMV
After a first initial CMV PCR screening performed at the National Institute for Public Health and 
the Environment (RIVM), a second confirmatory PCR was performed at the Leiden University Medical 
Center (LUMC) (20). For this purpose, DNA was extracted from DBS by using the QIAamp DNA 
minikit according to the previously described protocol (21). For each test one full DBS was punched 
by using an automated DBS puncher (1296-071, Perkin Elmer-Wallac, Zaventem, Belgium). CMV 
DNA amplification of a 126-bp fragment from the immediate-early antigen region was performed 
using an internally controlled quantitative real-time PCR as described previously (22, 23) on a CFX96 
Real-Time PCR Detection System (BioRad, Veenendaal, The Netherlands). The PCR was performed 
in triplicate, and the CMV viral load expressed in IU/ml.
3.2.3. Neonatal screening data
The genetic metabolic disorders included in the Dutch neonatal screening program in 2008 are 
listed in Table 1. The screening is carried out on DBS and involves five regional accredited screening 
laboratories, among which the National Institute for Public Health and the Environment (RIVM). 










































using Tandem Mass Spectrometry (MS/MS) or Immunochemistry as reported in Table 1. The data 
were provided by the National Institute of Public Health and the Environment (RIVM), Department of 
Prevention Programs. The cut off values of the parameters used for referral of the child are described 
in the national guideline for neonatal screening (24). An analyte below or above the cut-off levels 
would strongly indicate the presence of a rare genetic metabolic disorder, though a confirmatory 
test would be needed on a second DBS. Thus, the whole cohort of children included in the study was 
screened for analytes above or below the cut-off levels. Furthermore, among the factors described 
to influence the metabolites measured on DBS, gestational age and birthweight are the most 
important and well-characterized (13). These factors were taken into account in the analysis, and 
the markers were first assessed in premature versus term infants, and then in dysmature versus non-
dysmature infants, within the whole cohort. Prematurity was defined as birth before 37 weeks of 
gestation while dysmaturity as weight at birth less than -2 SD for gestational age. Then, the analysis 





Glutaricaciduria type 1 (GA I) C5DC MS/MS 1: 335455
Isovaleric academia (IVA) C2, C5 MS/MS 1: 351429
Maple syrup urine disease (MSUD) Leucine, Valine MS/MS 1:567692
Homocystinuria (HCU) Met MS/MS 1:167727
3-methylcrotonyl-CoA- carboxylase
Deficiency (3-MCC)
C5OH MS/MS 1: 194211
HMG-CoA lyase deficiency C5OH MS/MS 1:100000 [34]2
multiple CoA carboxylase deficiency (MCD) C5OH MS/MS 1:200000 [35]
Phenylketonuria (PKU) Phenylalanine, 
Tyrosine
MS/MS 1: 11865
Fatty acid oxidation disorders
Medium chain acylCoA dehydrogenase
Deficiency (MCAD)




Very long chain acylCoA dehydrogenase
Deficiency (VLCAD)
C14:1, C16 MS/MS 1: 144706
Carnitine transporter deficiency (CTD) C0 MS/MS 1:40000 [36]
Endocrine disorders
Congenital hypothyroidism (CH) T4, TSH, TBG Immunochemistry 1:3000 – 1:4000 [37]
Congenital adrenal hyperplasia (CAH) 17-OHP AutoDELFIA 1:10000 – 1:20000 [38]
Other
Galactosemia (GAL) GALT, TGAL Enzymatic method 1: 49530
Biotinidase deficiency (BTD) BIOT Enzymatic method 1: 49865
1 Unless otherwise specified the incidence is retrieved from the Dutch Diagnosis Registration Metabolic Diseases (DDRMD) 










































of the metabolites in relation to cCMV and cCMV outcome was subsequently stratified for these 
factors in order to evaluate if they were of significant influence.
3.2.4. Statistics
The differences in the levels of the metabolic markers between the different categories - cCMV 
status, CMV viral load, symptoms at birth, and LTI - were assessed by using an independent-samples 
t-test. A Chi-square test was used to assess the differences in the proportion of prematures and 
dysmatures in relation to cCMV and LTI. Several analytes including C5OH, C5DC, C5 and C16OH 
showed results below the limit of reliable quantification and were therefore excluded from 
the analysis. The carnitines included in the present study (C0, C2, C8, C10, C14:1 and C16) identify 
fatty acid disorders associated to different pathways which are short, medium, long and very long 
chain fatty acids metabolism. Therefore, in order to gain more insights into these pathways total 
carnitine (TC), acylcarnitines molar ratio (AFR), short chain index (SCI), medium chain index (MCI) 
and long chain index (LCI) were additionally calculated as previously described (25), with slight 
modifications according to the carnitine available in this study. TC was calculated by addition of all 
available acylcarnitines (AC) and free carnitine (FC); AFR was calculated as the ratio between AC/FC; 
SCI as C2 divided by TC level; MCI as the sum of C8 and C10 divided by TC level; LCI as the C14 and C16 
divided by TC level. A p value <0.05 was considered statistically significant. Due to the exploratory 
nature of this study, no multiple comparison correction was applied. Data were analyzed by using 
the Statistical Package for Social Sciences (SPSS, version 23, Chicago, IL, USA). 
3. 3.  RE SULTS
3.3.1. Study population and clinical data
The clinical data of the study population are shown in Table 2. Neonatal screening data were 
retrieved from 102 children with cCMV and 179 non-infected controls. In the control group, 12.4% 
of children (n = 22) had symptoms at birth and 8.4% (n = 15) showed any LTI. In the children with 
cCMV, 17.6% (n = 18) had symptoms at birth and 24.5% (n = 25) showed LTI. In this cohort, 10.8% of 
children with cCMV (n = 11) and 5.1% of children without cCMV (n = 9) were born preterm, while 2% 
of children with cCMV (n = 2) and 5.6% of children without cCMV (n = 10) were born dysmature, 
these differences were not significant. However, a significantly higher percentage of prematures 
was observed in the cCMV-infected group that developed LTI compared to cCMV-infected group 
that did not (24% and 6.5% respectively, p = 0.024), whereas this was not observed in the control 
group (data not shown). Additionally, within the cCMV-infected group, all children born premature 
with birthweight <2500 g developed LTI, and only one premature child with birthweight ≥ 2500 g did 
so, whereas none of the non-infected premature neonates developed LTI.
3.3.2. Neonatal screening data in relation to congenital CMV infection
First, the metabolic markers were assessed in relation to cCMV. For this purpose, CMV-positive 
children (n = 102) were compared with CMV-negative children (n = 179), and no significant differences 










































Table 2. Clinical data in the group with cCMV and controls.




















 Male 60 (58.8) 48(57.1) 12 (66.7) 96 (53.6) 83 (53.2) 12 (54.5)
 Female 42 (41.2) 36 (42.9) 6 (33.3) 83 (46.4) 73 (46.8) 10 (45.5)
Gestational age (weeks)4
 <32 1 (1.0) 0 (0.0) 1 (5.6) 2 (1.1) 0 (0.0) 2 (9.1)
 32 - < 37 10 (9.8) 0 (0.0) 10 (55.6) 7 (3.9) 0 (0.0) 7 (31.8)
 ≥ 37 91 (89.2) 84 (100) 7 (38.9) 169 (94.4) 156 (100) 13 (59.1)
Birthweight (g)5
 <1500 1 (1.0) 0 (0.0) 1 (5.6) 0 (0.0) 0 (0.0) 0 (0.0)
 1500-2499 5 (5.0) 0 (0.0) 5 (27.8) 10 (5.6) 0 (0.0) 10 (45.4)
 ≥2500 95 (94.1) 83 (100) 12 (66.7) 168 (94.4) 156 (100) 12 (54.5)
Premature 11 (10.8) - 11 (61.1) 9 (5.1) - 9 (40.9)
Dysmature 2 (2.0) - 2 (11.1) 10 (5.6) - 10 (45.5)
Long term impairment
 Hearing impairment6 3 (2.9) 2 (2.4) 1 (5.6) 0 (0.0) 0 (0.0) 0 (0.0)
 Visual impairment7 3 (2.9) 3 (3.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Neurological impairment8 5 (4.9) 3 (3.6) 2 (11.1) 8 (4.5) 8 (5.1) 0 (0.0)
 Motor impairment9 11 (10.8) 8 (9.5) 3 (16.7) 2 (1.1) 2 (1.3) 0 (0.0)
 Cognitive impairment10 4 (3.9) 2 (2.4) 2 (11.1) 2 (1.1) 2 (1.3) 0 (0.0)
 Speech/language impairment11 17 (16.7) 10 (11.9) 7 (38.9) 9 (5.0) 8 (5.1) 1 (4.5)
 One or more impairment12 25 (24.5) 15 (17.9) 10 (55.6) 15 (8.4) 14 (9.0) 1 (4.5)
1 Asymptomatic at birth; 2 Symptomatic at birth; 3 For one CMV-negative child data on symptoms at birth were not available; 
4 For one CMV-negative child gestational age was not available; 5 For one CMV-positive and one CMV-negative child 
birthweight was not available; 6 sensorineural hearing loss; 7 optic nerve atrophy, cortical visual impairment, congenital 
cataract; 8 cerebral palsy, epilepsy, microcephaly, ADHD, autism; 9 motor impairment (fine, gross or balance) based on test 
or diagnosis or sensory processing disorder or developmental coordination disorder; 10 cognitive impairment based on test 
or diagnosis; 11 language impairment based on test or diagnosis, speech-impairment, oral motor skill difficulties or auditory 
processing disorder; 12 Any long-term impairment, in one or more domains.
Furthermore, as previously mentioned, gestational age and birthweight are important and well 
known factors influencing the metabolites measured on DBS. Because of the significant percentage 
of premature and dysmature infants in the group with symptoms at birth, we aimed to evaluate 
if these variables affected the metabolic markers in this cohort. For this purpose, we compared 
neonates born premature (n = 20) with non-premature (n = 260), and dysmature neonates (n = 
12) with non-dysmature neonates (n = 267) using the total cohort, both children with and without 
cCMV. A significantly decreased concentration of T4 and biotinidase activity (BIOT) was observed 
in the premature group compared to non-premature, as well as a significantly increased 17OHP 
concentration (Table 3) (p < 0.001). No differences in concentration were found between dysmature 
neonates and non-dysmature neonates (data not shown). Given the diversity of clinical signs in 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the aforementioned metabolic changes, or rather a combinations of clinical signs. Hence, an 
additional sensitivity analysis was performed by first comparing the group of symptomatic neonates 
(n = 40) with the asymptomatic neonates (n = 240) without excluding premature neonates. 
Then the group of premature was excluded, and symptomatic neonates (n = 20) were compared 
to asymptomatic neonates (n = 240). The results and significance changed suggesting that 
the observed differences were mainly driven by prematurity (data not shown). 
Therefore, we next assessed the markers in relation to cCMV by stratifying for prematurity. 
Premature cCMV-negative children (n = 9) were compared to premature cCMV-positive children 
(n = 11), and term cCMV-negative (n = 169) children were compared to the term cCMV-positive 
(n = 91). The premature cCMV-positive showed lower levels of essential amino acids compared to 
premature controls, statistically significant for leucine and phenylalanine (p = 0.01 and p = 0.04 
respectively) (Table 3 and Fig. 1). No differences were found when comparing term cCMV-positive 
with term cCMV-negative (Fig. 1).  
Next, in order to assess the influence of CMV viral load on the metabolic markers, the cCMV-
positive group was divided into two groups according to the median viral load in DBS, which was 
3.1 log (IU/ml), namely low (n = 50) and high viral load (n = 50) group. The high viral load group 
had significantly higher concentration of palmitoylcarnitine (C16) (p = 0.002) (Table 4 and 
Fig. 2). This was not influenced by the presence of premature neonates (data not shown). As a 
*
**
Figure 1. Essential amino acids in relation to cCMV in term and preterm infants. Left panel: essential amino acids 
in CMV-negative and CMV-positive term infants (n=169 and n=91, respectively). Right panel: essential amino 
acids in CMV-negative and CMV-positive pre-term infants (n=9 and n=11, respectively). The mean from each 










































result, the acylcarnitine molar ratio (AFR) and the long-chain index (LCI) were increased 
(both p = 0.008) (Table 4).
Finally, the genetic metabolic disorders, included in the neonatal screening, were assessed 
in relation to cCMV. Six children without cCMV showed an increased 17-ϒ-hydroxyprogesteron 
(17OHP) concentration. However, when taking into account the gestational age, only two infants 
had dubious 17OHP results. Furthermore, one child with cCMV showed a low concentration of free 
carnitine (C0). The analysis of clinical data of these infants did not show any underlying disorders 
related to congenital adrenal hyperplasia nor to carnitine transporter deficiency. Therefore, none 
of the metabolites’ concentrations are affected by any of the genetic conditions included in this 
neonatal screening.
Table 4. Metabolic markers in relation to CMV viral load.
Mean (SE)
Viral Load cCMV infection1
low load2 (n=50) high load3 (n=50) p-value
Essential amino acids
Methionine 18.4 (0.8) 18.2 (0.7) 0.846
Leucine 157.7 (6.9) 147.2 (6.1) 0.255
Valine 128.1 (5.2) 127.2 (5.9) 0.911
Phenylalanine 65.5 (2.5) 68.7 (3.2) 0.431
Hormone
T4 79.9 (2.9) 87.5 (3.1) 0.075
17OHP 0.8 (0.1) 0.91 (0.04) 0.082
Carnitines
C0 18.1 (1.3) 17.6 (1.0) 0.764
C2 19.0 (1.4) 22.5 (1.6) 0.113
C8 0.033 (0.002) 0.033 (0.003) 0.951
C10 0.049 (0.002) 0.054 (0.003) 0.208
C14:1 0.06 (0.01) 0.06 (0.01) 0.961
C16 2.4 (0.2) 3.1 (0.1) 0.002
Enzymes
BIOT 99.3 (3.2) 99.3 (2.8) 0.993
GALT 99.0 (3.4) 102.8 (4.1) 0.471
Pathways
TC4 39.81 (2.61) 43.42 (2.47) 0.318
AFR5 1.28 (0.06) 1.51 (0.06) 0.008
SCI6 0.48 (0.01) 0.51 (0.01) 0.029
MCI7 0.0023 (0.0001) 0.0021 (0.0001) 0.164
LCI8 0.066 (0.003) 0.076 (0.003) 0.008
1 CMV viral load measured in DBS. For two infected neonates the DBS was not available, therefore CMV viral load could 
not be assessed. 2 CMV viral load below the median (3.1 log (IU/ml)); 3 CMV viral load above the median (3.1 log (IU/ml)); 4 
Total carnitine (TC); 5 Acylcarnitines molar ratio (AFR); 6 Short chain index (SCI); 7 Medium chain index (MCI); 8 Long chain 










































3.3.3. Neonatal screening data in relation to long-term impairment
Next, neonatal screening data were analysed in the group of children with cCMV in relation to LTI 
development in one or more of the following domains of impairments: hearing, visual, neurologic, 
motor, cognitive, and speech-language. Given the previously shown effect of prematurity on 
different analytes, the analysis was stratified for this factor, and infected premature neonates who 
developed LTI (n = 6) were compared to infected premature neonates without LTI (n = 5). A lower 
BIOT was observed in the neonates who developed LTI compared to those who did not (p = 0.009) 
(Table 3), while this was not observed when comparing infected term neonates who developed LTI 
(n = 19) with infected term neonates without LTI (n = 72) (data not shown). Finally, in order to 
establish whether a relationship between the metabolites and LTI development may occur 
independently of cCMV, the same analysis was performed in the control group. The difference 
between non-infected premature neonates that developed LTI and those who did not, could not 
be assessed because none of the nine prematures developed LTI. Whereas no differences were 
observed when comparing non-infected term neonates who developed LTI (n = 15) with non-
infected term neonates who did not (n = 154).
3.4.  DISCUSSION 
Few studies have evaluated the metabolic effect of cCMV, and this is the first exploratory study on 
biomarkers in neonatal DBS of cCMV infected children in relation to long-term outcome (9, 10). 
A reliable biomarker for cCMV long-term outcome that does not require additional neonatal tests 
*
Figure 2. Palmytoilcarnitine (C16) in relation to CMV viral load. Low viral load: CMV-positive infants with viral 
load below the median measured in DBS (n=50). High viral load: CMV-positive infants with viral load above 










































could provide the means to introduce the long debated newborn screening program for cCMV 
in DBS (26). Indeed, this would define subgroups of children that would benefit from clinical, 
audiological follow-up and possibly antiviral treatment. 
cCMV outcome is the result of a multifactorial process that accounts for viral, maternal, fetal, and 
child factors. The host metabolism has already been shown to be altered following CMV infection, 
both in vivo and in vitro (4, 6-10), therefore it may play a role in cCMV outcome. This exploratory 
study shows that, overall, there were no differences in concentrations of metabolic and endocrine 
parameters included in the neonatal screening between cCMV-positive children and controls. 
Likewise, between cCMV-infected children who developed LTI and cCMV-infected children who 
did not, suggesting that these neonatal screening data cannot be used as predictors for long-term 
outcome in the general population. The effects we demonstrated were detected when prematurity 
was taken into account and, though the numbers of individuals may be a limiting factor, if confirmed 
in other cohorts, these findings give useful insights into metabolic changes in relation to cCMV 
in infected preterm neonates. The main metabolic changes concerned lower concentration of 
essential amino acids in premature cCMV-infected newborns (Fig. 1).
Importantly, gestational age and birthweight are the best characterized variables responsible for 
the variation of metabolites, mainly attributed to fetal stress and immature functions of liver and 
kidney. A lower concentration of T4, BIOT and an increased concentration of 17OHP has already been 
demonstrated in preterm infants (27-31). In this cohort, similar variations were found, indicating that 
these changes are attributable to prematurity rather than the infection. 
Moreover, we aimed to evaluate whether higher CMV viral loads may alter the host metabolism 
more efficiently than lower viral loads, and found a significantly higher concentration of C16 in 
the former (Fig. 2). Though this may be a coincidental finding, the relationship between CMV 
infection and palmitic acids was described before. In a study of pregnant women with primary CMV 
infection, the palmitic acids was found decreased in AF of transmitters mothers as well as increased 
in AF of symptomatic neonates (9). Palmitate (16:0), which is the end product of fatty acid synthase 
pathway, is the precursor of longer chain fatty acids. The CMV envelope is enriched for longer chain 
fatty acids and its infectivity is reduced by the inhibition of fatty acid elongases (ELOVLs), an enzyme 
involved in their biosynthesis (32). Therefore, the increase of C16 in the high viral load group may 
simply reflect the increased viral burden. 
Finally, because in this cohort maternal seroimmunity to CMV before birth and trimester of 
vertical transmission were unknown, the influence of these conditions could not be assessed. 
Therefore, significant metabolites differences, in relation to cCMV and cCMV outcome, cannot 
be entirely excluded if such conditions were taken into account. Nevertheless, this cohort study, 
retrieved from a large population screening, does reflect a real population of newborns with cCMV 
in all its diversity, ranging from no symptoms at birth and no LTI to symptoms at birth with severe 
LTI. Furthermore, in view of the described differences in sensitivity of the CMV PCR on DBS (33), 
it is important note that with the high sensitivity of our PCR (estimated > 85%), high specificity 
(> 99.9%) and the cCMV birth prevalence of 0.5%, the chance of a CMV false-negative result is 1/1000 











































In conclusion, although these findings demonstrate limitations in the use of routine neonatal 
screening data as predictors for long-term cCMV outcome, a possible influence of cCMV in 
the amino acids metabolism of preterm neonates, and of higher viral loads in the metabolism of 
longer chain fatty acids were shown. Finally, by considering the use of routine neonatal screening 
data, this study represents a first step in identifying prognostic markers for cCMV outcome.
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Congenital Cytomegalovirus infection (cCMV) is the leading infection in determining permanent 
long-term impairments (LTI), and its pathogenesis is largely unknown due to the complex interplay 
between viral, maternal, placental, and child factors. The cellular activity, considered to be 
the result of the response to exogenous and endogenous factors, is captured by the determination 
of gene expression profiles. In this study, we determined whole blood transcriptomes in relation to 
cCMV, CMV viral load and LTI development at 6 years of age by using RNA isolated from neonatal 
dried blood spots (DBS) stored at room temperature for 8 years. As DBS were assumed to mainly 
reflect the neonatal immune system, particular attention was given to the immune pathways 
using the global test. Additionally, differential expression of individual genes was performed using 
the voom/limma function packages. We demonstrated feasibility of RNA sequencing from archived 
neonatal DBS of children with cCMV, and non-infected controls, in relation to LTI and CMV viral 
load. Despite the lack of statistical power to detect individual genes differences, pathway analysis 
suggested the involvement of innate immune response with higher CMV viral loads, and of anti-
inflammatory markers in infected children that did not develop LTI. Finally, the T cell exhaustion 
observed in infected neonates, in particular with higher viral load, did not correlate with LTI, 
therefore other mechanisms are likely to be involved in the long-term immune dysfunction. 
Despite these data demonstrate limitation in determining prognostic markers for LTI by means of 
transcriptome analysis, this exploratory study represents a first step in unraveling the pathogenesis 
of cCMV, and the aforementioned pathways certainly merit further evaluation. 
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Human Cytomegalovirus (CMV) is one of the most common causes of congenital viral infection, 
leading to a significant number of children with permanent disabilities. The overall birth prevalence 
of congenital CMV infection (cCMV) in industrialized countries is between 0.6% and 0.7% (1, 2). 
Among the congenitally infected infants, 12.7% are estimated to have symptoms at birth, ranging 
from mild, such as petechiae, to severe, such as microcephaly (1, 2). An estimated 40-58% of these 
symptomatic children develop permanent long-term disabilities, such as hearing loss, cognitive 
and motor developmental delay (1). Although symptomatic neonates have a considerable risk to 
develop permanent long-term impairments (LTI), approximately 13% of the asymptomatic children 
will also develop permanent LTI (1). Despite the current insights into the clinical outcome of cCMV, 
the multifactorial process that determines whether a child is symptomatic at birth or will develop 
LTI is largely unknown. 
The control of cCMV, and cCMV-related disease, may be the result of a complex interaction 
between viral, maternal, placental, fetal and child factors (3). The clinical impact of cCMV has 
mainly been evaluated in relation to maternal factors, such as the CMV immune status before 
pregnancy or the time of vertical transmission. The vertical transmission rate is higher among 
women without prior CMV infection than among previously exposed women (2), indicating that 
pre-existing immunity can be protective. Vertical transmission occurring in the first 20 weeks of 
pregnancy leads to a worse clinical outcome than transmission occurring later in pregnancy (4, 5). 
The latter is probably related to an increased susceptibility to infection due to fetal organogenesis, 
and a still developing fetal immune system. Although the pathogenesis of LTI is poorly understood, 
the fetal and neonatal immune system likely play an important role in controlling the infection, 
thereby influencing LTI development (3). Several studies have demonstrated a CMV-specific 
adaptive immune response in congenitally infected children, such as ϒϒ and ϒϒ T cells or B cells (6-10), 
as well as an innate immune response (11, 12). However, only few studies have evaluated these 
responses in relation to clinical outcome at birth, whereas the majority has not done so in relation 
to LTI development. An increase of NK cells was observed in congenitally infected children, and 
their frequency was higher in those who were symptomatic at birth (11). In proteomic studies, an 
increase of macrophage-derived cytokines was observed in congenitally infected children, whereas 
an increase of ϒ-defensin was observed in those who were asymptomatic at birth (12). Moreover, 
the cytokine profile of congenitally infected children, both asymptomatic and symptomatic, was 
different from that of their mothers with primary infection (13).
The gene expression profile captures a snapshot of the cellular activity which is the result of 
the response to genetic, environmental and epigenetic factors (14). After having established, 
through forensic studies, that reliable RNAs can be extracted from dried stains, a considerable 
amount of studies focused on neonatal dried blood spots (DBS) because they represent an important 
archived, and readily accessible specimen to study factors of disease development. Indeed, DBS are 
usually collected at birth for the screening of rare genetic metabolic disorders, and are stored for 
several years (15). Previous studies have shown that quantitative RNA measurements, either with 























9 years (14, 16-18). Additionally, since the transcriptional profiles of RNA derived from DBS in mice, 
stored for several months at room temperature, correlated with those from fresh whole blood (19), 
we assumed this may also be the case in humans. The transcriptome varies according to the cell 
types studied, and certain RNA markers are tissue-specific. Tissue-specific RNA molecules have 
been successfully extracted from blood and saliva stains, dried at room temperature for up to 16 
years, and used for genome-wide expression analysis (20, 21). Since DBS are produced by spotting 
whole blood on filter paper, they were assumed to mainly reflect the neonatal immune system. 
The aim of this exploratory study was to evaluate the feasibility of transcriptome analysis 
from archived neonatal DBS in relation to cCMV and LTI development. In particular, we wanted to 
determine whether the neonatal immune system at birth may be a determinant of LTI development 
at 6 years of age. This would provide insights into the immune regulation of cCMV, and, by identifying 
prognostic markers for clinical outcome, could provide the means to introduce the long-debated 
newborn screening program for CMV in DBS by defining subgroups of infants that would benefit 
from clinical and audiological follow-up, and possibly antiviral treatment (22). Our investigations 
revealed that transcriptome analysis of RNA from neonatal DBS stored at room temperature for 
8 years of a nation-wide retrospective cohort of children with cCMV and controls is possible, and 
could potentially be used to unravel the pathogenesis of cCMV and CMV-related disease. 
4. 2 .  M ATERIAL S AND METHODS
4.2.1. Study population and clinical data
A previously described nationwide, retrospective cohort was used in this study (23). The cohort 
was derived from a total group of 31,484 children, born in 2008 in the Netherlands, which was 
retrospectively tested for cCMV by PCR of CMV DNA in neonatal DBS at five years of age. In total, 
156 children (0.5%) were diagnosed with cCMV. Clinical data were retrieved from 133 congenitally 
CMV-infected children and from 274 non-infected children. Children were defined as symptomatic 
at birth if they had one or more of the following signs or symptoms in the neonatal period: 
prematurity, being small for gestational age, microcephaly, hepato- or splenomegaly, generalized 
petechiae or purpura, hypotonia, abnormal laboratory findings (elevated liver transaminases, 
hyperbilirubinemia, neutropenia or thrombocytopenia), cerebral ultrasound abnormalities, 
ophthalmologic abnormalities or neonatal hearing impairment. LTI was defined as the presence 
of impairment in one or more domain (hearing, visual, neurological, motor, cognitive and speech-
language). The cCMV associated LTI in the original cohort has been described in detail (24). In 
brief, hearing impairment was defined as sensorineural hearing loss ≥ 40 dB; visual impairment was 
defined as a visual acuity below 0.3; neurological impairment  included cerebral palsy, epilepsy, 
microcephaly, autism spectrum disorder and ADHD; motor developmental delay was based upon 
the physical therapist’s report and if available on a score below the fifth centile in the Movement 
Assessment Battery for Children; cognitive developmental delay was defined as an intelligence 
quotient less than or equal to 70 if this was tested, or it was based on a diagnosis by a medical 
specialist; speech and language development were assessed by the speech therapist or speech and 
hearing centre. Additionally, the severity of the LTI was assessed by accumulating the number of 























maternal seroimmunity to CMV before birth was unknown, it was assumed that cCMV infection 
could have resulted from either maternal primary or secondary infection. Due to the retrospective 
design of the study, there was no standardized clinical and laboratory assessment performed at 
birth. Therefore, we cannot exclude the possibility that we might have misclassified some newborns 
without clinically apparent disease or with mild and transient symptoms in the asymptomatic group. 
However, because of the Dutch child health care system, the chance of having missed major signs 
or symptoms can be considered negligible (23, 24).
For the study presented in this article, DBS were selected based on the clinical outcome of 
the infants, with a total of 6 CMV-negative without any clinical signs, 6 CMV-positive with LTI and 6 
CMV-positive without LTI. This study was approved by the Medical Ethics Committee of the Leiden 
University Medical Center, and all the parents of the children included have given written informed 
consent for the use of clinical data and DBS.
4.2.2. DNA extraction from DBS and qPCR of CMV
After a first initial CMV PCR screening performed at the National Institute for Public Health and 
the Environment (RIVM), a second confirmatory PCR was performed at the Leiden University Medical 
Center (LUMC) (23). For this purpose, DNA was extracted from DBS by using the QIAamp DNA 
minikit according to the previously described protocol (25). For each test, one full DBS was punched 
by using an automated DBS puncher (1296-071, Perkin Elmer-Wallac, Zaventem, Belgium). CMV DNA 
amplification of a 126-bp fragment from the immediate-early antigen region was performed using 
an internally controlled quantitative real-time PCR, as described previously (26, 27), on the CFX96 
Real-Time PCR Detection System (BioRad, Veenendaal, The Netherlands). The PCR was performed 
in triplicate, and the CMV viral load was expressed in IU/ml.
4.2.3. RNA extraction from DBS
One full DBS was punched using an automated DBS puncher (1296-071, Perkin Elmer-Wallac, 
Zaventem, Belgium). RNA was extracted from DBS by using the NucleoSpin miRNA kit (Macherey-
Negel, Duren, Germany), according to the manufacturer’s instructions with a minor modification. 
This included pre-incubating the DBS with 300 µl of lysis buffer ML for 30 min at 37°C with agitation 
(1000 rpm) (28). The supernatant was transferred to the NucleoSpin Filter, and the procedure was 
carried out according to the manufacturer’s instruction. Small and large RNAs were purified in 
one fraction, without separation of small RNAs, and a DNase treatment was used to reduce DNA 
contamination. The RNA was eluted in 50 µl of RNase-free H
2
O, and RNA integrity was assessed 
using the RNA Nano 6000 Assay Kit on the Bioanalyzer 2100 system (Agilent Technologies, CA, 
USA). The RNA concentration was measured using a Qubit 2.0 flurometer (Life Technologies, 
CA, USA).
4.2.4. Library preparation and sequencing
An average amount of 185 ng of RNA was used as input material for library preparation. Sequencing 
libraries were generated using the TruSeq Stranded Total RNA Sample preparation kit for Illumina 























codes were added to attribute sequences to each sample. Briefly, rRNA was depleted from total 
RNA using rRNA removal magnetic beads (RRB). The remaining RNA was purified using RNAClean 
XP magnetic beads. As the RNA samples from DBS were already fragmented, the fragmentation step 
was skipped in order to avoid over-fragmentation. First strand cDNA was synthetized using random 
hexamer primers and SuperScript II reverse transcriptase. Second strand synthesis was performed 
using the polymerase provided with the kit. After adenylation of the 3’ end of the blunt-ended DNA 
fragments, the RNA index adapters were ligated, and PCR was carried out using the PCR master mix 
and primer cocktail provided by Illumina to amplify the DNA in the library that had adapter molecules 
on both ends. Library quality was assessed using the DNA 1000 Assay kit for the Agilent Bioanalyzer 
2100 system (Agilent Technologies, CA, USA), and the DNA amount was measured using a Qubit 
2.0 flurometer. Clustering of the index-coded samples was performed using the Illumina TruSeq 
PE Cluster Kit v3 (cBot-HS) according to the manufacturer’s instructions. After cluster generation, 
the libraries were sequenced on the Illumina HiSeq 2000 platform (6 samples per lane), and 76 base 
paired-end reads were generated for the first batch (n=6, 2 of each group) and 50 base paired-end 
reads for the second batch (n=12, 4 of each group). All 76 base reads were trimmed to 50 bases to 
allow for uniform subsequent analysis across all samples, and the batch effect was accounted for in 
downstream analysis. Due to lack of resources it was not possible to sequence the whole cohort.
4.2.5. Read mapping to the reference genome
Sequence files were generated in FASTQ format, and all RNA sequence files were processed using 
the BIOPET Gentrap pipeline version 0.7 developed at the LUMC (http://biopet-docs.readthedocs.
io/en/latest/releasenotes/release_notes_0.7.0/). The BIOPET Gentrap pipeline consists of FASTQ 
pre-processing (including quality control, quality trimming and adapter clipping), RNA-seq 
alignment, read and base quantification. FastQC version 0.11.2 was used for raw read quality control. 
Low quality read trimming was done using sickle version 1.33 with default settings. Cutadapt version 
1.9.1 with default settings was used for adapter clipping based on the detected adapter sequences 
by FastQC toolkit. RNA-seq reads were aligned against human reference genome GRCh38 using 
RNA-seq aligner GSNAP version 2014-12-23 with settings “--npaths 1 --quiet-if-excessive”. Ensembl 
human genome annotation version 87 was used for raw read counting. The gene read quantification 
step was performed using htseq-count version 0.6.1p1 with the setting “--stranded=reverse”.
4.2.6. Differential expression analysis: individual genes
We identified significant gene expression differences between congenitally infected children (n=12) 
and controls (n=6), as well as between congenitally infected children that developed LTI (n=6) and 
congenitally infected children that did not develop LTI (n=6). Moreover, we also assessed gene 
expression differences in relation to logarithm of CMV viral load treated as continuous variable. 
Genes with low fragment counts were removed by requiring at least 2 fragments per million of aligned 
fragments to be observed in at least 2 samples. Library size normalization factors were obtained 
with the trimmed mean of M-values (TMM) method (29). Linear modelling using Bioconductor/R 























level weights obtained from the voom function were used to model mean-variance relationship. All 
three analyses were corrected for the batch effect in the design matrix. Multiple testing correction 
using false discovery rate control of Benjamini and Hochberg was performed at the threshold 
of 0.05. 
4.2.7. Differential expression analysis: pathways
The Bioconductor/R package ‘global test’ designed by J. Goeman was used to evaluated differences 
in expression profiles of gene sets  between the different groups (31). These were a group of 
congenitally infected children (n=12) and a group of controls (n=6). Within the group of congenitally 
infected children, those that developed LTI (n=6) and those that did not develop LTI (n=6). An 
additional analysis was performed to find gene set expression profiles dependent on CMV viral load 
as continuous variable. This method has been shown to have more power to detect gene sets with 
small effect size (29, 32, 33). We selected a limited number of candidate gene sets (pathways) for 
use in the global test, before inspecting the data using the QuickGO browser (34). The pathways 
were selected based on their putative role in the etiology of the disease. An additional selection 
criterion was the specimen, i.e. DBS, which derives from whole blood and therefore mainly reflects 
the neonatal immune system. These pathways were T-, B-, and NK-cell activation, innate immune 
response, and inflammatory response with its regulation. Each pathway contained from 17 to 435 
genes. This analysis was performed on the voom-transformed data. Due to the exploratory nature 
of this study, and to the limited number of selected pathways, no multiple testing correction 
was applied.
Finally, an additional immune pathway that has emerged as one of the possible players in limiting 
the immune response during cCMV is the T cell exhaustion (7). However, this does not exist yet as 
a pathway in the QuickGo browser. Therefore, based on the transcriptional definition of exhaustion 
previously described (7, 35), and on our available data, a set of exhaustion genes was selected. An 
independent sample t-test was used to evaluate the difference in the square root of the reads per 
million (RPM) between the different categories. CMV+ vs CMV-, CMV+ without LTI vs CMV+ with 
LTI, CMV+ low load vs CMV+ high load. In the latter, the infected group was split in two according 
to the median log2 viral load measured in DBS which was 10.2, namely low (< 10.2) and high (≥ 10.2) 
viral load groups. However, p-values were not reported because this analysis had the sole purpose 
of illustrating trends. 
4. 3.  RE SULTS
4.3.1. Study population and clinical data
The clinical data of the congenitally infected children included in this study, as well as of the non-
infected controls, are listed in Table 1. A total of 12 children with cCMV, and 6 without cCMV, were 
included in order to assess the gene expression profile in relation to cCMV. Additionally, the 12 
children with cCMV were selected in order to assess differences in gene expression in relation to LTI 
development. For this purpose, 6 infected children were selected, who did not have any symptoms 























domains of impairment: neurological, motor, cognitive and speech/language (Table 1). Five children 
out of those who developed LTI also had symptoms at birth. Importantly, none of the children in 
the control group had symptoms at birth nor developed LTI. Given the diversity of the specific 
symptoms at birth and impairments at the age of six, the subjects  were selected in order to have 
a similar proportion of male and female across the groups. In this way, the influence of gender in 
the gene expression analysis was limited.
4.3.2. Library preparation and sequencing statistics
The average number of RNA-seq read pairs per sample was 38.5 million ± 4.8 million, with 38.9 
million ± 5.4 million for the CMV- samples and 38.4 million ± 4.7 million for the CMV+ samples. 
Within the CMV+ samples, those without LTI generated 37.6 million ± 5.9 million paired-end reads, 
and those with LTI generated 39.1 million ± 3.6 million paired-end reads. The mean RNA fragment 
size was 285 ± 8 bp, and the mean DNA fragment size was 165 ± 8 bp. On average, 92.25 % of bases 
exceeded Q30. The detailed information per sample is shown in Table 2.   









 Male 4 3 3
  Female 2 3 3
Gestational age (weeks)4 39 (36-40) 40 (37-41) 41 (37-41)
Birth weight (g)4 3040  (1890-4040) 3340 (2760-4240) 3298 (3070-4360)
CMV viral load5 3.1 (2.43-4.97) 3.1 (2.18-4.30) -
Long term impairment
 Hearing impairment6 0 0 0
 Visual impairment7 0 0 0
 Neurological impairment8 3 0 0
 Motor impairment9 6 0 0
 Cognitive impairment10 4 0 0
 Speech/language problem11 4 0 0
More than one impairment12 5 0 0
1 Congenitally infected children that develop LTI, 5 out of 6 had symptoms at birth including prematurity (n=1), dysmaturity 
(n=1), microcephaly (n=3); 2 Congenitally infected children that did not develop LTI, none of them had symptoms at birth; 
3 Non-infected controls, none of them had symptoms at birth nor LTI; 4 Values are medians with minimum and maximum; 5 
CMV viral load measured on DBS, values are log (IU/ml) medians with minimum and maximum; 6 Sensorineural hearing loss 
≥ 40 decibels; 7 Optic nerve atrophy or cortical visual impairment; 8 Cerebral palsy (n=1), epilepsy (n=1), microcephaly (n=1), 
autism (n=2), ADHD (n=1); 9 Motor impairment (fine, gross or balance) based on test or diagnosis or sensory processing 
disorder or developmental coordination disorder (n=6); 10 Cognitive impairment based on test or diagnosis (n=4); 11 Language 
impairment based on test or diagnosis, speech-impairment, oral motor skill difficulties or auditory processing disorder (n=4); 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3.3. Differential expression: individual genes
Next, we determined whether any other gene could be associated with cCMV, LTI development at 6 
years of age or CMV viral load. After low count features removal, ~25% of counts aligned on features 
and 18360 different genes were used in gene expression analysis. The R package LIMMA was used for 
the assessment of differential expression of individual genes between congenitally infected children 
(n=12) and non-infected controls (n=6). No statistically significant differences in gene expression 
were observed between the groups. We next assessed gene expression differences in relation to 
cCMV clinical outcome by comparing congenitally infected children that developed LTI at six years 
of age (n=6) to congenitally infected children that did not develop LTI (n=6). This analysis did not 
reveal any statistically significant differences between the groups. Finally, the differences in gene 
expression were assessed in relation to the logarithm of CMV viral load as continuous variable, and 
no statistically significant differences were observed.      
4.3.4. Differential expression: pathways
In order to evaluate whether different biological mechanisms may underlie different clinical 
outcomes, a global test was performed on manually pre-selected pathways based on their putative 
role in the etiology of cCMV disease. The selected pathways for T-, B-, and NK-cell activation, innate 
immune response, and inflammatory response were assessed in relation to cCMV, LTI development 
at 6 years of age and CMV viral load. The results are shown in Table 3. This analysis revealed trend 
significant results in relation to CMV viral load and LTI development. In particular, the innate immune 
response (p=0.046, Fig 1) and the NK-cell activation (p=0.086) may be associated to CMV viral load; 
whereas the regulation of inflammatory response (p=0.077, Fig 2) to LTI development. In all cases, 
a small number of genes appeared to be responsible for these trends. Several antiviral genes were 
positively associated with CMV viral load, i.e. ISG15 and RSAD2, whereas the anti-inflammatory 
cytokine IL-4 was associated with the congenitally infected children that did not develop LTI. 
Table 3. Global Test analysis
Pathways
cCMV1 LTI2 CMV viral load3 
p-values
Innate immune response (435 genes) 0.7064 0.432 0.046
T cell activation (51 genes) 0.375 0.203 0.195
B cell activation (30 genes) 0.367 0.125 0.254
NK cell activation (17 genes) 0.717 0.499 0.086
Inflammatory response (381 genes) 0.725 0.341 0.232
Regulation of inflammatory response (68 genes) 0.577 0.077 0.567
Negative regulation of inflammatory response (78 genes) 0.633 0.339 0.133
Positive regulation of inflammatory response (74 genes) 0.444 0.652 0.791
1 Gene sets expression differences between CMV- (n=6) and CMV+ (n=12); 2 Gene sets expression differences between 
























Figure 1. Global test: Innate immune response. Innate immune response in relation to CMV viral load as 
continuous variable measured on DBS, p=0.046. The gene names of x-axes are provided in supplementary 
S1 Table.
Figure 2. Global test: Regulation of inflammatory response. Regulation of inflammatory response in congenitally 
























Finally, as previously shown by others, one of the possible mechanisms limiting the T cell 
response to CMV during early life is considered to be T cell exhaustion (7). Therefore, we wondered 
whether the same phenomenon could be observed in our cohort when comparing the CMV- group 
(n=6) to the CMV+ group (n=12). Additionally, this pathway was assessed in relation to CMV viral load 
and development of LTI at 6 years of age. For this purpose, based on the transcriptional definition of 
exhaustion previously described (7, 35), as well as on our available data, a set of genes was selected 
and reported in Table 4. Of these genes, the RPM were reported for each comparison in order to 
observe the trend to be further explored. A trend of increased expression of differentiation markers, 
mainly CD57 and transcription factor T-bet, and of increased effector markers, primarily IFN-ϒ and 
granzyme, was observed in the CMV+ group compared to the CMV- group (Fig 3 A-D). Furthermore, 
a trend of increased expression of inhibitory markers, mainly PD-1 and LAG-3, was observed in 
the CMV+ group (Fig 3 A-D). Next, the CMV+ group was split in two groups according to the median 
log2 viral load measured in DBS which was 10.2, namely low and high viral load groups. Comparing 
the group with high viral load to the one with low viral load, the aforementioned observed trends 
relative to differentiation, effector and inhibitory markers were more pronounced than when 
comparing CMV+ to CMV-. Finally, when comparing the cCMV+ group that developed LTI to those 
who did not, no striking trends were observed (Fig 3 A-D).























































































































































































































































































































































































































































This study aimed to evaluate whether transcriptome analysis by next generation RNA sequencing on 
DBS derived from a retrospective nation-wide cohort of children with cCMV and controls is feasible, 
and whether useful insights could be obtained on the etiology of different cCMV outcomes. This 
would allow the identification of potential biomarkers for long-term outcome, which could provide 
the means to introduce the long-debated newborn screening program for cCMV in DBS (22). 
Indeed, this would define subgroups of children benefitting from clinical,  audiological follow-up, 
and possibly antiviral treatment. 
The global test for differential expression of gene sets revealed, although only with trend 
significant results, an important feature of cCMV in relation to whole blood transcriptome, i.e. 
CMV viral load is the main factor to influence the pre-selected immune pathways, whereas CMV 
disease seems to be secondary. In our study, numerous antiviral genes were positively associated 
with CMV viral load, suggesting the involvement of the innate immune system in response to cCMV 
in the newborns, in particular with higher viral loads. The fact that no striking differences were 
observed when comparing CMV+ to CMV-, suggests that the high viral load is the main initiator 
of this expression pattern. Therefore, the presence of neonates with low viral load in the CMV+ 
group may have diluted the differences between CMV+ and CMV-. Congenitally infected children 
excrete CMV for several years after birth, whereas in adults this lasts only several months (36, 37), 
suggesting a deficient cell-mediated immune response in early life (38). Therefore, it is tempting 
to speculate that the activation of the innate immunity in the fetus may have an important role in 
controlling cCMV, however this is difficult to determine. One of the possible mechanism for this 
limited T cell response to CMV during early life is considered to be T cell exhaustion (7). In our 
cohort, also the exhaustion pathway was more pronounced in the high viral load group compared 
to the low viral load group, with PD-1 being the marker influenced the most, as previously shown (7). 
Therefore, also in this case the difference in exhaustion pathway between CMV+ and CMV- could 
have been diluted because of the presence of low viral load individuals in the CMV+ group. However, 
the exhaustion pathway analysis needs further confirmation as we only reported expression 
trends. T cell exhaustion is characterized by loss of T cell functions, and is induced by persistent 
infections (7, 35). Primary CMV infection induces functional T cell exhaustion in both adults and 
fetuses, though considerably more pronounced in the latter. As this phenomenon is associated 
with prolonged exposure with higher viral loads, the high viral loads reported in fetuses may be 
the cause of this effect (39-41). The exhaustion may contribute to the prolonged CMV viral excretion 
in the children (7). The influence of viral load in the immune responses has been shown before, both 
in humans and in the murine models of CMV infection. Here, the degree of CMV-specific memory 
CD8 T cells accumulation, as well as the phenotypic T cell profile, was influenced by the viral load 
(42, 43). However, the role of CMV viral load in the clinical outcome still remains controversial. Some 
studies have correlated CMV viral load, measured in blood, with clinical outcome (44, 45), whereas 
others have not (46-48). The neonatal viral load may differ depending on the trimester of vertical 
transmission, or whether it was a primary maternal infection. Indeed, earlier infections may lead to 























CMV viral load in whole blood may not correlate to CMV loads in other neonatal compartments, and 
therefore may not fully reflect viral replication in all affected organs and tissues. 
The molecular mechanisms of LTI development are largely unknown, though the late-onset 
hearing loss is believed to be the result of a chronic productive infection throughout childhood 
(50, 51). In this context, a long-term dysfunctional immune response seems plausible, although 
it cannot be excluded that such dysfunction leads to a parallel uncontrolled inflammation that 
contributes to tissue damage. In studies of characterization of tissue damage in fetuses of 20-21 
weeks of gestation with cCMV, an association between the degree of tissue damage in the brain, 
as well as in the inner ear, with viral load, inflammatory response and placental functionality was 
shown (52, 53). A dysfunctional immune response that leads to uncontrolled viral replication, and 
immune-mediated damage was suggested. Therefore, a similar pathogenesis may be assumed 
when such infection becomes chronic. The exhaustion pathway that was found in congenitally 
infected children, especially those with higher CMV viral load, did not seem to correlate to clinical 
outcome at 6 years of age. This suggests that other mechanisms are involved in the long-term 
immune dysfunction. In our cohort, when comparing congenitally infected children that developed 
LTI to those infected who did not, a role for  the regulation of inflammatory responses seemed 
to partially contribute. Anti-inflammatory markers, such as the cytokine IL-4, were associated 
with congenitally infected children that did not develop LTI. The success of an immune response 
is the result of a balance between effector and regulatory mechanisms, therefore, the potential 
protective effect of IL-4 in those infected children that did not develop LTI may lie in its anti-
inflammatory property. Interestingly, in a cohort of healthy CMV infected individuals, the CD4 T-cell 
response associated with a protective immunity involved cytokine production of IFN, and/or IL-17, 
in association with IL-4 (54). Similarly to IL-10, IL-4 has been shown to possess the capacity of down-
regulating the production of pro-inflammatory mediators by microglia, both in humans and in mice 
(55-57), and its neuroprotective effect was associated with downregulation of brain inflammation 
in mice (58). When studying the regulation of the inflammatory response in children with cCMV 
and compare the group with LTI to that without LTI, we have to be aware that there may be other 
perinatal factors influencing the inflammatory pattern in DBS. Although we cannot fully exclude 
a role for non-cCMV related perinatal factors, there was no bacterial amniotic infection or neonatal 
sepsis in all children included in this study. 
Several reasons may have contributed to the fact that we did not find a strong impact of cCMV 
on whole blood transcriptomes from DBS. First of all, one of the groups of congenitally infected 
children did not have symptoms at birth nor LTI, which is the case in most children with cCMV, and 
the clinical signs of symptoms associated with LTI are very diverse. Second of all, in our cohort, 
the fetal infection may have been the result of a primary or secondary CMV infection in the mother, 
and may have taken place at any time during pregnancy, especially in the asymptomatic children. 
Third of all, the small sample size of the groups may have led to a lack of power both in the gene 
expression analysis of individual genes, as well as in the pathway analysis. Lastly, the RNA degradation 
on these specimens, due to e.g. ribonucleases, pH, humidity or UV light, may have contributed to 
the lack of significant differences among the sample groups. The degradation of RNA from dried 























been extracted from numerous conditions (59-64). From these studies, determinants for RNA 
stability appeared to be the specimen the RNA is extracted from, and the specific RNA molecule 
analyzed. In the former, the detection limit of blood-specific RNA has been shown to be lower than 
for other specimens (21). In the latter, some RNAs can be more stable in dried stains than others 
(21). Secreted RNAs, e.g. in fresh saliva, may be more susceptible to fast degradation by extracellular 
RNases, and therefore are not to be expected on dried stains (20). Importantly, for those RNAs 
detected on dried blood stored at room temperature, only few genes have been demonstrated to 
be differentially expressed during time  (20). Therefore, we assumed that those markers detected 
on DBS in our study were less prone to degradation, and relatively stable for long periods of time. 
Furthermore, the influence of RNA contamination in the downstream analysis, e.g. from skin cells or 
external microorganisms, may be considered negligible as the most abundant RNAs species come 
from the host whole blood (65). Despite the fact that enough data were generated in our study for 
the downstream analysis, with comparable cDNA fragment size as shown in forensic studies (21, 
59-64), we cannot exclude that fresh material may have revealed differences in expression patterns 
that we could not pick up.  
Furthermore, due to the retrospective nature of the study, cCMV diagnosis was carried out by 
performing PCR of viral DNA on DBS, which in comparison with PCR on urine or saliva has been 
associated with limited and variable sensitivity (66). Therefore, a negative CMV PCR on DBS does 
not fully exclude cCMV. However, it is important to note that with the relatively high sensitivity of 
our CMV PCR on DBS (estimated > 85%), high specificity (> 99.9%) and the cCMV birth prevalence 
of 0.5%, the chance of a CMV false-negative result is 1/1000 (23). Therefore, it is very unlikely that 
a cCMV positive child ended up in our cCMV negative control group. 
To the best of our knowledge, this is the first exploratory study assessing the feasibility of 
transcriptome sequencing using RNA isolated from archived neonatal DBS of children with cCMV, 
and non-infected controls, in relation to long-term outcome. Despite the lack of statistical power 
to detect individual gene expression differences, the pathway analysis suggested a potential 
differential gene expression in relation to CMV viral load and LTI. Therefore, this study represents 
a first step in unraveling the pathogenesis of cCMV, and in identifying prognostic markers for cCMV 
long-term outcome.   
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Table  S1. Gene names. Gene names of x-axis of Fig 1 concerning the innate immune response in relation to CMV 
































































































































































































































































































































































































Table  S1. (continued)
Table S2. Read counts per gene. (XLSX). Avaiable online.
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Congenital CMV infection (cCMV) is the most common congenital infection causing permanent 
long-term impairments (LTI). cCMV immunopathogenesis is largely unknown due to the complex 
interplay between  viral, maternal, placental and child factors. In this study, a large retrospective 
nation-wide cohort of children with cCMV and their mothers was used. HLA-C, HLA-E, and 
HLA-G were assessed in 96 mother-child pairs in relation to symptoms at birth and LTI at six 
years of age. The mothers were additionally typed for killer cell immunoglobulin-like receptors. 
The maternal HLA-G 14 bp deletion/deletion polymorphism was associated with a worse outcome, 
as the immunomodulation effect of higher proteins levels may induce less CMV control, with 
a direct impact on placenta and fetus. The absence of maternal HLA-C belonging to the C2 
group was associated with symptoms at birth, as activating signals on decidual NK may override 
inhibitory signals, contributing to a placental pro-inflammatory environment. Here, the increased 
HLA-E*0101 and HLA-C mismatches, which were associated with symptoms at birth, may enhance 
maternal allo-reactivity to fetal Ags, and cause sub-optimal viral clearance. Finally, HLA-C non-
inherited maternal antigens (NIMAs) were associated to LTI. The tolerance induced in the fetus 
towards NIMAs may indirectly induce a sub-optimal CMV antiviral response throughout childhood. 
In light of our findings, the potential role of maternal-child HLA in controlling CMV infection and 
cCMV-related disease, and the clinical value as predictor for long-term outcome certainly deserve 
further evaluation.  
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Human CMV is one of the most common causes of congenital viral infection, leading to a significant 
number of children with hearing loss and neurodevelopmental delay. The overall birth prevalence 
of congenital CMV infection (cCMV) in industrialized countries lies between 0.6 and 0.7% (1, 2). 
Among the congenitally infected infants, 12.7% are estimated to have symptoms at birth including 
petechiae, jaundice, hepatosplenomegaly, thrombocytopenia, chorioretinitis, and microcephaly 
(1, 2). An estimated 40-58% of these symptomatic children will develop long-term impairments 
(LTI), such as hearing loss, cognitive and motor developmental delay (1). Of the 87.3% asymptomatic 
infants, around 13.5% will also develop LTI (1). Despite the current insights into the clinical outcome 
of cCMV, the multifactorial process that determines whether a child will be symptomatic at birth or 
will develop LTI is still poorly understood.
The vertical transmission rate is higher among women without prior CMV infection than 
among previously exposed women, suggesting a role for maternal immunity in the risk of vertical 
transmission (2). Vertical transmission takes place via placental infection. Once CMV infects 
the placenta, the extensive local damage and inflammation lead to placental dysfunction, which 
in turn can impair fetal development (3). The clinical impact of fetal infection is largely determined 
by vertical transmission in the first 20 weeks of pregnancy, during which the fetal immune system 
is still developing (4, 5). Importantly, the fetal and neonatal immune system may also play a role 
in controlling the infection, thereby influencing LTI development (6). A persistent productive 
infection may lead to late-onset or progression of sensorineural hearing loss, even though a role 
of immunopathology cannot be entirely excluded (7, 8). Hence, clinical outcome is the result of 
a multifactorial process that comprises maternal, placental, fetal, and child factors. 
Pregnancy is considered a semi-allograft, in that the fetus may have HLA antigens (Ags) that 
the mother does not have. At the maternal-fetal interface the majority of trophoblast cells are in 
direct contact with maternal cells, and several mechanisms are in place to prevent rejection of 
the fetal semi-allograft. Extravillous trophoblast cells do not express HLA-A, -B, -DR, -DQ and –DP 
(9), but they do express HLA-C and the non-classical HLA-E and HLA–G. HLA-C and HLA-E prevent 
maternal NK cell-mediated cytotoxicity through binding with killer cell immunoglobulin-like 
receptors (KIRs) expressed on decidual NK cells (dNK). dNK cells are the most abundant leukocyte 
population in the placenta (9), therefore they play a fundamental role in pregnancy. KIR genotypes 
can be distinguished into two haplotypes. The KIR-A haplotype mainly contains inhibitory receptors, 
such as KIR2DL1, whereas, the KIR-B haplotype also contains one or more activating receptors, such 
as KIR2DS1 (10, 11). NK cytotoxicity is controlled through a balance of both activating and inhibitory 
receptors on dNK cells (12-15). Furthermore, HLA-G modulates the response of different cellular 
subsets, including dNK, APC, T cells, and B cells (16, 17). The complex maternal-fetal immune cross-
talk at the interface creates a tolerogenic niche for the normal development of the fetus, and it 
differs from the peripheral immune system of both mother and child (18). Indeed, immune cells 
can be generated locally with a different function than the one acquired at the periphery. For 
example, CD8 T cells express significantly lower levels of perforin and granzyme-B, and DC are 






















HLA combination, which may generate different immune effector and regulatory mechanisms 
(20, 21). Maternal-fetal HLA-C mismatches (mm) induce a shift towards higher levels of effector 
and regulatory T cells in the decidua (20). In addition, specific combinations of maternal KIRs and 
fetal HLA-C can induce pregnancy complications (22, 23). Indeed, the HLA-C ligands for KIRs are 
divided into two groups, the C1 allotype binds inhibitory KIRs whereas the C2 allotype binds both 
activating and inhibitory KIRs (10, 11). Therefore, while KIR2DL1/HLA-C2 leads to inhibition, KIR2DS1/
HLA-C2 leads to activation of dNK (15, 24). The risk of recurrent miscarriage increases in women 
with KIR-A haplotype when they have fewer C2 genes than the fetus, or when the fetus inherited 
C2 from the father (18, 25). Indeed, the proper dNK activation is essential to facilitate trophoblast 
invasion and a successful placentation (26). Furthermore, lower levels of soluble HLA-G (sHLA-G) 
have been described in the circulation of pregnant women with pre-eclampsia, intrauterine growth 
retardation, and recurrent spontaneous abortion (27, 28). 
With respect to CMV, the role of HLA in the local immune response in the placenta is largely 
unknown. With regard to HLA-G, higher CMV viral loads in urine of children homozygous for 
the HLA-G 14 bp deletion were found (29). In addition, higher levels of sHLA-G were shown in 
serum and amniotic fluid of women with primary CMV infection and in symptomatic neonates (30). 
The aim of this study was to determine if the combination of maternal and child HLA Ags influences 
the short- and long-term outcome of cCMV, thus providing new insights into cCMV immune 
regulation and pathogenesis. Our investigations focused on the role of HLA-C, HLA-E, and HLA-G, 
which are the only HLA molecules expressed at the placenta.
5. 2 .  M ATERIAL AND METHODS
5.2.1. Study population and clinical data
A previously described nationwide, retrospective cohort was used in this study (31, 32). The cohort 
was derived from a total group of 31,484 children, born in 2008 in the Netherlands, which was 
retrospectively tested for cCMV by PCR of CMV DNA in neonatal dried blood spot (DBS) at five years 
of age. In total, 156 children (0.5 %) were diagnosed with cCMV. Clinical data were retrieved from 
125 congenitally CMV infected children and from 263 non-infected children. For this study, buccal 
swabs from 104 children with cCMV and their mothers were obtained for HLA-typing. Two buccal 
swabs [FLOQSwabs hDNA Free, 20-mm breaking point in 174.5mm long dry tube (COPAN ITALIA 
SPA, Brescia, Italy)] were retrieved from each individual. Children were defined as symptomatic 
at birth if they had one or more of the following signs or symptoms in the neonatal period: 
prematurity, being small for gestational age, microcephaly, hepato- or splenomegaly, generalized 
petechiae or purpura, hypotonia, abnormal laboratory findings (elevated liver transaminases, 
hyperbilirubinemia, neutropenia or thrombocytopenia), cerebral ultrasound abnormalities, 
ophthalmologic abnormalities or neonatal hearing impairment. LTI was defined as the presence 
of impairment in one or more domain (hearing, visual, neurological, motor, cognitive and speech-
language). Because in this cohort maternal seroimmunity to CMV before birth was unknown, it 
was assumed that cCMV infection could have resulted from either maternal primary or secondary 






















Medical Center, and all the parents of the children included have given written informed consent in 
accordance with the Declaration of Helsinki.
5.2.2. DNA extraction from DBS and qPCR of CMV 
After a first initial CMV PCR screening performed at the National Institute for Public Health and 
the Environment (RIVM), a second confirmatory PCR was performed at the Leiden University Medical 
Center (LUMC) (31). For this purpose, DNA was extracted from DBS by using the QIAamp DNA 
minikit according to the previously described protocol (33). For each test one full DBS was punched 
by using an automated DBS puncher (1296-071, Perkin Elmer-Wallac, Zaventem, Belgium). CMV DNA 
amplification of a 126-bp fragment from the immediate-early antigen region was performed using 
an internally controlled quantitative real-time PCR, as described previously (34, 35), on the CFX96 
Real-Time PCR Detection System (BioRad, Veenendaal, The Netherlands). The PCR was performed 
in triplicate, and the CMV viral load was expressed in IU/ml.
5.2.3. DNA extraction from buccal swabs
DNA was extracted from the buccal swabs  by using the QIAamp DNA (blood) mini kit (QIAGEN, 
Hilden, Germany) according to the manufacturer’s instruction, with an additional PBS pre-
incubation of 30 minutes at room temperature. Additionally, the pre-incubation fluid from two 
swabs was applied to one QIAamp spin column, in order to concentrate the DNA. The DNA was 
eluted in 150µl of Tris-EDTA-4 buffer for further analyses.
5.2.4. HLA and KIR typing
All mothers and children were DNA typed at low resolution for HLA-C locus (14 alleles) using 
the Reverse Sequence Specific Oligonucleotides PCR technique. For this purpose, a commercially 
available assay was applied, LIFECODES C SSO Typing kits (Immucor, Norcross, GA, US). Data were 
analysed using MatchIT software (Immucor-Lifecodes). The HLA-C alleles included in this study 
were selected based on 5604 randomly selected healthy Dutch blood donors who were previously 
genotyped (36). This group is considered to be a proper representation of the gene distribution in 
the general population (37), and the HLA-C frequencies are depicted in Table S1 in Supplementary 
Material. HLA-C allotypes were divided in two groups, namely HLA-C1 and HLA-C2, based on 
the presence of SER77ASN80 (C1) and ASN77LYS80 (C2) at position 80 of the α1 domain, as previously 
described (38).
All mothers and children were typed for the two most common HLA-E functional alleles, HLA-
E*01:01 and HLA-E*01:03 (39). Eight different HLA-E proteins have been identified from 26 coding 
sequences, but the aforementioned ones, due to their functional differences, are the two most 
commonly analyzed worldwide (39). Due to a non-synonymous mutation these two functional 
alleles differ in one aa position in codon 107 of the α heavy chain, HLA-E*01:03 encoded proteins 
show higher cell surface expression and peptide-binding affinity than HLA-E*01:01proteins (40). 
Determinations of the HLA-E*01:01/01:03 variants (SNP ID rs1264457) were carried out by using 






















PCR System (ThermoFisher Scientific, MA, USA) in a 96 well-plate using a thermocycling profile as 
follows: 10 min 95°C followed by 40 cycles of 95°C (15 seconds), 60°C (1 min) and finally after cycling 
60°C (30 seconds) with 1.5 µl of diluted DNA extract and 8.5 µl of reaction mix. Data were analyzed 
using ViiA™ 7 Software.
All mothers and children were typed for the HLA-G locus by using a TaqMan assay for the 14-bp 
insertion/deletion polymorphism in exon 8 of the 3’ untranslated region with primers and probes 
previously described (41). Nine different HLA-G proteins from 28 alleles have been described (42), 
however, the polymorphism included in this study is one of the most commonly associated with 
pregnancy (43-47). The TaqMan assay consisted of 1.5µl diluted DNA extract and 15 µl reaction 
mixture containing: 7.5 µl TaqMan Universal Master Mix II with UNG (ThermoFisher Scientific, MA, 
USA), 300 nM of forward and reverse primers, 200 nM of  HLAG14FAM (insertion) and HLAGdelCY5 
(deletion) probes. The PCR was performed on a Light Cycler®96 Detection System (Roche Applied 
Science, Mannheim, Germany) in a 96 well-plate using a thermocycling profile as follows: 10 min 
95°C followed by 50 cycles of 95°C (10 s), 58°C (50 s) and finally after cycling 37°C (30 s). Data were 
analyzed with Light Cycler®96 Analysis Software 1.1.
All mothers were genotyped at low resolution for KIR receptors. The KIR genotype differs 
based on the absence of activating KIRs (haplotype AA) or on the presence of different numbers of 
activating KIRs (haplotype AB or BB). In particular, the BB or AB haplotype is defined as the presence 
of one or more of the following genes: KIR2DL2, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, 
and KIR3DS1. The AA haplotype is defined by the absence of all the above mentioned genes and 
the presence of the following genes: KIR2DL1, KIR2DL3, KIR2DS4, and KIR3DL1. The KIR genotyping 
was performed using 11 homemade PCR reactions per individual, according to a previously described 
protocol (48). In each reaction, 2 µl of diluted DNA extract was amplified in 20 µl of SybrGreen-based 
PCR mix (IQ Sybr Green Supermix, BIORAD, CA, US) containing 0.3 pmol/µl of primers. The PCR was 
performed on a Light Cycler®96 Detection System (Roche Applied Science, Mannheim, Germany) in 
a 96 well-plate using a thermocycling profile as follows: 10 min at 95°C followed by 40 cycles of 95°C 
(15 seconds) and 62°C (60 seconds). Data were analyzed with Light Cycler®96 Software 1.1. 
5.2.5. Statistical analysis
Data were analyzed by using the Statistical Package for Social Sciences (SPSS, version 23, Chicago, 
IL, USA). The chi-square test was used to evaluate the observed and expected genotypes frequency, 
the number of HLA mismatches, missing-self (ms), non-inherited maternal antigens (NIMAs), and 
the combinations between maternal KIR with child HLA-C, in relation to symptoms at birth and 
LTI. With expected low values, a Fischer’s exact test was used instead. The maternal and fetal HLA 
allele frequencies were tested for Hardy-Weinberg Equilibrium (HWE), stating that in the absence of 
other influences the genotype frequency in a certain population remains constant from generation 
to generation (49). In addition, a univariate logistic regression was performed to investigate 























5. 3.  RE SULTS
5.3.1. Study population and clinical data
The clinical data of the congenitally infected children included in this study are depicted in Table 1. 
A total of 96 mother-child pairs, were successfully typed for at least one of the HLA genes included 
in this study. Eight mother-child pairs could not be typed  due to low DNA quality and concentration. 
Nineteen (20%) children had symptoms at birth, and 11 (58%) of those  had LTI. In addition, 16 (21%) 
asymptomatic children had LTI. Overall, 27 (28%) of infected children developed any LTI.
5.3.2. Maternal and child HLA-C, HLA-E, and HLA-G genotypes in relation to cCMV 
clinical outcome
First, we evaluated whether the maternal genotype plays a role in cCMV outcome. For this purpose, 
we tested whether the genotype frequencies of the HLA-C groups, C1 and C2, and of the HLA-E and 
HLA-G alleles from the mothers were in Hardy-Weinberg equilibrium (HWE). The HLA-C groups of 
mothers with children symptomatic at birth were not in HWE (p=0.046) (Table S2 in Supplementary 
Material). In our cohort, a significantly higher percentage of mothers was homozygous for 
HLA-C1 in the group of children symptomatic at birth compared to the asymptomatic group, 
whereas the percentage of mothers homozygous or heterozygous for HLA-C2 was lower (Table 2). 









 Male 57 44 13
  Female 39 33 6
Gestational age (weeks)3 39 (28-42) 39 (37-42) 36 (28-41)
Birth weight (g)3 3435 (900-5110) 3540 (2635-5110) 2800 (900-4170)
Long term impairment
 Hearing impairment4 3 2 1
 Visual impairment5 2 2 0
 Neurological impairment6 5 2 3
 Motor impairment7 13 9 4
 Cognitive impairment8 7 4 3
 Speech/language problem9 18 10 8
One or more impairment10 27 16 11
1 Asymptomatic at birth; 2 Symptomatic at birth: premature (n=11), dysmature (n=2); microcephaly (n=5); neonatal hearing 
loss (n=1); abnormal cranial ultrasound (n=1); 3 Values are medians with minimum and maximum; 4 sensorineural hearing 
loss; 5 optic nerve atrophy (n=1), cortical visual impairment (n=1); 6 cerebral palsy (n=1), epilepsy (n=1), microcephaly (n=1), 
ADHD (n=1), autism (n=3); 7 motor impairment (fine, gross or balance) based on test or diagnosis or sensory processing 
disorder or developmental coordination disorder; 8 cognitive impairment based on test or diagnosis; 9 language impairment 
based on test or diagnosis, speech-impairment, oral motor skill difficulties or auditory processing disorder; 10 Any long-term 






















The functional difference between HLA-C1 and HLA-C2 suggests a possible association of these 
alleles with clinical outcome in our cohort (23, 50, 51), with absence of maternal HLA-C2 being 
a risk factor. Indeed, the odds of having symptomatic neonates was higher when mothers were 
homozygous for HLA-C1 than when mothers were homozygous for HLA-C2 or heterozygous (OR = 
3.950, 95% CI 1.378 – 11.320, p=0.011). Consequently, only 5.3% of children symptomatic at birth were 
homozygous for HLA-C2 (Table 2). 
The genotype frequencies of HLA-E and HLA-G alleles from the mothers were in HWE in all 
groups (Table S2 in Supplementary Material). Despite this, a significantly higher percentage of 
mothers homozygous for HLA-G deletion (HLA-G del/del) was observed in the group of children that 
developed LTI compared to those who did not; this percentage was also higher in the symptomatic 
group compared to the asymptomatic group, though not significant (Table 3). HLA-G del/del is 
Table 2. HLA-C, KIR and cCMV clinical outcome


















 Mother 0.021* 0.084
  C1C2 21.1 52.6 38.5 49.3
  C1C1 63.2 30.3 30.8 39.1
  C2C2 15.8 17.1 30.8 11.6
 Child 0.371 0.712
  C1C2 52.6 46.1 50 46.4
  C1C1 42.1 35.5 30.8 39.1
  C2C2 5.3 18.4 19.2 14.5
HLA-C mm3 84.2 68.4 0.172 80.8 68.1 0.223
HLA-C1 mm4 15.8 11.8 0.701˜ 19.2 10.1 0.300˜
HLA-C2 mm5 31.6 10.5 0.031˜* 19.2 13 0.519˜
HLA-C ms6 78.9 72.4 0.560 96.2 65.2 0.002*
HLA-C1 ms7 5.3 13.2 0.454˜ 7.7 13 0.722˜
HLA-C2 ms8 10.5 18.4 0.514˜ 19.2 15.9 0.761˜
KIR haplotype mother9 0.659 0.356
 A 36.8 31.5 40 29.9
 B 63.2 68.5 60 70.1
Maternal KIR A– Child C210 21.1 20.5 1.000˜ 20 20.9 0.925
1 Any long-term impairment, in one or more domains of impairments: hearing, visual neurologic, motor, cognitive, and 
speech-language; 2 Absence of any long-term impairment; 3 HLA-C mm: HLA-C mismatches; 4 HLA-C1 mm: HLA-C mismatches 
in the C1 group, the mother is homozygous for C2 and the child is heterozygous; 5 HLA-C2 mm: HLA-C mismatches in 
the C2 group, the mother is homozygous for C1 and the child is heterozygous; 6 HLA-C ms: HLA-C missing-self; 7 HLA-C1 
ms: HLA-C missing-self in the C1 group, the mother is heterozygous and the child is homozygous for HLA-C2; 8 HLA-C2 ms: 
HLA-C missing-self in the C2 group, the mother is heterozygous and the child is homozygous for HLA-C1; 9 Maternal KIR 
A haplotype is defined as the absence of activating KIRs (AA) and KIR B haplotype as the presence of different numbers of 
activating KIRs (AB or BB); 10 Combination of maternal KIR A haplotype with HLA-C2 positive child (either C1C2 or C2C2); 9,10 






















related to higher HLA-G protein levels (52, 53), soluble and possibly membrane-bound; therefore 
our findings suggest that the functional difference of the two alleles is associated with clinical 
outcome, with the maternal homozygous status being a risk factor. Indeed, the odds of developing 
LTI was higher when mothers were HLA-G del/del (OR 3.542, 95% CI 1.397 – 8.977, p=0.008). Likewise, 
the odds of having symptoms at birth were higher when mothers were HLA-G del/del, although 
not significant (not shown). Next, given the role of HLA-G during CMV infection, the HLA-G del/
del polymorphism was assessed in relation to CMV viral load. For this purpose, the study group 
was divided into two groups according to the viral load measured in DBS namely low (< 500 IU/
ml) and high (> 500 IU/ml) viral load groups. A higher percentage of mothers with HLA-G del/del 
was observed in the high viral load group compared to the low viral load group (41.4 and 12.0% 
respectively, p=0.008), whereas this was not observed in the children (30.0 and 32.0% respectively, 
p=0.852) (Table S3 in Supplementary Material).
Finally, we evaluated whether the child’s genotype plays a role in cCMV outcome. The genotype 
frequencies of the HLA-C groups, and HLA-G alleles in the children were in HWE in all groups, 
whereas the HLA-E alleles were not, both in the symptomatic and asymptomatic groups (p=0.037 
and p=0.024, respectively) (Table S2 in Supplementary Material). A higher percentage of children 
heterozygous for HLA-E was observed in the symptomatic group compared to the asymptomatic 
group whereas the percentage of homozygotes, either HLA-E*0101 or HLA-E*0103, was lower 
Table 3. HLA-G and cCMV clinical outcome


















 Mother 0.174 0.023*
  del/del 52.6 29.9 55.6 26.1
  ins/ins 10.5 15.6 11.1 15.9
  del/ins 36.8 54.5 33.3 58
 Child 0.459 0.514
  del/del 26.3 32.5 37 29
  ins/ins 10.5 19.5 11.1 20.3
  del/ins 63.2 48.1 51.9 50.7
HLA-G del mm3 5.3 10.4 0.683˜ 3.7 11.6 0.437˜
HLA-G ins mm4 31.6 11.7 0.070˜ 25.9 11.6 0.116˜
HLA-G del ms5 5.3 14.3 0.449˜ 3.7 15.9 0.169˜
HLA-G ins ms6 5.3 14.3 0.449˜ 7.4 14.5 0.500˜
1 Any long-term impairment, in one or more domains of impairments: hearing, visual neurologic, motor, cognitive, and 
speech-language; 2 Absence of any long-term impairment; 3 HLA-G del mm: HLA-G deletion mismatches, the mother is 
homozygous for HLA-G insertion and the child is heterozygous; 4 HLA-G ins mm: HLA-G insertion mismatches, the mother 
is homozygous for HLA-G deletion and the child is heterozygous; 5 HLA-G del ms: HLA-G deletion missing-self, the mother is 
heterozygous and the child is homozygous for HLA-G insertion; 6 HLA-G ins ms: HLA-G insertion missing-self, the mother is 






















(Table 4). HLA-E*0103 is associated with higher proteins levels (40); therefore our findings suggest 
that the functional difference of the two alleles is not associated with clinical outcome.
5.3.3. Maternal-fetal HLA-C, HLA-E, and HLA-G mismatches in relation to cCMV 
clinical outcome
We next investigated whether maternal-fetal HLA mm are associated with a worse cCMV outcome. 
For this purpose, mm were calculated on the basis of the presence of an Ag in the fetus, which was 
absent in the mother because the inherited paternal antigen (IPA) was different from both maternal 
alleles (Table 5). The mm were compared between children symptomatic and asymptomatic at 
birth, as well as between children who developed LTI and those who did not. A significantly higher 
percentage of HLA-C2 mm was observed in the symptomatic group compared to the asymptomatic 
group (Table 2). Most likely, the mm derived from the higher percentage of mothers homozygous 
for HLA-C1 while a higher percentage of symptomatic neonates was heterozygous (Table 2). 
Therefore, the functional consequence of HLA-C2 absence in the mother might be the main risk 
factor, even though the odds of having symptoms at birth were significantly higher as well with 
HLA-C2 mm (OR = 3.923, 95% CI 1.166-13.201, p=0.027). 
To exclude the possibility that symptoms at birth were associated with specific HLA-C KIR 
combinations rather than maternal genotypes or maternal-fetal mm, the number of HLA-C1/HLA-C2 
KIR epitope combinations were analyzed. No differences in preferential fetal HLA-C/maternal KIR 
combinations were observed (Table 2). In addition, a significantly higher percentage of HLA-E*0101 
mm was observed in the symptomatic group compared to the asymptomatic (Table 4). The HLA-E 
mm may be driven by the neonatal aberrant distribution of the genotypes. However, because 
the difference in HLA-E genotypes would probably have no functional consequences, the mm may 
be the primary risk factor. Indeed, the odds of developing symptoms at birth were significantly 
higher when HLA-E*0101 mm were present (OR = 4.343, 95% CI 1.357- 13.897, p=0.013). In addition, 
the HLA-E*0101 mm was assessed in relation to CMV viral load, and a higher percentage of HLA-
E*0101 mm was found in the high viral load group compared to the low viral load group (23.2% and 
0.0% respectively, p=0.005) (Table S3 in Supplementary Material). Finally, no differences in HLA-G 
mm were observed with respect to symptoms nor to LTI development (Table 3).
5.3.4. HLA-C, HLA-E and HLA-G missing-self/NIMAs in relation to cCMV clinical 
outcome
We finally assessed whether missing-self/NIMAs influence cCMV clinical outcome. For this purpose, 
missing-self was defined  as an Ag in the mother, which was absent in the child because the IPA was 
different from the NIMA (Table 5). From the mothers’ perspective, missing-self implies a mechanism 
of recognition by dNK of trophoblasts lacking maternal self-molecules. Missing-self does not 
necessarily indicate mismatches because the IPA could still be the same as the inherited maternal 
antigen (Table 5). The maternal Ag, that was missing in the child, is considered by the child a NIMA. 
Therefore, despite being the same aforementioned Ag, other mechanisms than recognition by dNK 






















Table 4. HLA-E and cCMV clinical outcome
 


















 Mother 0.499 0.809
  0101/0101 21.1 27.6 23.1 27.5
  0103/0103 36.8 23.7 30.8 24.6
  0101/0103 42.1 48.7 46.2 47.8
 Child7 0.015* 0.714
  0101/0101 15.8 35.5 33.3 30.9
  0103/0103 10.5 27.6 18.5 26.5
  0101/0103 73.7 36.8 48.1 42.6
HLA-E*0101 mm3 36.8 11.8 0.016˜* 26.9 13 0.129˜
HLA-E*0103 mm4 15.8 9.2 0.413˜ 15.4 8.7 0.453˜
HLA-E*0101 ms5 10.5 17.1 0.728˜ 15.4 15.9 1.000˜
HLA-E*0103 ms6 10.5 17.1 0.728˜ 23.1 13 0.343˜
1 Any long-term impairment, in one or more domains of impairments: hearing, visual neurologic, motor, cognitive, and speech-
language; 2 Absence of any long-term impairments; 3 HLA-E*0101 mm: HLA-E*0101 mismatches, the mother is homozygous 
for HLA-E*0103 and the child is heterozygous; 4 HLA-E*0103 mm: HLA-E*0103 mismatches, the mother homozygous for HLA-
E*0101 and the child is heterozygous; 5 HLA-E*0101 ms: HLA-E*0101 missing-self, the mother is heterozygous and the child 
is homozygous for HLA-E*0103; 6 HLA-E*0103 ms: HLA-E*0103 missing-self, the mother is heterozygous and the child is 
homozygous for HLA-E*0101. 7 N=27 neonates with LTI, and N=68 neonates without LTI. ˜ Fischer’s exact test used. * p < 0.05.
Table 5. Definitions: mismatches, missing-self and NIMAs.
Genotype combinations1 Maternal perspective Child perspective
Maternal genotype Fetal genotype Mismatch (mm)2 Missing-self (ms)3 NIMAs4
a/b a/a no yes yes
a/b b/b no yes yes
a/b a/c yes yes yes
a/b c/b yes yes yes
a/a a/b yes no no
b/b a/b yes no no
a/a a/a no no no
a/b a/b no no no
b/b b/b no no no
1 Combinations of maternal and child HLA genotype by using 3 hypothetical genes (a, b, c); 2 Mismatches (mm) are defined 
as the Ag that the child has but the mother does not have, because the inherited paternal antigen (IPA) is different from both 
maternal alleles; 3 Missing-self (ms) is defined as the Ag that the mother has and the child does not because the inherited 
paternal antigen (IPA) differs from the non-inherited maternal antigen (NIMAs); 4 Non-inherited maternal antigens (NIMAs) 






















self/NIMAs. In our cohort, there were no significant differences in HLA-C, HLA-E, and HLA-G 
missing-self/NIMAs in relation to symptoms at birth. However, for LTI development, a significantly 
higher percentage of HLA-C missing-self/NIMAs, but not of HLA-E and HLA-G missing-self/NIMAs, 
was observed (Tables 2-4). The aforementioned results suggest that the HLA-C missing-self/NIMA 
may be considered as a risk factor for LTI development, rather than for symptoms at birth. Indeed, 
the odds of developing LTI was significantly higher when the child had HLA-C mismatched NIMAs 
(OR 13.3, 95% CI 1.701 – 104.535, p=0.014).
5.4.  DISCUSSION
To gain more insights into cCMV pathogenesis and its clinical consequences, the role of HLA-C, 
HLA-E, and HLA-G genotypes was evaluated in a large cohort of children with cCMV and their 
mothers. HLA-C, HLA-E, and HLA-G are the only HLA molecules expressed by the trophoblasts, 
and therefore they might play a role in cCMV outcome. To systematically discuss the findings, they 
will be described in relation to the compartments involved in the virus-host interaction, which are 
maternal, placental, fetal, and child. 
First of all, the nature of maternal infection and her immune response can influence cCMV 
outcome. In our cohort, the maternal HLA-G del/del genotype was associated with a worse cCMV 
outcome. This could be explained by the immunosuppressive effect of this genotype which is 
associated with the presence of higher HLA-G proteins levels, soluble and possibly membrane-
bound (52, 53). Indeed, HLA-G can inhibit various immune cell subsets (16, 17). The hypothetical 
model to account for maternal HLA-G genotype in relation to cCMV outcome is depicted in 
Figure 1. In addition, CMV induces up-regulation of HLA-G in order to escape the host defense 
and, after an initial local replication, CMV dissemination is likely to be cell-associated, occurring 
mainly through endothelial and monocytes/macrophages (54). Hence, higher HLA-G protein 
levels might create a favorable environment for CMV, facilitating replication and dissemination. 
Interestingly, this HLA-G del/del polymorphism has been associated to active CMV infection with 
higher viral loads in children (29). In our cohort, maternal samples during pregnancy were not 
available. However, neonatal CMV viral load determined in DBS was related to the HLA-G genotype 
of the mother, as reflected by the higher percentage of mothers HLA-G del/del in the high viral load 
group compared to the low viral load group (Table S3 in Supplementary Material). This suggests 
that a reduced maternal control of CMV infection may increase the viral loads at the placenta and, 
consequently, in the fetus. Placental CMV infection triggers an inflammatory response that alters 
the trophoblast, inducing placental dysfunction and fetal impairments, such as intrauterine growth 
retardation (55-57). Interestingly, in a group of pregnant women with primary CMV infection and 
neonates with CMV disease, the placental thickness was increased (58). In addition, in another 
cohort of pregnant women with primary CMV infection, increased sHLA-G levels were observed in 
both maternal serum and amniotic fluid of symptomatic fetuses (30). However, no information was 
available on the maternal and child HLA-G genotypes.
Vertical transmission occurs through placental infection, which therefore was considered after 
the maternal immune response. The hypothetical model to account for our findings in the placenta 






















symptomatic neonates had HLA-E*0101 mm, and a higher extent of HLA-C mm. HLA mm have been 
shown to result in the occurrence of maternal fetus-specific T cells, both in the maternal peripheral 
blood and at the maternal-fetal interface (20, 59). In normal conditions, this does not impair 
pregnancy because there is a parallel increase of regulatory mechanisms modulating such responses 
(20). However, viral infections can increase the levels of pro-inflammatory cytokines, chemokines, 
and the influx of T cells in decidual tissues (60, 61). In this situation, the regulatory mechanisms might 
not be able to efficiently inhibit allogeneic lymphocytes (19), which could damage the placenta. 
Furthermore, because CMV peptides can be presented in the context of HLA-C and HLA-E (62-64), 
mm could lead to suboptimal viral clearance at the placenta, as  maternal CMV-specific cells would 
not efficiently recognize CMV presented in the context of allo-HLA. This has been described in 
allogeneic hematopoietic stem cell transplantation, where the clinical activity of donor-derived 
virus-specific T cells can be abolished if the immunodominant T cells are restricted by HLA not 
shared by the host (65). Consequently, this may result in higher placental and fetal viral loads. 
Indeed, a higher percentage of maternal-fetal HLA-E*0101 mm was found in the high viral load group 
compared to the low viral load group, and the same was observed for HLA-C mm (76.8% and 56.0% 
respectively, p=0.049) (Table S3 in Supplementary Material). Finally, dNK cells are the predominant 
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Figure 1. Placental CMV infection according to maternal HLA-G genotype. A. Mothers homozygous for 
HLA-G deletion are predisposed to having higher levels of sHLA-G, and possibly membrane-bound HLA-G, 
proteins in those tissues where HLA-G is expressed, such as endothelial cells and monocytes/macrophages. 
When maternal T cells encounter an infected cell with higher levels of HLA-G, it is inhibited. This creates 
a favorable environment  for CMV replication and dissemination. Consequently, more extensive infection of 
the placenta leads  to increased CPE,  inflammation, thickening and dysfunction. This in turn contributes to 
a worse outcome. B. Mothers homozygous for HLA-G insertion, or heterozygous, are predisposed to having 
lower levels of sHLA-G, and possibly membrane-bound HLA-G, proteins. When maternal T cells encounter an 
infected cell with lower levels of HLA-G protein, it is activated. CMV replication and dissemination is therefore 
contained. Consequently, lower numbers of infected cells and viral loads reach the placenta, with a reduced 






















leukocyte population at the placenta, and they play a central role in the immune cross-talk and in 
the placentation process. The combination of maternal AA KIR with fetal HLA-C2 was associated 
with increased risk of pre-eclampsia, as it led to the absence of activated dNK and poor placentation 
(23). Indeed, HLA-C2 has a stronger inhibition capacity when binding to its inhibitory KIR (KIR2DL1) 
than C1 with its corresponding receptor (KIR2DL2/3) (23, 50, 51). In our cohort, clinical outcome 
was not associated with specific maternal KIR-fetal HLA-C combinations. Rather, the absence of 
maternal HLA-C belonging to the C2 group was associated with a worse cCMV outcome at birth. In 
the absence of HLA-C2, the activating signals on dNK cells may prevail the inhibitory signals, which 
in turn promote a pro-inflammatory response. In addition, it has been shown that expression of 
KIR2DS1 by dNK increases their cytotoxic function towards infected maternal decidual stromal cells, 
which could possibly lead to a reduction of placental virus-induced pathology (24). In our cohort, 
the presence of the maternal gene KIR2DS1 was not associated with a better short- and long-term 
outcome (Table S4 in Supplementary Material). However, these results would need to be confirmed 
as the lack of statistical power may have been a limiting factor in detecting a small effect. Taken 
together, the aforementioned mechanisms may contribute to the complex multifactorial process 
of placental immunopathology and dysfunction, which has a direct impact on outcome at birth. 
Importantly, besides the fact that placental inflammation has been described in relation to cCMV 
(55-57), prematurity has also been associated to chronic placental inflammation in the absence of 
infections (66). Given the relatively high percentage of premature infants with cCMV in our cohort, 
we evaluated whether the aforementioned markers shown to be associated with symptoms may 
have been influenced by this. After excluding the 11 premature infants, a slight change in p-values, 
but with the same trend of percentages, was observed in relation to symptoms at birth (data not 
shown), most likely due to the lack of statistical power. This suggests that we cannot fully exclude 
that the relatively high percentage of premature infants in the symptomatic group partially 
influenced the association between the aforementioned biomarkers and symptoms. Taking into 
account the association between cCMV and prematurity (67), it may be plausible to assume that 
prematurity is an effect of both cCMV and the aforementioned HLAs.  
The child’s immune response was considered after the placental compartment, and 
the hypothetical model to account for our findings in relation to cCMV outcome is shown in 
Figure 3. Although certain cCMV clinical consequences are present directly after birth, some of 
the permanent impairments have an onset in the first years after birth, or may progress during 
childhood (1). The late-onset hearing loss is commonly considered as the result of a chronic 
disease syndrome, of which the molecular mechanisms have not been elucidated yet, though data 
suggest they are due to a chronic productive infection throughout childhood (7, 8). For this reason, 
the child’s immune response to CMV may play a central role in preventing LTI. In our cohort, a high 
percentage of children with LTI had maternal-fetal HLA-C NIMAs. Their role in LTI development 
may lie in the tolerance induced in the fetus towards NIMAs. Indeed, during pregnancy and after 
birth, the child is exposed to maternal allogeneic cells because of the transfer of maternal cells to 
the fetus, namely maternal microchimerism (68, 69). The developing neonatal immune system does 
not consider NIMAs as non-self, but rather develops long-lasting regulatory mechanisms to prevent 






















The survival rate of kidney grafts with a mismatched Ag identical to the recipient’s NIMA was better 
than in situations where the mismatched Ag was not a NIMA (70, 71). Similar effects have been 
shown in case of stem cell, cord blood and bone marrow transplantation (72-74). Fetal T cells can 
recognize NIMAs presented by maternal cells via the shared HLA, or by fetal APC in the context 
of HLA class I and class II. One of the first steps in the tolerance towards NIMAs is the induction of 
NIMA-specific Tregs, which suppress the fetal antimaternal immunoresponse and persist at least till 
early adulthood (75, 76). In addition, tolerogenic APCs presenting NIMAs are induced, and suppress 
NIMAs-specific T cells (77, 78). These mechanisms may influence the child’s immune response. 
First, the NIMA-specific Tregs may create a general tolerogenic environment that indirectly impair 
the immune response to CMV. Second, through a mechanism called linked immunosuppression, 
a certain level of tolerance specific for CMV can be induced (78). Indeed, fetal APCs could present 
both NIMAs and CMV Ag, as maternal cells can be infected or because maternal cells reside in 
infected fetal tissues. This may result in a less efficient antiviral response during childhood, which 
possibly leads to a more persistent viral replication and tissue damage. Therefore, while the NIMA 
effect may be beneficial in transplantation, it could prevent an optimal antiviral response due to 
a partial tolerance to CMV as well. Similar to symptoms at birth, we evaluated whether the relatively 
high percentage of premature infants in the symptomatic group may have influenced the results 
relative to LTI. After excluding the premature infants, the results and significance did not change 
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Figure 2. Placental immunopathology. A. Viral infections can increase the levels of pro-inflammatory cytokines 
and chemokines, and increase the influx of T cells in decidual tissues (60, 61). B. The regulatory mechanisms 
might not be able to efficiently modulate the maternal fetus-specific lymphocytes, specific for HLA-C and 
HLA-E, which can therefore directly or indirectly recognize trophoblast cells. C. HLA-C and HLA-E mm could 
prevent an optimal viral clearance because maternal CMV-specific cells would not efficiently recognize CMV 
presented in the context of allo-HLA. D. In the absence of maternal HLA-C2, the balance between activating 
and inhibitory signals on dNK cells may be more skewed towards dNK cells activation, because HLA-C1 has less 
inhibitory capacity on dNK. This activation could in turn promote a pro-inflammatory response, exacerbating 






















(data not shown), suggesting that the relatively high percentage of premature does not influence 
the association between HLA-C NIMAs and LTI development.   
This study is not without limitations. First of all, potential effects of CMV on the expression of 
the studied HLA Ags could not be taken into account. Indeed, CMV has developed strategies to 
evade host immunity and to establish latency, e.g. by down-regulating classical HLA molecules 
and up-regulating non-classical HLA (54, 79-81). Second, a CMV-independent role of these HLA 
combinations in adverse pregnancy outcome cannot be totally excluded. However, we did not 
observe the previously described HLA KIR combinations associated with pregnancy complications, 
further suggesting that our observations specifically apply to cCMV.
To the best of our knowledge, this is the first study on maternal-fetal HLA in a large cohort 
of children with cCMV. If our hypotheses are correct, symptoms at birth are mainly caused by 
the immunopathology that takes place at the maternal-fetal interface, as a result of a multifactorial 
process of sub-optimal viral clearance, enhanced allo-reactivity, and increased inflammation. 
Whereas the inefficient long-term control of CMV infection, that plays a role in LTI development, 
might have been partially caused by the NIMA effect. This study gives useful insights and generates 
new hypotheses on cCMV pathogenesis in all compartments involved during cCMV. Furthermore, if 
confirmed in other cohorts, these findings could be evaluated as potential prognostic markers for 
clinical outcome. Indeed, a reliable marker for cCMV outcome could provide the means to introduce 
the long-debated newborn screening program for CMV in DBS by defining subgroups of neonates 
that would benefit from clinical, audiological follow-up, and possibly antiviral treatment (82).
Figure 3. NIMA effect and linked immunosuppression in cCMV long-term outcome. A. During pregnancy, 
maternal cells pass through the placenta to the fetus and can engraft in several fetal tissues, that may be 
infected by CMV, and persist at least till adulthood. Maternal cells can be either CMV infected or not, and can 
carry HLA Ags that the child does not have, i.e. NIMAs. B. After NIMAs recognition by fetal T cells, tolerogenic 
APCs, with reduced T cell activating capacity, are induced in order to suppress a fetal anti-maternal immune 
response. These tolerogenic APCs may be also specific for CMV, as maternal cells can be infected or can 
reside in infected fetal tissues, and suppress CMV-specific T cells (linked immunosuppression). C. The antiviral 
response in the child is therefore less efficient, possibly leading to a more persistent viral replication with 
a chronic productive infection, and tissue damage.
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Table S1. HLA-C frequency in 5604 randomly selected healthy Dutch blood donors
HLA-C alleles Positive Negative %
C*01 323 5281 5,8%
C*02 575 5029 10,3%
C*03 1665 3939 29,7%
C*04 1287 4317 23,0%
C*05 764 4840 13,6%
C*06 898 4706 16,0%
C*07 3140 2464 56,0%
C*08 233 5371 4,2%
C*12 466 5138 8,3%
C*14 117 5487 2,1%
C*15 287 5317 5,1%
C*16 343 5261 6,1%
C*17 97 5507 1,7%


























































































































































































































































































































































































































































































































































































































































































HLA-G del/del mother4 12.0 41.4 0.008*
HLA-G del/del child5 32.0 30.0 0.852
HLA-E*0101 mm6 0.00 23.2 0.005˜*
HLA-C mm7 56.0 76.8 0.049*
1 The study group was divided in two groups according to the CMV viral load measured in DBS. For one child the DBS was 
not available and the viral load could not be assessed; 2 Low: viral loads in DBS < 500 IU/ml; 3 High: viral loads in DBS ≥ 500 IU/
ml; 4 Mothers homozygous for HLA-G deletion; 5 Children homozygous for HLA-G deletion; 6 HLA-E*0101 mm: HLA-E*0101 
mismatches, the mother is homozygous for HLA-E*0103 and the child is heterozygous; 7 HLA-C mm: HLA-C mismatches; 6,7 N 
high group = 69. ˜ Fischer’s exact test used. * p < 0.05.
Table S4. Individual KIRs and cCMV clinical outcome
KIRs 

















KIR2DL1 100.0 89.0 0.198~ 100.0 88.1 0.102~
KIR2DL2 47.4 53.4 0.638 44.0 55.2 0.338
KIR2DL3 100.0 86.3 0.115~ 92.0 88.1 0.723~
KIR2DL5 42.1 47.9 0.649 52.0 44.8 0.537
KIR2DS1 42.1 34.2 0.525 40.0 34.3 0.614
KIR2DS2 47.4 54.8 0.563 44.0 56.7 0.277
KIR2DS3 21.1 21.9 1.000~ 32.0 17.9 0.145
KIR2DS4 100.0 97.3 1.000~ 100.0 97.0 1.000~
KIR2DS5 36.8 30.1 0.575 40.0 28.4 0.285
KIR3DL1 100.0 97.3 1.000~ 100.0 97.0 1.000~
KIR3DS1 42.1 35.6 0.602 44.0 34.3 0.393
1 Any long-term impairment, in one or more domains of impairments: hearing, visual neurologic, motor, cognitive, and 
speech-language; 2 Absence of any long-term impairment; ˜ Fischer’s exact test used.
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Congenital Cytomegalovirus infection (cCMV) is the most common cause of congenital infections 
worldwide causing permanent long-term impairment (LTI). cCMV immunopathogenesis remains 
largely unknown due to the complex interplay between  viral, maternal, placental and child factors. 
The aim of this study was to determine the possible role of particular HLA antigens, of the number 
of HLA mismatches (mm) and non-inherited maternal antigens (NIMAs) in a large retrospective 
nation-wide cohort of children with cCMV and their mothers. HLA Class I (HLA-A, HLA-B and 
HLA-C) and HLA Class II (HLA-DR and HLA-DQ) were assessed in 96 mother-child pairs in relation 
to a control group of 5604 Dutch blood donors, but no significant differences were observed. 
Next, although these HLA antigens could not be assessed in relation to symptoms at birth, nor 
to LTI, due to the low number of cases, they could be evaluated in relation to CMV viral load. 
HLA-DRB1*04, and potentially HLA-B*51, was shown to have a protective role in the children as its 
frequency was increased in the low viral load group compared to the high viral load group, and this 
remained significant after correction. The number of HLA mm and of NIMAs were not associated 
to symptoms at birth nor to LTI or viral load. In conclusion, although none of the HLA alleles could 
be put forward as prognostic marker for long-term outcome, our findings give useful insights into 
cCMV pathogenesis, and identify potential HLAs that correlate with a better viral control.
1.  
































Congenital cytomegalovirus infection (cCMV) is the most common congenital infection in 
industrialized countries with an overall birth prevalence between 0.6 and 0.7% (Dollard et al., 2007, 
Kenneson and Cannon, 2007). Despite the considerable knowledge of cCMV clinical outcome, 
the multifactorial process that determines whether a neonate will have symptoms at birth or will 
develop permanent long-term impairment (LTI) is still poorly understood. In 12.7% of neonates, 
cCMV leads to symptoms at birth, such as petechiae, jaundice, hepatosplenomegaly, and 
microcephaly (Kenneson and Cannon, 2007, Dollard et al., 2007). An estimated 40-58% of these 
symptomatic neonates will develop LTI, such as hearing loss, cognitive and motor delay (Dollard 
et al., 2007). Importantly, of the 87.3% asymptomatic neonates at birth,  around 13.5% will develop 
permanent sequelae (Dollard et al., 2007). 
cCMV pathogenesis is the result of a complex multifactorial process that comprises maternal, 
placental, fetal and child factors. The nature of maternal infection and her immune response have 
an important role in cCMV and its outcome. Indeed, the risk of vertical transmission is 30-40% 
among women without prior CMV infection, while among previously exposed women this risk is at 
least 10-fold lower (Kenneson and Cannon, 2007). The risk of symptomatic CMV disease is mainly 
associated to maternal infection occurring in the first, and second trimester of pregnancy (Pass et 
al., 2006, Enders et al., 2011). Although previous studies have demonstrated a fetal and neonatal 
CMV-specific immune response, its role in controlling CMV disease still needs to be clarified 
(Vermijlen et al., 2010, Lidehall et al., 2013, Hassan et al., 2007).
The CMV-specific T cell mediated immune response is dependent of  the HLA type of the individual 
(Goldrath and Bevan, 1999, Davis and Bjorkman, 1988).  CMV-specific T cells restricted to certain HLA 
alleles may mount a more effective immune response than others. In transplantation, several HLA 
alleles have been shown to have a central role in CMV infection and disease (Du et al., 2007, Futohi 
et al., 2015, Acar et al., 2014, Bal et al., 2013, Chen et al., 2001). Importantly, pregnancy is considered 
a semi-allograft as the fetus can have HLA Ags that the mother does not have. The maternal 
immune system may recognize  these Ags of paternal origin, as it has been demonstrated both in 
the maternal peripheral blood and in the placenta (Tilburgs et al., 2009, van Kampen et al., 2001). 
During pregnancy exchange of cells between mother and fetus will result in microchimerism 
(Maloney et al., 1999, Bianchi et al., 1996). The microchimeric cells carry Ags that the recipient does 
not have, which may result in sensitization of the mother or tolerance in the fetus (Bracamonte-
Baran and Burlingham, 2015). However, different regulatory mechanisms are in place to prevent 
an allo-reactive immune response and create a tolerogenic environment for the undisturbed fetal 
development. For instance, decidual T cell activation is associated with a concomitant induction of 
functional T regulatory cells (Tilburgs et al., 2009). Furthermore, the extravillous trophoblasts do 
not express HLA-A, -B, -DR, -DQ and -DP (Moffett-King, 2002), but only HLA-C and non-classical 
HLA-E and -G.   
The role of maternal and child HLA has mainly been shown in pregnancy complications such 
as pre-eclampsia, intrauterine growth retardation and recurrent spontaneous abortion (Faridi and 



























the placental tolerogenic environment may be altered, resulting in an enhanced alloreactivity 
(Tilburgs and Strominger, 2013), which in turn may affect cCMV outcome. The aim of this study was 
to assess the maternal and child HLA molecules in relation to cCMV, neonatal viral load and clinical 
outcome from birth till 6 years of age.  
6. 2 .  M ATERIAL S AND METHODS
6.2.1. Study population and clinical data
A previously described nationwide, retrospective cohort was used in this study (Korndewal et al., 
2015b). The cohort was derived from a total group of 31,484 children, born in 2008 in the Netherlands, 
which was retrospectively tested for cCMV infection by PCR of CMV DNA in neonatal dried blood 
spot (DBS) at five years of age. In total, 156 children (0.5%) were diagnosed with cCMV. After 
approval by the Medical Ethics Committee of the Leiden University Medical Center, the parents 
of 125 congenitally CMV infected children and of 263 non-infected children gave written informed 
consent for the retrieval of clinical data. For this study, 104 children with cCMV and their mothers 
additionally provided buccal swabs for HLA typing. Two buccal swabs were retrieved from each 
subject (FLOQSwabs hDNA Free, 20-mm breaking point in 174.5mm long dry tube, COPAN ITALIA 
SPA, Brescia, Italy). Children were defined as symptomatic at birth if they had one or more of 
the following signs or symptoms in the neonatal period: prematurity, being small for gestational age, 
microcephaly, hepato- or splenomegaly, generalized petechiae or purpura, hypotonia, abnormal 
laboratory findings (e.g. neutropenia or thrombocytopenia), cerebral ultrasound abnormalities, 
ophthalmologic abnormalities or neonatal hearing impairment. LTI was defined as the presence of 
impairment in one or more domains (hearing, visual, neurological, motor, cognitive and speech-
language). The cCMV associated LTI in the original cohort has been described in detail (Korndewal 
et al., 2017). In brief, hearing impairment was defined as sensorineural hearing loss ≥ 40 dB; visual 
impairment was defined as a visual acuity below 0.3; neurological impairment  included cerebral 
palsy, epilepsy, microcephaly, autism spectrum disorder and ADHD; motor developmental delay 
was based upon the physical therapist’s report and if available on a score below the fifth centile 
in the Movement Assessment Battery for Children; cognitive developmental delay was defined as 
an intelligence quotient less than or equal to 70 if this was tested, or it was based on a diagnosis 
by a medical specialist; speech and language development were assessed by the speech therapist 
or speech and hearing centre. In this cohort maternal seroimmunity to CMV before birth was 
unknown, hence it was assumed that cCMV could have resulted from either maternal primary or 
secondary infection.
6.2.2. DNA extraction from buccal swabs and HLA typing
DNA was extracted from the buccal swabs by using QIAamp DNA (blood) mini kit (QIAGEN, Hilden, 
Germany) according to the manufacturer’s instruction with minor modifications. The buccal 
swabs were incubated with PBS for 30 minutes at room temperature. The pre-incubation fluid was 
applied to one QIAamp spin column and eluted in 150 µl of Tris-EDTA-4 buffer. All mothers and 



























HLA-DR (14 alleles) and HLA-DQ (7 alleles). For class I, a commercially available assay was applied, 
LIFECODES HLA-A, B and C SSO Typing kits (Immucor, Norcross, GA, US). Data were analysed 
using MatchIT software (Immucor-Lifecodes). For class II, a locally developed SSO technique was 
used as previously described (Verduyn et al., 1993), and data were analysed using SCORE software 
(Wolfgang-Helmberg).
6.2.3. DNA extraction from DBS and qPCR of CMV 
After a first initial CMV PCR screening performed at the National Institute for Public Health and 
the Environment, a second confirmatory PCR was performed at the Leiden University Medical Center 
(Korndewal et al., 2015b). DNA was extracted from DBS by using the QIAamp DNA minikit according 
to the previously described protocol (de Vries et al., 2012). For each test one full DBS was punched 
by using an automated DBS puncher (1296-071, Perkin Elmer-Wallac, Zaventem, Belgium). CMV 
DNA amplification of a 126-bp fragment from the immediate-early antigen region was performed 
using an internally controlled quantitative real-time PCR, as described previously (de Vries et al., 
2009, Kalpoe et al., 2004), on the CFX96 Real-Time PCR Detection System (BioRad, Veenendaal, 
The Netherlands). The PCR was performed in triplicate, and the viral load expressed in IU/ml.
6.2.4. Statistical analysis
Data were analyzed by using the Statistical Package for Social Sciences (SPSS, version 23, Chicago, 
IL, USA). The frequency of the HLA alleles in the study group was compared to the frequency in 
5604 healthy Caucasian Dutch blood donor by using the two-sided Fisher’s exact test (van Rooijen 
et al., 2012). The p-values were corrected for multiple comparisons (pm) conform to the Šidák 
method (Sidák, 1967). Odds ratios and corresponding 95% confidence intervals were calculated 
according to the Woolf Haldane test (Haldane, 1956, Woolf, 1955). A large control group could lead 
to significant differences which are clinically irrelevant. Therefore p-values were standardized (ps) 
to a smaller sample size following the method of Good (Good, 1982). Next, the study group was split 
into two groups according to the median viral load measured on DBS, namely high and low viral 
load group. The choice of the median was dictated by the study design, which involved several HLA 
molecules potentially leading to lack of statistical power, not allowing further division of the total 
group, and by the fact that there is no commonly accepted cut-off to define high and low viral load. 
The frequency of the HLA alleles in the  high viral load group was compared to the frequency in 
the low viral load group by using the same method without correction for the sample size, which 
was similar in both groups. A Mann-Whitney test was used to further assess the distribution of viral 
load in relation to the HLA alleles of interest. Next, the maternal and child HLA allele frequencies 
were tested for Hardy-Weinberg Equilibrium (HWE), stating that in absence of other influences 
the genotype frequency in a certain population remains constant from generation to generation 
(Hardy, 1908). This has been suggested as a measure of disease association when analysing the case 
group per se as, by definition, the control group has to hold the HWE (Namipashaki et al., 2015, Lee, 
2003, Nielsen et al., 1998). The HWE was assessed for both maternal and child genotypes by using 



























of HLA mismatches (mm), and non-inherited maternal antigens (NIMAs), in relation to symptoms at 
birth, LTI and viral load. With expected low values, a Fischer’s exact test was used instead. A p-value 
< 0.05 was considered statistically significant.
6. 3.  RE SULTS
6.3.1.  Study population and clinical data
A total of 96 mother-child pairs were successfully typed for at least one of the following HLA alleles, 
HLA-A, HLA-B, HLA-C, HLA-DR and HLA-DQ. Eight mother-child pairs could not be typed because 
of lack of DNA quality and concentration. The clinical data of the congenitally infected children 
included in this study are shown in Table 1. Nineteen (20%) children had symptoms at birth. Of these 
children, 11 (58%) had LTI at the age of 6 years. Additionally, 16 (21%) asymptomatic children had LTI. 
Overall, 27 (28%) of the total group of children with cCMV developed any LTI. The control group 
consisted of 5604 randomly selected healthy Dutch blood donors who were previously genotyped 
(van Rooijen et al., 2012). In the control group, which was in HWE, 3318 (59%) were females and 
the mean (SD) age was 36.2 (8.7) years. No additional clinical information nor CMV serostatus were 
available. Therefore, it was assumed that 50% was CMV-positive at the moment of typing (Korndewal 
et al., 2015a). This group is considered to be a proper representation of the HLA gene distribution in 
the Dutch population (Schipper et al., 1996). 









 Male 57 44 13
  Female 39 33 6
Gestational age (weeks)3 39 (28-42) 39 (37-42) 36 (28-41)
Birth weight ( g)3 3435 (900-5110) 3540 (2635-5110) 2800 (900-4170)
Long term impairment
 Hearing impairment4 3 2 1
 Visual impairment5 2 2 0
 Neurological impairment6 5 2 3
 Motor impairment7 13 9 4
 Cognitive impairment8 7 4 3
 Speech/language problem9 18 10 8
One or more impairment10 27 16 11
1 Asymptomatic at birth; 2 Symptomatic at birth: premature (n=11), dysmature (n=2); microcephaly (n=5); neonatal hearing 
loss (n=1); abnormal cranial ultrasound (n=1) 3 Median and range; 4 sensorineural hearing loss; 5 optic nerve atrophy (n=1), 
cortical visual impairment (n=1); 6 cerebral palsy (n=1), epilepsy (n=1), microcephaly (n=1), ADHD (n=1), autism (n=3); 7 motor 
impairment (fine, gross or balance) based on test or diagnosis or sensory processing disorder or developmental coordination 
disorder; 8 cognitive impairment based on test or diagnosis; 9 language impairment based on test or diagnosis, speech-
impairment, oral motor skill difficulties or auditory processing disorder; 10 Any long-term impairment, in one or more 



























6.3.2.  Analysis of maternal and child genotype frequencies
First, we evaluated whether any HLA alleles included in this study was associated with cCMV. For this 
purpose, the frequency of HLA Class I (A, B and C) and Class II (DR and DQ) alleles were analysed in 
96 mother-child pairs, and compared to the HLA frequencies in 5604 Dutch healthy blood donors. 
Data are reported in Table S1 in Supplementary material. Initial uncorrected association analysis 
revealed an increased frequency of HLA-B*39 and HLA-DRB1*12 compared to the control group in 
the mothers (10.4% and 4.1% p = 0.0066 for HLA-B*39; 9.6% and 3.7% p = 0.0097 for HLA-DRB1*12). 
Whereas, in the children, an increased frequency of HLA-C*02 and HLA-DRB1*12, and a decreased 
frequency of HLA-C*16, compared to the control group were observed (17.9% and 10.3% p = 0.0254 
for HLA-C*02; 9.6% and 3.7% p = 0.0097 for HLA-DRB1*12; 1.1% and 6.1% p = 0.0456 for HLA-C*16). 
After correction, none of the aforementioned associations remained significant.  
Next, the study group was evaluated in more details, and the genotype frequencies of HLA-A, 
HLA-B, HLA-C, HLA-DR and HLA-DQ from the mothers and their children were tested for the HWE. 
There was not enough discriminative power to determine if in the total group of alleles the HWE 
was maintained, both in the mothers and in the children. However, for HLA-DQ alleles, which are 
less polymorphic, the HWE could be assessed. For the mother, no deviations from the HWE were 
observed, whereas for the children a deviation was reported (Table 2). Additionally, all homozygote 
and heterozygote alleles for all loci were in HWE for both mothers and children (Table 2). 
Finally, in order to evaluate whether any HLA allele included in this study was associated with 
CMV viral load, we split our study group in two according to the median viral load measured on DBS, 
which was 3.2 log (IU/ml), namely low (n = 47) and high viral load group (n = 48). The frequency of 
the HLA alleles of the high viral load group  was compared to the frequency of the low viral load 
group, both in the mothers and in the children. In our cohort, the maternal viral load could not be 
assessed as maternal samples during pregnancy were not available, therefore the maternal HLA 
frequency was assessed only in relation to the child CMV viral load. Initial uncorrected association 
analysis revealed a few correlations (Table S2 in Supplementary material). In the mothers, HLA-C*03 
was found increased in the high viral load group compared to the low (42.6% and 21.3% respectively, 
p = 0.0455). In the children, HLA-DRB1*04 was found decreased in the high viral load group 
compared to the low (10.6% and 37.0% respectively, p = 0.0034), as well as HLA-DQ8 (10.6% and 
30.4% respectively, p = 0.0218). However, given the high linkage between HLA-DR4 and HLA-DQ8, 
the increase of HLA-DQ8 percentage in the high viral load group may be considered as a secondary 
effect to the increase of HLA-DRB1*04. After correction for multiple comparison, only HLA-DRB1*04 
remained significant (p = 0.0401) (Table S2 in Supplementary material). Therefore, a Mann-Whitney 
test was used to further assess the distribution of viral load between HLA-DRB1*04 positive and 
HLA-DRB1*04 negative children. The median viral load was significantly lower in the HLA-DRB1*04 
positive children compared to the HLA-DRB1*04 negative children (p = 0.017), whereas this was not 
observed in the mothers (p = 0.627) (Fig. 1). Additionally, HLA-DRB1*04 was evaluated in relation 
to symptoms at birth and LTI, and no associations were found (data not shown). Furthermore, 
as several evidences have been supporting a protective role of HLA-B*51 during infections, we 
wondered whether the same trend could be observed in the context of cCMV. In the children, 



























group (17.4% and 4.3% respectively, p = 0.050, pm = 0.694) (Table S2 in Supplementary material), 
and the median neonatal viral load was slightly lower in HLA-B*51 positive children compared to 
the HLA-B*51 negative children (p = 0.220) (Fig 2). These trends were not observed in the mothers 
(Table S2 in Supplementary material and Fig. 2). Finally, the frequency of the HLA alleles in relation to 
symptoms at birth (n = 19) and LTI (n = 27) could not be addressed due to the lack of statistical power.
6.3.3. Maternal-fetal HLA Class I and Class II mismatches in relation to cCMV clinical 
outcome
We next investigated whether maternal-fetal HLA mm were associated with a worse cCMV 
outcome. This was evaluated for HLA-A, HLA-B, HLA-DR and HLA-DQ as for HLA-C was already 
addressed (Rovito, 2018). For this purpose, mm were calculated on the basis of the presence of 
an Ag in the fetus, which was absent in the mother because the inherited paternal antigen was 
different from both maternal alleles (Table 3). The percentage of mm were compared between 
children symptomatic and asymptomatic at birth, as well as between children who developed LTI 
and those who did not. No differences in percentage of mm were observed in relation to symptoms 
at birth nor to LTI development (Table 4). Mm were additionally evaluated in relation to CMV viral 
Table 2. Hardy-Weinberg Equilibrium for HLA-Class I and HLA-Class II
Mothers Children
Chi-square p-value Chi-square p-value
HLA-A
 total1 N/A4 N/A N/A N/A
 homozygosity2 0.99 0.319 1.15 0.283
 heterozygosity3 0.20 0.654 0.23 0.632
HLA-B
 total N/A N/A N/A N/A
 homozygosity 0.86 0.355 0.13 0.718
 heterozygosity 0.07 0.787 0.01 0.912
HLA-C
 total N/A N/A N/A N/A
 homozygosity 0.21 0.644 0.18 0.672
 heterozygosity 0.04 0.843 0.04 0.845
HLA-DR
 total N/A N/A N/A N/A
 homozygosity 0.01 0.913 0.76 0.382
 heterozygosity 0.00 0.969 0.10 0.749
HLA-DQ
 total 0.88 0.830 8.80 0.032*
 homozygosity 0.18 0.675 0.00 1.000
 heterozygosity 0.04 0.837 0.00 1.000
1 Hardy-Weinberg Equilibrium for all HLA-A allele frequencies included in this study; 2 Hardy-Weinberg Equilibrium for 
the HLA-A homozygous alleles; 3 Hardy-Weinberg Equilibrium for the HLA-A heterozygous alleles; 4 N/A = not assessable, 



























load, by comparing mm percentage between low and high viral load groups, both in the mothers 
and in the children. No difference in the mm percentage were observed between high and low viral 
load groups (data not shown). 
6.3.4. Non-inherited maternal HLA Class I and HLA Class II in relation to cCMV 
clinical outcome 
We finally assessed whether NIMAs influenced cCMV clinical outcome. This was evaluated for 













































Figure 1. Maternal and child HLA-DRB1*04 in relation to neonatal viral load measured in DBS (log(IU/ml)). 






































Figur 2. Maternal and child HLA-B*51 in relation to neonatal viral load measured in DBS (log(IU/ml)). Horizontal 



























Table 3. Definitions of mismatches and NIMAs.
Genotype combinations1
mm2 NIMAs3Maternal genotype Fetal genotype
a/b a/a no yes
a/b b/b no yes
a/b a/c yes yes
a/b c/b yes yes
a/a a/b yes no
b/b a/b yes no
a/a a/a no no
a/b a/b no no
b/b b/b no no
1 Combinations of maternal and child genotype by using 3 hypothetical genes (a, b, c); 2 mm: mismatches, defined as the Ag 
that the child has but the mother does not have, because the inherited paternal antigen is different from both maternal 
alleles; 3 NIMAs: non-inherited maternal antigens, defined as the Ag that the mother has and the child does not because 
the inherited paternal antigen differs from the non-inherited maternal antigen.  
Table 4. HLA mismatches and NIMAs in relation to cCMV clinical outcome.
 
 

















HLA-A mm8 78.9 64.5 0.229 76.9 63.8 0.223
HLA-B mm 94.7 80 0.179˜ 88.5 80.9 0.543˜
HLA-DR mm 63.2 80 0.137˜ 68 79.7 0.236
HLA-DQ mm 47.4 64 0.185 52 63.8 0.302
HLA-A NIMAs9 89.5 72.4 0.145˜ 80.8 73.9 0.487
HLA-B NIMAs 84.2 88 0.703˜ 88.5 86.8 1.000˜
HLA-DR NIMAs 78.9 80 1.000˜ 80 79.7 0.975
HLA-DQ NIMAs 63.2 57.3 0.645 56 59.4 0.766
1 Symptomatic at birth; 2 Asymptomatic at birth; 3 Any long-term impairment, in one or more domains of impairments: 
hearing, visual neurologic, motor, cognitive, and speech-language; 4 Absence of any long-term impairment; 5 HLA-B, HLA-DR 
and HLA-DQ n = 75; 6 HLA-DR and HLA-DQ n = 25; 7 HLA-B n = 68; 8 mm = mismatches, defined as the Ag that the child has 
but the mother does not have because the inherited paternal antigen differed from both maternal alleles; 9 NIMAs = non-
inherited maternal antigens, defined as the Ag in the mother which was absent in the child because the inherited paternal 
antigen differed from the NIMAs. ˜ Fischer’s exact test.  
this purpose, NIMA was defined  as an Ag in the mother, which was absent in the child because 
the inherited paternal antigen was different from the NIMA (Table 3). The percentage of NIMAs 
were compared between children symptomatic and asymptomatic at birth, as well as between 
children who developed LTI and those who did not. In our cohort, no differences in percentage 



























were additionally assessed in relation to CMV viral load, but no differences were observed between 
high and low viral load groups (data not shown). Interestingly, HLA-DR4 has been associated with 
genetic susceptibility to rheumatoid arthritis, and, in HLA-DR4 negative patients, HLA-DR4 NIMAs 
was found increased, suggesting that the maternal presence of this allele may have a role (ten Wolde 
et al., 1993). Therefore, we wondered whether, in HLA-DRB1*04 negative infected children, HLA-
DRB1*04 NIMAs could still influence CMV viral load (Fig. S1 in Supplementary material). However, 
no NIMAs effect was observed in our cohort (p = 0.486), suggesting that the protective effect of 
HLA-DRB1*04 is driven by the presence of this allele in the child. Finally, HLA-DRB1*04 NIMAs were 
not associated with symptoms at birth nor to LTI (data not show). 
6.4.  DISCUSSION 
This study aimed to determine whether certain maternal and child HLA alleles play a role in cCMV. 
Therefore, HLA of Class I and Class II were assessed in relation to cCMV and cCMV clinical outcome 
in a large retrospective nation-wide cohort of children with cCMV.  
The analysis of maternal and child genotype frequencies in relation to cCMV, which was 
performed comparing the HLA alleles frequencies to the frequencies in a control group of healthy 
blood donors, did not show any striking association with cCMV. However, for the purpose of this 
study different control groups may be needed. From the maternal point of view, a group of CMV 
infected women who did not transmit the virus to the fetus would be more appropriate. Whereas 
from the neonatal point of view, a group of neonates that was exposed to CMV but did not get 
infected would be more suitable. This can be quite difficult to achieve as these HLA studies require 
large study groups.
For the aforementioned reasons, we looked in more details into our study group by first 
evaluating the HWE, and then the HLA frequencies in relation to neonatal viral load. The HWE 
could be determined only for the less polymorphic HLA-DQ, which was not in HWE in the group of 
children. Whether HLA-DQ has a role in cCMV would need to be further assessed as it has shown to 
have a minor function in our cohort. Additionally, in the children, HLA-DRB1*04 appeared to have 
a protective role during cCMV as its frequency was increased in the low viral load group compared 
to the high viral load group, and the median neonatal viral load was lower in HLA-DRB1*04 positive 
children (Table S2 IN Supplementary material and Fig 1). This remained significant even after 
statistical correction. Interestingly, HLA-DR4 has been associated with genetic susceptibility to 
rheumatoid arthritis, and, in HLA-DR4 negative patients, HLA-DR4 NIMAs was found increased 
(ten Wolde et al., 1993). However, in our cohort, HLA-DRB1*04 NIMAs did not influence CMV viral 
load. Therefore, the protective effect of HLA-DRB1*04 is most likely driven by the presence of 
the allele in the children (Fig. S1 in Supplementary material). Furthermore, HLA-DRB1*04 was not 
associated with clinical outcome, suggesting that it may have a specific role in the viral control 
rather than CMV-related disease. Consequently, it may be assumed a similar trend of that observed 
between child HLA-DRB1*04 and neonatal viral load, if maternal viral load during pregnancy was 
available. Importantly, the impact of HLA-DRB1*04 in CMV infection has already been shown. In 



























DRB1*04 positive patients (Acar et al., 2014), and in kidney transplantation this allele protected 
from HBV, HCV and CMV infections (Gharesi-Fard et al., 2014). Additionally, as several evidences 
have been supporting a protective role of HLA-B*51 during infections, we wondered whether 
the same trend could be observed in the context of cCMV. Indeed, in kidney and allogeneic stem 
cell transplantation, HLA-B*51 has been shown to have a protective role towards CMV infection (Bal 
et al., 2013, Chen et al., 2001), while in infections, such as HIV, it was associated with an efficient 
immune control (Zhang et al., 2011). In our cohort, HLA-B*51 appeared to have a trend towards 
a better viral control, as its frequency was increased in the children of the low viral load group (Fig. 
2). However, to confirm a possible protective role of HLA-DRB1*04 and HLA-B*51 more studies in 
other cohort of congenitally infected children would be needed. In our cohort, CMV viral load 
was not correlated to symptoms at birth nor to LTI development at 6 years of age (Rovito et al., 
2017b, Rovito et al., 2017a). However, the predictive role of CMV viral load in blood for congenital 
CMV disease may differ depending on the timing of infection and whether there was a primary or 
recurrent maternal infection, which cannot be established in our cohort. Additionally, this cohort 
study, retrieved from a large population screening, does reflect a real population of newborns with 
cCMV in all its diversity, ranging from no symptoms at birth and no LTI to symptoms at birth with 
severe LTI. Therefore, the predictive value of CMV viral load could not be assessed for individual 
clinical outcomes. Importantly, the correlation between CMV viral load and clinical outcome has not 
been established yet as some studies have shown a correlation between CMV viral load and clinical 
outcome (Lanari et al., 2006, Forner et al., 2015), whereas others have not (Halwachs-Baumann et 
al., 2002, Binda et al., 2010, Ross et al., 2009). 
Although the majority of the HLA molecules included in this study are not expressed at 
the placenta, an allogeneic response has been shown to occur due to the fetal microchimerism 
(Payne, 1957, van Kampen et al., 2001, van Kampen et al., 2002, Verdijk et al., 2004). Viral infections 
can increase the levels of pro-inflammatory cytokines and chemokines at the maternal-fetal 
interface, and intensify the decidual T cells influx (Constantin et al., 2007, Nancy et al., 2012). Here, 
the increased level of allogeneic maternal cells specific for fetal Ag that are not expressed by 
the trophoblast, may contribute to placental immunopathology by increasing the inflammation. 
The role of HLA mm in CMV infection has mainly been shown in transplantation. In allogeneic 
hematopoietic stem cell transplantation, CMV DNAemia, CMV disease and CMV resistance were 
associated with the presence of HLA mm (Sedky et al., 2014, Schonberger et al., 2010). Additionally, 
in kidney transplantation HLA mm were shown to be an important determinant of CMV-associated 
graft loss (Gatault et al., 2013). In the context of cCMV, HLA-A, HLA-B, HLA-DR and HLA-DQ mm, 
as well as NIMAs, were not significantly associated with clinical outcome, nor with CMV viral load. 
Even though the sample size may be a limiting factor in determining any significant HLA association, 
the HLA molecules expressed at the placenta, which are HLA-C, HLA-E and HLA-G, may exert a more 
important role in cCMV (Rovito, 2018). Interestingly, in uncomplicated pregnancies a significant 
correlation between the total number of HLA mm and an increased number of activated decidual 
T cells was reported (Tilburgs et al., 2009). However, HLA-C mm were the most influential in 



























et al., 2009). In our cohort, a slightly higher percentage of HLA-A and HLA-B mm were observed 
in the symptomatic group compared to the asymptomatic group, though not significant (Table 4).
Finally, some limitations characterise this study. First of all, potential effects of CMV on 
the expression of the HLA molecules included in this study could not be addressed. Indeed, CMV 
has developed strategies to evade host immunity and to establish latency, e.g. by down-regulating 
classical HLA molecules and up-regulating non-classical HLA (Gong et al., 2012, Onno et al., 
2000, Huard and Fruh, 2000, Wilkinson et al., 2008). This could further influence the degree of 
HLA association with cCMV and cCMV clinical outcome. Second of all, the relatively small sample 
size may have limited the statistical power to detect any significant association. Third, due to 
the retrospective design of the study, cCMV diagnosis was performed by DBS testing, which in 
comparison with urine or saliva has been associated with limited sensitivity in some studies (Ross 
et al., 2014, Boppana et al., 2010, Inoue and Koyano, 2008). Urine specimens are commonly used 
for detection of cCMV due to the high viruria observed in congenitally infected infants, and this is 
still considered the gold standard method (Halwachs-Baumann et al., 2002). Urine and saliva are 
considered equally reliable for detection of cCMV (Yamamoto et al., 2006), and CMV viral load is 
usually lower in blood than in urine (Halwachs-Baumann et al., 2002). DBS can be considered a proper 
and reliable alternative specimen to fresh blood. Indeed, a positive correlation between CMV viral 
load measured on DBS and on whole blood, or on plasma, both in the context of cCMV and CMV in 
transplantation, has been previously shown (Christoni et al., 2012, Limaye et al., 2013). Importantly, 
even considering the relative reduction of CMV viral load on DBS during storage (Christoni et al., 
2012), the specimens that could be potentially more affected from the aforementioned differences 
between blood and urine, or saliva, are those with low viral load. However, it is important to note 
that with the high sensitivity of our CMV PCR on DBS (estimated > 85%), high specificity (> 99.9%) and 
the cCMV birth prevalence of 0.5%, the chance of a CMV false-negative result is 1/1000 (Korndewal 
et al., 2015b). Therefore, the influence of the sensitivity of the CMV PCR on DBS on our conclusions 
can be considered negligible. Finally, the DBS specimens are available, almost, worldwide because 
they are collected for the screening of rare genetic metabolic disorders. This allowed us to perform 
a large-scale retrospective study for long-term cCMV outcome, which would be challenging in 
a prospective setting. 
In conclusion, although none of the HLA alleles could be put forward as prognostic marker 
for cCMV or cCMV clinical outcome, our findings give useful insights into cCMV pathogenesis, 
and identify HLA-DRB1*04 and HLA-B*51 as potential HLAs correlating with a better viral control. 
Importantly, in view of the virus-host interaction at the maternal-fetal interface, the HLA expressed 
at the placenta may have a more substantial role in cCMV and cCMV clinical outcome (Rovito, 2018). 
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Figure S1. Maternal-child HLA-DRB1*04 combinations in relation to neonatal viral load measured in DBS 
(log(IU/ml)). Mother(-)/Child(-): mother and child HLA-DRB1*04 negative; Mother(-)/Child(+): mother 
HLA-DRB1*04 negative and child HLA-DRB1*04 positive; Mother(+)/Child(+): mother and child HLA-DRB1*04 















































Table S1. HLA frequencies of mothers and children compared to the control group
Antigen
Mothers1 Controls4 Odds ratio and 95% C.I.7 Fisher’s Exact8
Pos2 Neg3 Pos5 Neg6 % OR Lower Upper P8 Pm9 Ps10
A*01 29 66 30.5 1887 3717 33.7 0.87 0.564 1.353 0.5845 1.0000 0.5000
A*02 51 44 53.7 2745 2859 49.0 1.21 0.804 1.806 0.4080 1.0000 0.5000
A*03 26 69 27.4 1640 3964 29.3 0.92 0.587 1.447 0.7341 1.0000 0.5000
A*11 13 82 13.7 649 4955 11.6 1.25 0.698 2.233 0.5175 1.0000 0.5000
A*23 1 94 1.1 134 5470 2.4 0.65 0.128 3.269 0.7285 1.0000 0.5000
A*24 21 74 22.1 921 4683 16.4 1.47 0.903 2.382 0.1619 0.9708 0.5000
A*25 1 94 1.1 122 5482 2.2 0.71 0.140 3.600 0.7244 1.0000 0.5000
A*26 4 91 4.2 248 5356 4.4 1.06 0.408 2.755 1.0000 1.0000 0.5000
A*29 6 89 6.3 299 5305 5.3 1.29 0.575 2.877 0.6425 1.0000 0.5000
A*30 2 93 2.1 276 5328 4.9 0.52 0.146 1.820 0.3302 0.9997 0.5000
A*31 9 86 9.5 314 5290 5.6 1.85 0.936 3.645 0.1136 0.9103 0.5000
A*32 6 89 6.3 355 5249 6.3 1.07 0.480 2.395 1.0000 1.0000 0.5000
A*33 2 93 2.1 113 5491 2.0 1.29 0.363 4.605 0.7177 1.0000 0.5000
A*34 0 95 0.0 17 5587 0.3 1.67 0.100 28.002 1.0000 1.0000 0.5000
A*36 1 94 1.1 9 5595 0.2 9.35 1.651 52.947 0.1548 0.9654 0.5000
A*66 0 95 0.0 33 5571 0.6 0.87 0.053 14.316 1.0000 1.0000 0.5000
A*68 6 89 6.3 517 5087 9.2 0.71 0.320 1.591 0.4709 1.0000 0.5000
A*69 0 95 0.0 9 5595 0.2 3.08 0.178 53.368 1.0000 1.0000 0.5000
A*74 0 95 0.0 5 5599 0.1 5.33 0.293 97.084 1.0000 1.0000 0.5000





























Mothers1 Controls4 Odds ratio and 95% C.I.7 Fisher’s Exact8
Pos2 Neg3 % Pos5 Neg6 % OR Lower Upper P8 Pm9 Ps10
B*07 21 75 21,9 1391 4213 24,8 0,86 0,532 1,398 0,5530 1,0000 0,5000
B*08 21 75 21,9 1436 4168 25,6 0,83 0,510 1,339 0,4790 1,0000 0,5000
B*13 2 94 2,1 229 5375 4,1 0,62 0,175 2,191 0,4391 1,0000 0,5000
B14 3 93 3,1 217 5387 3,9 0,93 0,316 2,719 1,0000 1,0000 0,5000
B62 11 85 11,5 837 4732 15,0 0,76 0,409 1,413 0,3881 1,0000 0,5000
B63 0 96 0,0 44 5525 0,8 0,64 0,039 10,523 1,0000 1,0000 0,5000
B75 1 95 1,0 16 5553 0,3 5,29 0,982 28,470 0,2525 1,0000 0,5000
B76 0 96 0,0 1 5568 0,0 19,23 0,779 475,189 1,0000 1,0000 0,5000
B77 0 96 0,0 9 5560 0,2 3,03 0,175 52,480 1,0000 1,0000 0,5000
B*18 5 91 5,2 414 5190 7,4 0,75 0,317 1,790 0,5537 1,0000 0,5000
B*27 9 87 9,4 405 5199 7,2 1,39 0,707 2,740 0,4239 1,0000 0,5000
B*35 17 79 17,7 1090 4514 19,5 0,91 0,541 1,535 0,7946 1,0000 0,5000
B*37 2 94 2,1 181 5423 3,2 0,79 0,223 2,800 0,7708 1,0000 0,5000
B*38 4 92 4,2 186 5418 3,3 1,41 0,543 3,682 0,5625 1,0000 0,5000
B*39 10 86 10,4 229 5375 4,1 2,84 1,478 5,468 0,0066 0,2325 0,5000
B60 13 83 13,5 676 4832 12,3 1,15 0,646 2,064 0,6404 1,0000 0,5000
B61 7 89 7,3 198 5310 3,6 2,24 1,050 4,786 0,0880 0,9749 0,5000
B*41 1 95 1,0 86 5518 1,5 1,00 0,197 5,098 1,0000 1,0000 0,5000
B*42 1 95 1,0 9 5595 0,2 9,25 1,634 52,387 0,1563 0,9989 0,5000
B*44 28 68 29,2 1257 4347 22,4 1,44 0,925 2,237 0,1383 0,9974 0,5000
B*45 1 95 1,0 60 5544 1,1 1,44 0,281 7,366 1,0000 1,0000 0,5000
B*46 0 96 0,0 9 5595 0,2 3,05 0,176 52,811 1,0000 1,0000 0,5000
B*47 0 96 0,0 29 5575 0,5 0,98 0,059 16,144 1,0000 1,0000 0,5000
B*48 0 96 0,0 5 5599 0,1 5,28 0,290 96,071 1,0000 1,0000 0,5000
B*49 4 92 4,2 84 5520 1,5 3,18 1,205 8,386 0,0604 0,9171 0,5000
B50 1 95 1,0 84 5520 1,5 1,03 0,202 5,222 1,0000 1,0000 0,5000
B*51 9 87 9,4 590 5014 10,5 0,92 0,469 1,811 0,8668 1,0000 0,5000
B*52 3 93 3,1 50 5554 0,9 4,12 1,367 12,400 0,0593 0,9131 0,5000
B*53 0 96 0,0 40 5564 0,7 0,71 0,043 11,662 1,0000 1,0000 0,5000
B*54 0 96 0,0 2 5602 0,0 11,61 0,554 243,488 1,0000 1,0000 0,5000
B*55 2 94 2,1 239 5365 4,3 0,59 0,168 2,095 0,4404 1,0000 0,5000
B*56 1 95 1,0 77 5527 1,4 1,12 0,220 5,708 1,0000 1,0000 0,5000
B*57 8 88 8,3 368 5236 6,6 1,36 0,670 2,781 0,5298 1,0000 0,5000
B*58 1 95 1,0 93 5511 1,7 0,93 0,182 4,705 1,0000 1,0000 0,5000
B*67 0 96 0,0 1 5603 0,0 19,36 0,783 478,175 1,0000 1,0000 0,5000
B*71 0 96 0,0 19 5550 0,3 1,47 0,088 24,604 1,0000 1,0000 0,5000
B72 1 95 1,0 26 5543 0,5 3,29 0,626 17,235 0,3703 1,0000 0,5000
B*73 0 96 0,0 2 5602 0,0 11,61 0,554 243,488 1,0000 1,0000 0,5000
B*78 0 96 0,0 3 5601 0,1 8,29 0,425 161,645 1,0000 1,0000 0,5000
B*81 0 96 0,0 3 5601 0,1 8,29 0,425 161,645 1,0000 1,0000 0,5000
C*01 4 91 4.2 323 5281 5.8 0.80 0.310 2.082 0.6594 1.0000 0.5000
C*02 15 80 15.8 575 5029 10.3 1.68 0.970 2.918 0.0881 0.7249 0.5000





























Mothers1 Controls4 Odds ratio and 95% C.I.7 Fisher’s Exact8
Pos2 Neg3 % Pos5 Neg6 % OR Lower Upper P8 Pm9 Ps10
C*04 18 77 18.9 1287 4317 23.0 0.80 0.480 1.334 0.3910 0.9990 0.5000
C*05 19 76 20.0 764 4840 13.6 1.61 0.976 2.669 0.0959 0.7563 0.5000
C*06 14 81 14.7 898 4706 16.0 0.93 0.531 1.637 0.8876 1.0000 0.5000
C*07 46 49 48.4 3140 2464 56.0 0.74 0.492 1.104 0.1455 0.8893 0.5000
C*08 3 92 3.2 233 5371 4.2 0.87 0.297 2.551 1.0000 1.0000 0.5000
C*12 13 82 13.7 466 5138 8.3 1.80 1.006 3.230 0.0890 0.7287 0.5000
C*14 2 93 2.1 117 5487 2.1 1.25 0.351 4.443 1.0000 1.0000 0.5000
C*15 7 88 7.4 287 5317 5.1 1.57 0.737 3.334 0.3422 0.9972 0.5000
C*16 4 91 4.2 343 5261 6.1 0.75 0.291 1.953 0.6623 1.0000 0.5000
C*17 2 93 2.1 97 5507 1.7 1.51 0.423 5.389 0.6813 1.0000 0.5000
C*18 0 95 0.0 2 5602 0.0 11.73 0.559 246.054 1.0000 1.0000 0.5000
DRB1*01 21 73 22,3 1234 4370 22,0 1,04 0,638 1,681 0,9007 1,0000 0,5000
DR17 24 70 25,5 1524 3990 27,6 0,91 0,572 1,446 0,7275 1,0000 0,5000
DR18 0 94 0,0 8 5506 0,1 3,43 0,196 59,819 1,0000 1,0000 0,5000
DRB1*04 20 74 21,3 1557 4047 27,8 0,72 0,437 1,170 0,2004 0,9563 0,5000
DRB1*07 16 78 17,0 1098 4506 19,6 0,86 0,505 1,472 0,6013 1,0000 0,5000
DRB1*08 3 91 3,2 361 5243 6,4 0,55 0,190 1,622 0,2845 0,9908 0,5000
DRB1*09 1 93 1,1 160 5444 2,9 0,54 0,108 2,752 0,5242 1,0000 0,5000
DRB1*10 2 92 2,1 132 5472 2,4 1,12 0,314 3,967 1,0000 1,0000 0,5000
DRB1*11 22 72 23,4 930 4674 16,6 1,56 0,966 2,515 0,0929 0,7448 0,5000
DRB1*12 9 85 9,6 210 5394 3,7 2,85 1,436 5,645 0,0097 0,1273 0,4957
DRB1*13 23 71 24,5 1393 4211 24,9 0,99 0,621 1,589 1,0000 1,0000 0,5000
DRB1*14 8 86 8,5 373 5231 6,7 1,38 0,675 2,806 0,4084 0,9994 0,5000
DRB1*15 25 69 26,6 1356 4248 24,2 1,15 0,727 1,816 0,6272 1,0000 0,5000
DRB1*16 3 91 3,2 165 5439 2,9 1,26 0,428 3,697 0,7569 1,0000 0,5000
DQ7 35 59 37,2 1641 3894 29,6 1,42 0,930 2,154 0,1124 0,5661 0,5000
DQ8 16 78 17,0 1073 4462 19,4 0,87 0,512 1,492 0,6926 0,9997 0,5000
DQ9 7 87 7,4 504 5031 9,1 0,85 0,403 1,812 0,7179 0,9999 0,5000
DQB1*02 33 61 35,1 2204 3400 39,3 0,84 0,550 1,284 0,4564 0,9860 0,5000
DQB1*04 3 91 3,2 340 5264 6,1 0,59 0,202 1,730 0,3770 0,9636 0,5000
DQB1*05 33 61 35,1 1840 3764 32,8 1,11 0,729 1,703 0,6584 0,9995 0,5000
DQB1*06 41 53 43,6 2470 3134 44,1 0,98 0,654 1,481 1,0000 1,0000 0,5000
Antigen
Children11 Controls Odds ratio and 95% C.I. Fisher’s Exact
Pos Neg % pos neg % OR lower upper P Pm Ps
A*01 31 64 32.6 1887 3717 33.7 0.96 0.626 1.478 0.9129 1.0000 0.5000
A*02 48 47 50.5 2745 2859 49.0 1.06 0.710 1.592 0.8362 1.0000 0.5000
A*03 23 72 24.2 1640 3964 29.3 0.78 0.490 1.252 0.3074 0.9994 0.5000
A*11 10 85 10.5 649 4955 11.6 0.94 0.491 1.788 0.8720 1.0000 0.5000
A*23 4 91 4.2 134 5470 2.4 2.00 0.765 5.233 0.2932 0.9990 0.5000
A*24 19 76 20.0 921 4683 16.4 1.30 0.784 2.141 0.3314 0.9997 0.5000





























Children11 Controls Odds ratio and 95% C.I. Fisher’s Exact
Pos Neg % pos neg % OR lower upper P Pm Ps
A*26 3 92 3.2 248 5356 4.4 0.82 0.278 2.389 0.7997 1.0000 0.5000
A*29 2 93 2.1 299 5305 5.3 0.47 0.134 1.672 0.2421 0.9961 0.5000
A*30 2 93 2.1 276 5328 4.9 0.52 0.146 1.820 0.3302 0.9997 0.5000
A*31 8 87 8.4 314 5290 5.6 1.63 0.801 3.335 0.2557 0.9973 0.5000
A*32 8 87 8.4 355 5249 6.3 1.43 0.704 2.924 0.3933 1.0000 0.5000
A*33 0 95 0.0 113 5491 2.0 0.25 0.016 4.105 0.2658 0.9979 0.5000
A*34 0 95 0.0 17 5587 0.3 1.67 0.100 28.002 1.0000 1.0000 0.5000
A*36 0 95 0.0 9 5595 0.2 3.08 0.178 53.368 1.0000 1.0000 0.5000
A*66 2 93 2.1 33 5571 0.6 4.45 1.210 16.336 0.1149 0.9129 0.5000
A*68 8 87 8.4 517 5087 9.2 0.96 0.470 1.942 1.0000 1.0000 0.5000
A*69 0 95 0.0 9 5595 0.2 3.08 0.178 53.368 1.0000 1.0000 0.5000
A*74 0 95 0.0 5 5599 0.1 5.33 0.293 97.084 1.0000 1.0000 0.5000
A*80 0 95 0.0 2 5602 0.0 11.73 0.559 246.054 1.0000 1.0000 0.5000
B*07 21 73 22,3 1391 4213 24,8 0,89 0,546 1,438 0,6316 1,0000 0,5000
B*08 22 72 23,4 1436 4168 25,6 0,90 0,559 1,451 0,7209 1,0000 0,5000
B*13 3 91 3,2 229 5375 4,1 0,90 0,306 2,627 1,0000 1,0000 0,5000
B14 2 92 2,1 217 5387 3,9 0,67 0,189 2,369 0,5864 1,0000 0,5000
B62 16 78 17,0 837 4732 15,0 1,19 0,695 2,030 0,5619 1,0000 0,5000
B63 2 92 2,1 44 5525 0,8 3,36 0,923 12,196 0,1771 0,9996 0,5000
B75 0 94 0,0 16 5553 0,3 1,78 0,106 29,903 1,0000 1,0000 0,5000
B76 0 94 0,0 1 5568 0,0 19,64 0,795 485,310 1,0000 1,0000 0,5000
B77 0 94 0,0 9 5560 0,2 3,10 0,179 53,599 1,0000 1,0000 0,5000
B*18 6 88 6,4 414 5190 7,4 0,92 0,412 2,053 0,8439 1,0000 0,5000
B*27 9 85 9,6 405 5199 7,2 1,42 0,723 2,806 0,4183 1,0000 0,5000
B*35 13 81 13,8 1090 4514 19,5 0,69 0,384 1,224 0,1895 0,9998 0,5000
B*37 2 92 2,1 181 5423 3,2 0,81 0,228 2,861 0,7704 1,0000 0,5000
B*38 4 90 4,3 186 5418 3,3 1,44 0,554 3,765 0,5562 1,0000 0,5000
B*39 3 91 3,2 229 5375 4,1 0,90 0,306 2,627 1,0000 1,0000 0,5000
B60 17 77 18,1 676 4832 12,3 1,61 0,954 2,727 0,1114 0,9911 0,5000
B61 6 88 6,4 198 5310 3,6 1,96 0,875 4,413 0,1566 0,9989 0,5000
B*41 0 94 0,0 86 5518 1,5 0,34 0,021 5,481 0,4053 1,0000 0,5000
B*42 0 94 0,0 9 5595 0,2 3,12 0,180 53,936 1,0000 1,0000 0,5000
B*44 24 70 25,5 1257 4347 22,4 1,20 0,755 1,911 0,4567 1,0000 0,5000
B*45 0 94 0,0 60 5544 1,1 0,48 0,030 7,900 0,6271 1,0000 0,5000
B*46 0 94 0,0 9 5595 0,2 3,12 0,180 53,936 1,0000 1,0000 0,5000
B*47 1 93 1,1 29 5575 0,5 3,03 0,580 15,839 0,3937 1,0000 0,5000
B*48 0 94 0,0 5 5599 0,1 5,39 0,296 98,119 1,0000 1,0000 0,5000
B*49 2 92 2,1 84 5520 1,5 1,77 0,494 6,316 0,6535 1,0000 0,5000
B50 0 94 0,0 84 5520 1,5 0,35 0,021 5,614 0,6500 1,0000 0,5000
B*51 10 84 10,6 590 5014 10,5 1,06 0,553 2,015 1,0000 1,0000 0,5000
B*52 0 94 0,0 50 5554 0,9 0,58 0,036 9,503 1,0000 1,0000 0,5000
B*53 0 94 0,0 40 5564 0,7 0,73 0,044 11,911 1,0000 1,0000 0,5000





























Children11 Controls Odds ratio and 95% C.I. Fisher’s Exact
Pos Neg % pos neg % OR lower upper P Pm Ps
B*55 3 91 3,2 239 5365 4,3 0,86 0,292 2,512 0,7987 1,0000 0,5000
B*56 1 93 1,1 77 5527 1,4 1,14 0,224 5,832 1,0000 1,0000 0,5000
B*57 10 84 10,6 368 5236 6,6 1,77 0,922 3,382 0,1377 0,9973 0,5000
B*58 1 93 1,1 93 5511 1,7 0,95 0,186 4,807 1,0000 1,0000 0,5000
B*67 0 94 0,0 1 5603 0,0 19,77 0,800 488,360 1,0000 1,0000 0,5000
B*71 0 94 0,0 19 5550 0,3 1,51 0,090 25,129 1,0000 1,0000 0,5000
B72 0 94 0,0 26 5543 0,5 1,11 0,067 18,297 1,0000 1,0000 0,5000
B*73 0 94 0,0 2 5602 0,0 11,86 0,565 248,675 1,0000 1,0000 0,5000
B*78 0 94 0,0 3 5601 0,1 8,47 0,434 165,090 1,0000 1,0000 0,5000
B*81 0 94 0,0 3 5601 0,1 8,47 0,434 165,090 1,0000 1,0000 0,5000
C*01 4 91 4.2 323 5281 5.8 0.80 0.310 2.082 0.6594 1.0000 0.5000
C*02 17 78 17.9 575 5029 10.3 1.95 1.152 3.294 0.0254 0.3023 0.5000
C*03 35 60 36.8 1665 3939 29.7 1.39 0.913 2.109 0.1416 0.8821 0.5000
C*04 19 76 20.0 1287 4317 23.0 0.85 0.518 1.411 0.5405 1.0000 0.5000
C*05 15 80 15.8 764 4840 13.6 1.22 0.704 2.111 0.5461 1.0000 0.5000
C*06 16 79 16.8 898 4706 16.0 1.09 0.637 1.856 0.7790 1.0000 0.5000
C*07 52 43 54.7 3140 2464 56.0 0.95 0.632 1.420 0.8352 1.0000 0.5000
C*08 2 93 2.1 233 5371 4.2 0.62 0.174 2.175 0.4390 0.9997 0.5000
C*12 9 86 9.5 466 5138 8.3 1.21 0.615 2.380 0.7063 1.0000 0.5000
C*14 1 94 1.1 117 5487 2.1 0.74 0.146 3.758 0.7242 1.0000 0.5000
C*15 4 91 4.2 287 5317 5.1 0.91 0.350 2.361 1.0000 1.0000 0.5000
C*16 1 94 1.1 343 5261 6.1 0.24 0.048 1.224 0.0456 0.4794 0.5000
C*17 0 95 0.0 97 5507 1.7 0.30 0.018 4.797 0.4124 0.9994 0.5000
C*18 0 95 0.0 2 5602 0.0 11.73 0.559 246.054 1.0000 1.0000 0.5000
DRB1*01 22 72 23,4 1234 4370 22,0 1,10 0,682 1,771 0,7083 1,0000 0,5000
DR17 22 72 23,4 1524 3990 27,6 0,81 0,504 1,308 0,4158 0,9995 0,5000
DR18 0 94 0,0 8 5506 0,1 3,43 0,196 59,819 1,0000 1,0000 0,5000
DRB1*04 22 72 23,4 1557 4047 27,8 0,81 0,501 1,299 0,4159 0,9995 0,5000
DRB1*07 22 72 23,4 1098 4506 19,6 1,27 0,790 2,053 0,3598 0,9981 0,5000
DRB1*08 4 90 4,3 361 5243 6,4 0,72 0,278 1,870 0,5242 1,0000 0,5000
DRB1*09 1 93 1,1 160 5444 2,9 0,54 0,108 2,752 0,5242 1,0000 0,5000
DRB1*10 2 92 2,1 132 5472 2,4 1,12 0,314 3,967 1,0000 1,0000 0,5000
DRB1*11 10 84 10,6 930 4674 16,6 0,62 0,327 1,190 0,1595 0,9121 0,5000
DRB1*12 9 85 9,6 210 5394 3,7 2,85 1,436 5,645 0,0097 0,1273 0,4957
DRB1*13 27 67 28,7 1393 4211 24,9 1,23 0,787 1,926 0,4003 0,9992 0,5000
DRB1*14 8 86 8,5 373 5231 6,7 1,38 0,675 2,806 0,4084 0,9994 0,5000
DRB1*15 25 69 26,6 1356 4248 24,2 1,15 0,727 1,816 0,6272 1,0000 0,5000
DRB1*16 0 94 0,0 165 5439 2,9 0,17 0,011 2,813 0,1160 0,8219 0,5000
DQ7 26 68 27,7 1641 3894 29,6 0,92 0,584 1,442 0,7334 0,9999 0,5000
DQ8 19 75 20,2 1073 4462 19,4 1,07 0,650 1,774 0,7937 1,0000 0,5000
DQ9 9 85 9,6 504 5031 9,1 1,11 0,563 2,180 0,8560 1,0000 0,5000





























Children11 Controls Odds ratio and 95% C.I. Fisher’s Exact
Pos Neg % pos neg % OR lower upper P Pm Ps
DQB1*04 4 90 4,3 340 5264 6,1 0,77 0,296 1,994 0,6605 0,9995 0,5000
DQB1*05 32 62 34,0 1840 3764 32,8 1,06 0,694 1,631 0,8250 1,0000 0,5000
DQB1*06 44 50 46.8 2470 3134 44.1 1.12 0.745 1.679 0.6021 0.9984 0.5000
1 HLA alleles frequencies in the mothers; 2 Mothers positive for the specific HLA allele; 3 Mothers negative for the specific HLA 
allele; 4 Control group of 5604 randomly selected healthy Dutch blood donors; 5 Controls positive for the specific HLA allele; 
6 Controls negative for the specific HLA allele; 7 Odds ratio (OR) and 95% confidence intervals (95% C.I.) calculated based on 
the Woolf-Haldane method; 8 Two-sided Fisher’s exact test comparing HLA alleles frequencies between study and control 
group; 9 Pm: corrected p-values for multiple comparisons (Šidák method); 10 Ps: standardized p-values to a smaller sample size 
(Good method); 11 HLA alleles frequencies in the children.





Low viral load4 Odds ratio and 95% C.I.5 Fisher’s Exact6
Pos2 Neg3 % pos neg % OR5 lower upper P6 Pm7
A*01 11 36 23.4 18 29 38.3 0.50 0.208 1.213 0.1798 0.9489
A*02 26 21 55.3 24 23 51.1 1.18 0.530 2.638 0.8364 1.0000
A*03 14 33 29.8 12 35 25.5 1.23 0.504 2.999 0.8180 1.0000
A*11 8 39 17.0 5 42 10.6 1.66 0.523 5.287 0.5516 1.0000
A*23 0 47 0.0 1 46 2.1 0.33 0.013 8.217 1.0000 1.0000
A*24 12 35 25.5 9 38 19.1 1.43 0.547 3.723 0.6212 1.0000
A*25 0 47 0.0 1 46 2.1 0.33 0.013 8.217 1.0000 1.0000
A*26 2 45 4.3 2 45 4.3 1.00 0.165 6.053 1.0000 1.0000
A*29 3 44 6.4 3 44 6.4 1.00 0.215 4.659 1.0000 1.0000
A*30 0 47 0.0 2 45 4.3 0.19 0.009 4.100 0.4946 1.0000
A*31 2 45 4.3 7 40 14.9 0.30 0.067 1.320 0.1582 0.9244
A*32 3 44 6.4 3 44 6.4 1.00 0.215 4.659 1.0000 1.0000
A*33 2 45 4.3 0 47 0.0 5.22 0.244 111.718 0.4946 1.0000
A*36 0 47 0.0 1 46 2.1 0.33 0.013 8.217 1.0000 1.0000
A*68 3 44 6.4 3 44 6.4 1.00 0.215 4.659 1.0000 1.0000
B*07 10 38 20,8 10 37 21,3 0,97 0,371 2,560 1,0000 1,0000
B*08 9 39 18,8 12 35 25,5 0,68 0,262 1,780 0,4669 1,0000
B*13 1 47 2,1 1 46 2,1 0,98 0,098 9,755 1,0000 1,0000
B*18 3 45 6,3 2 45 4,3 1,40 0,262 7,469 1,0000 1,0000
B*27 4 44 8,3 5 42 10,6 0,78 0,210 2,910 0,7401 1,0000
B*35 8 40 16,7 9 38 19,1 0,85 0,305 2,371 0,7944 1,0000
B*37 1 47 2,1 1 46 2,1 0,98 0,098 9,755 1,0000 1,0000
B*38 1 47 2,1 3 44 6,4 0,40 0,057 2,839 0,3616 1,0000
B*39 3 45 6,3 7 40 14,9 0,42 0,109 1,583 0,1986 0,9980
































Low viral load4 Odds ratio and 95% C.I.5 Fisher’s Exact6
Pos2 Neg3 % pos neg % OR5 lower upper P6 Pm7
B*42 0 48 0,0 1 46 2,1 0,32 0,013 8,046 0,4947 1,0000
B*44 14 34 29,2 13 34 27,7 1,07 0,446 2,586 1,0000 1,0000
B*45 0 48 0,0 1 46 2,1 0,32 0,013 8,046 0,4947 1,0000
B*49 1 47 2,1 3 44 6,4 0,40 0,057 2,839 0,3616 1,0000
B*51 4 44 8,3 5 42 10,6 0,78 0,210 2,910 0,7401 1,0000
B*52 3 45 6,3 0 47 0,0 7,31 0,367 145,464 0,2421 0,9996
B*55 0 48 0,0 2 45 4,3 0,19 0,009 4,015 0,2421 0,9996
B*56 1 47 2,1 0 47 0,0 3,00 0,119 75,524 1,0000 1,0000
B*57 4 44 8,3 4 43 8,5 0,98 0,248 3,854 1,0000 1,0000
B*58 1 47 2,1 0 47 0,0 3,00 0,119 75,524 1,0000 1,0000
B50 0 48 0,0 1 46 2,1 0,32 0,013 8,046 0,4947 1,0000
B60 9 39 18,8 4 43 8,5 2,33 0,699 7,731 0,2321 0,9994
B61 5 43 10,4 2 45 4,3 2,30 0,488 10,861 0,4353 1,0000
B62 8 40 16,7 3 44 6,4 2,67 0,716 9,945 0,1986 0,9980
B64 0 48 0,0 1 46 2,1 0,32 0,013 8,046 0,4947 1,0000
B65 1 47 2,1 1 46 2,1 0,98 0,098 9,755 1,0000 1,0000
B72 0 48 0,0 1 46 2,1 0,32 0,013 8,046 0,4947 1,0000
B75 1 47 2,1 0 47 0,0 3,00 0,119 75,524 1,0000 1,0000
C*01 2 45 4.3 2 45 4.3 1.00 0.165 6.053 1.0000 1.0000
C*02 8 39 17.0 7 40 14.9 1.16 0.396 3.406 1.0000 1.0000
C*03 20 27 42.6 10 37 21.3 2.66 1.091 6.495 0.0455 0.4543
C*04 10 37 21.3 8 39 17.0 1.30 0.475 3.568 0.7939 1.0000
C*05 7 40 14.9 11 36 23.4 0.59 0.211 1.635 0.4323 0.9994
C*06 6 41 12.8 8 39 17.0 0.73 0.240 2.209 0.7730 1.0000
C*07 22 25 46.8 23 24 48.9 0.92 0.413 2.049 1.0000 1.0000
C*08 1 46 2.1 2 45 4.3 0.59 0.074 4.630 1.0000 1.0000
C*12 5 42 10.6 8 39 17.0 0.60 0.189 1.912 0.5516 1.0000
C*14 2 45 4.3 0 47 0.0 5.22 0.244 111.718 0.4946 0.9999
C*15 3 44 6.4 4 43 8.5 0.76 0.177 3.267 1.0000 1.0000
C*16 2 45 4.3 2 45 4.3 1.00 0.165 6.053 1.0000 1.0000
C*17 1 46 2.1 1 46 2.1 1.00 0.100 9.968 1.0000 1.0000
C*01 2 45 4.3 2 45 4.3 1.00 0.165 6.053 1.0000 1.0000
DR17 12 35 25,5 12 34 26,1 0,97 0,390 2,422 1,0000 1,0000
DRB1*01 12 35 25,5 9 37 19,6 1,39 0,532 3,631 0,6212 1,0000
DRB1*04 9 38 19,1 11 35 23,9 0,76 0,288 2,015 0,6212 1,0000
DRB1*07 8 39 17,0 8 38 17,4 0,98 0,341 2,783 1,0000 1,0000
DRB1*08 2 45 4,3 1 45 2,2 1,67 0,211 13,150 1,0000 1,0000
DRB1*09 1 46 2,1 0 46 0,0 3,00 0,119 75,565 1,0000 1,0000
DRB1*10 1 46 2,1 1 45 2,2 0,98 0,098 9,758 1,0000 1,0000
DRB1*11 11 36 23,4 11 35 23,9 0,97 0,380 2,487 1,0000 1,0000
DRB1*12 7 40 14,9 2 44 4,3 3,30 0,740 14,675 0,1582 0,8934
































Low viral load4 Odds ratio and 95% C.I.5 Fisher’s Exact6
Pos2 Neg3 % pos neg % OR5 lower upper P6 Pm7
DRB1*14 2 45 4,3 6 40 13,0 0,34 0,075 1,564 0,1582 0,8934
DRB1*15 11 36 23,4 13 33 28,3 0,78 0,313 1,953 0,6411 1,0000
DRB1*16 1 46 2,1 2 44 4,3 0,57 0,073 4,530 0,6168 1,0000
DQ7 17 30 36,2 18 28 39,1 0,88 0,386 2,026 0,8322 1,0000
DQ8 8 39 17,0 8 38 17,4 0,98 0,341 2,783 1,0000 1,0000
DQ9 6 41 12,8 1 45 2,2 4,75 0,766 29,457 0,1109 0,5608
DQB1*02 15 32 31,9 18 28 39,1 0,74 0,317 1,705 0,5199 0,9941
DQB1*04 2 45 4,3 1 45 2,2 1,67 0,211 13,150 1,0000 1,0000
DQB1*05 17 30 36,2 16 30 34,8 1,06 0,458 2,455 1,0000 1,0000





Low viral load9 Odds ratio and 95% C.I. Fisher’s Exact
pos neg % pos neg % OR lower upper P Pm
A*01 16 31 34.0 15 32 31.9 1.10 0.470 2.567 1.0000 1.0000
A*02 24 23 51.1 23 24 48.9 1.09 0.488 2.420 1.0000 1.0000
A*03 10 37 21.3 13 34 27.7 0.72 0.282 1.813 0.6320 1.0000
A*11 4 43 8.5 6 41 12.8 0.66 0.185 2.364 0.7398 1.0000
A*23 4 43 8.5 0 47 0.0 9.83 0.514 187.879 0.1170 0.8248
A*24 10 37 21.3 9 38 19.1 1.14 0.423 3.042 1.0000 1.0000
A*25 1 46 2.1 1 46 2.1 1.00 0.100 9.968 1.0000 1.0000
A*26 1 46 2.1 2 45 4.3 0.59 0.074 4.630 1.0000 1.0000
A*29 2 45 4.3 0 47 0.0 5.22 0.244 111.718 0.4946 0.9999
A*30 0 47 0.0 2 45 4.3 0.19 0.009 4.100 0.4946 0.9999
A*31 3 44 6.4 5 42 10.6 0.61 0.149 2.476 0.7142 1.0000
A*32 2 45 4.3 6 41 12.8 0.35 0.077 1.601 0.2673 0.9871
A*66 1 46 2.1 1 46 2.1 1.00 0.100 9.968 1.0000 1.0000
A*68 5 42 10.6 3 44 6.4 1.65 0.404 6.703 0.7142 1.0000
B*07 9 38 19,1 11 35 23,9 0,76 0,288 2,015 0,6212 1,0000
B*08 12 35 25,5 10 36 21,7 1,22 0,477 3,139 0,8080 1,0000
B*13 2 45 4,3 1 45 2,2 1,67 0,211 13,150 1,0000 1,0000
B*18 2 45 4,3 4 42 8,7 0,52 0,105 2,574 0,4349 1,0000
B*27 3 44 6,4 6 40 13,0 0,49 0,125 1,924 0,3161 0,9998
B*35 6 41 12,8 7 39 15,2 0,83 0,265 2,572 0,7730 1,0000
B*37 1 46 2,1 1 45 2,2 0,98 0,098 9,758 1,0000 1,0000
B*38 2 45 4,3 2 44 4,3 0,98 0,161 5,923 1,0000 1,0000
B*39 1 46 2,1 2 44 4,3 0,57 0,073 4,530 0,6168 1,0000
B*44 16 31 34,0 8 38 17,4 2,37 0,916 6,148 0,0966 0,9034
B*47 0 47 0,0 1 45 2,2 0,32 0,013 8,043 0,4946 1,0000
B*49 1 46 2,1 1 45 2,2 0,98 0,098 9,758 1,0000 1,0000
































Low viral load9 Odds ratio and 95% C.I. Fisher’s Exact
pos neg % pos neg % OR lower upper P Pm
B*52 1 46 2,1 0 46 0,0 3,00 0,119 75,565 1,0000 1,0000
B*55 0 47 0,0 3 43 6,5 0,13 0,007 2,606 0,1170 0,9428
B*56 1 46 2,1 0 46 0,0 3,00 0,119 75,565 1,0000 1,0000
B*57 7 40 14,9 3 43 6,5 2,30 0,603 8,781 0,3161 0,9998
B*58 1 46 2,1 0 46 0,0 3,00 0,119 75,565 1,0000 1,0000
B60 10 37 21,3 7 39 15,2 1,48 0,522 4,164 0,5930 1,0000
B61 3 44 6,4 2 44 4,3 1,40 0,262 7,477 1,0000 1,0000
B62 6 41 12,8 10 36 21,7 0,54 0,186 1,595 0,2837 0,9995
B63 2 45 4,3 0 46 0,0 5,11 0,239 109,397 0,4946 1,0000
B65 1 46 2,1 1 45 2,2 0,98 0,098 9,758 1,0000 1,0000
C*01 2 45 4.3 2 45 4.3 1.00 0.165 6.053 1.0000 1.0000
C*02 6 41 12.8 10 37 21.3 0.56 0.191 1.636 0.4111 0.9983
C*03 18 29 38.3 17 30 36.2 1.09 0.478 2.498 1.0000 1.0000
C*04 10 37 21.3 9 38 19.1 1.14 0.423 3.042 1.0000 1.0000
C*05 5 42 10.6 10 37 21.3 0.46 0.151 1.418 0.2596 0.9729
C*06 10 37 21.3 6 41 12.8 1.79 0.611 5.229 0.4111 0.9983
C*07 25 22 53.2 26 21 55.3 0.92 0.412 2.053 1.0000 1.0000
C*08 1 46 2.1 1 46 2.1 1.00 0.100 9.968 1.0000 1.0000
C*12 7 40 14.9 2 45 4.3 3.37 0.758 14.995 0.1582 0.8733
C*14 1 46 2.1 0 47 0.0 3.07 0.122 77.169 1.0000 1.0000
C*15 1 46 2.1 3 44 6.4 0.41 0.058 2.901 0.6168 1.0000
C*16 1 46 2.1 0 47 0.0 3.07 0.122 77.169 1.0000 1.0000
C*01 2 45 4.3 2 45 4.3 1.00 0.165 6.053 1.0000 1.0000
C*02 6 41 12.8 10 37 21.3 0.56 0.191 1.636 0.4111 0.9983
DR17 11 36 23,4 11 35 23,9 0,97 0,380 2,487 1,0000 1,0000
DRB1*01 14 33 29,8 8 38 17,4 1,96 0,747 5,146 0,2228 0,9514
DRB1*04 5 42 10,6 17 29 37,0 0,22 0,075 0,634 0,0034 0,0401*
DRB1*07 15 32 31,9 7 39 15,2 2,51 0,935 6,744 0,0868 0,6636
DRB1*08 2 45 4,3 1 45 2,2 1,67 0,211 13,150 1,0000 1,0000
DRB1*09 0 47 0,0 1 45 2,2 0,32 0,013 8,043 0,4946 0,9997
DRB1*10 1 46 2,1 1 45 2,2 0,98 0,098 9,758 1,0000 1,0000
DRB1*11 5 42 10,6 5 41 10,9 0,98 0,278 3,432 1,0000 1,0000
DRB1*12 6 41 12,8 3 43 6,5 1,95 0,496 7,640 0,4856 0,9997
DRB1*13 16 31 34,0 11 35 23,9 1,62 0,662 3,948 0,3621 0,9955
DRB1*14 3 44 6,4 5 41 10,9 0,59 0,146 2,419 0,4856 0,9997
DRB1*15 10 37 21,3 14 32 30,4 0,63 0,249 1,579 0,3506 0,9944
DQ7 14 33 29,8 12 34 26,1 1,20 0,489 2,919 0,8180 1,0000
DQ8 5 42 10,6 14 32 30,4 0,29 0,098 0,856 0,0218 0,1428
DQ9 7 40 14,9 2 44 4,3 3,30 0,740 14,675 0,1582 0,7004
DQB1*02 19 28 40,4 17 29 37,0 1,15 0,505 2,633 0,8322 1,0000
































Low viral load9 Odds ratio and 95% C.I. Fisher’s Exact
pos neg % pos neg % OR lower upper P Pm
DQB1*05 19 28 40,4 13 33 28,3 1,70 0,722 3,992 0,2764 0,8961
DQB1*06 22 25 46,8 21 25 45,7 1,05 0,467 2,345 1,0000 1,0000
1 HLA alleles frequencies in the mothers with children with viral load measured on DBS above the median (3.2 log (IU/ml)); 
2 Mothers positive for the specific HLA allele; 3 Mothers negative for the specific HLA allele; 4 HLA alleles frequencies in 
the mothers with children with viral load measured on DBS below the median; 5 Odds ratio (OR) and 95% confidence intervals 
(95% C.I.) calculated based on the Woolf-Haldane method; 6 Two-sided Fisher’s exact test comparing HLA alleles frequencies 
between high and low viral load group; 7 Pm: corrected p-values for multiple comparisons (Šidák method); 8 HLA alleles 
frequencies in the children with viral load measured on DBS above the median; 9 HLA alleles frequencies in the children with 
viral load measured on DBS below the median. * Significant p-value after correction.


C H A P T E R 7GENER AL DISCUSSION
1.  

















This thesis aimed to identify prognostic markers, for short- and long-term clinical outcome, and 
correlates of protection, for future vaccine development. In order to identify such biomarkers, 
a retrospective nationwide cohort of children with (n=125) and without congenital CMV infection 
(cCMV) (n=263) was used. The findings of this thesis allowed us to get more insights into cCMV 
pathogenesis, and into the potential processes leading to immune dysfunction, and therefore to 
a worse clinical outcome. Thus, Chapter 7 delves into some important aspects of each chapter 
first, with particular attention to the possible mechanisms of cCMV pathogenesis and its clinical 
implications, i.e Summarising Discussion. This is followed by a paragraph that attempts to integrate 
all the findings in one final model, with special emphasis on what could be done in the future 
research to complete the findings of this thesis, i.e. Concluding Discussion. 
7.1.   SUM M ARIZING DISCUSSION 
7.1.1. Neonatal T and B cell markers in relation to symptoms, LTI and viral load
In Chapter 2 the immune system of the neonates was assessed by means of quantification of 
the most common DNA rearrangements occurring at the receptor level of B cells, αβ and γδ T 
cells. Our findings suggested that the intrauterine infection may have an effect on thymopoiesis, 
leading to a reduced thymic production of αβ T cells. Because CMV can infect thymic ephitelial 
cells (1, 2), and because smaller thymuses have been described in CMV infected newborns (3), 
our hypothesis seems plausible. Infected thymic ephitelial cells, which are fundamental for T cell 
development and maturation, could impair the output of naïve T cells. T cells play a central role in 
controlling CMV infection and disease, therefore, if the initial impairment was permanent one could 
assume a reduced long-term control of the infection, with a consequent worse long-term outcome. 
However, the reduced thymic output at birth was not associated to long-term impairments (LTI), 
suggesting that it is temporary and that other mechanisms are in place to compensate such initial 
impairment. In our cohort, the infected group had higher number of γδ T cells. The role of γδ T 
cells during cCMV has already been shown, but in the context of primary maternal infection, with 
antiviral activity when incubated with CMV-infected cells (4). Therefore, they could be potential 
candidates for such compensation, at least in the early phase of the infection, because they develop 
earlier than αβ T cells during the immune ontogeny, and react rapidly upon activation (5). Having 
higher levels of γδ T cells at birth did not correlate with a better long-term outcome, but positively 
correlated with CMV viral load, further suggesting their role in the early phase of cCMV. Interestingly, 
the reduced thymic output did not get worse with higher viral load. However, we do not know if 
higher blood viral load corresponds to higher viral load in the thymus. Therefore, we cannot exclude 
that a more severe local infection leads to a more reduced thymic output. The infected group had 
an increased number of circulating and newly derived bone marrow B cells compared to the control 
group. Therefore, even though we know that CMV can infect the bone marrow, a different 
pathogenetic mechanism may be assumed between the αβ T cell and B cell compartment, because, 
overall, cCMV does not induce a reduced B output as for αβ T cells. As the number of circulating 
and newly derived bone marrow B cells were comparable in all analyses, we concluded that cCMV 












And such a B cell production positively correlated with viral load, suggesting a causal relationship 
between high viral loads and cell activation, as previously suggested (6). Although, overall, infected 
neonates had higher number of B cells at birth, for those who developed LTI, this number was lower, 
comparable to non-infected controls. It is tempting to speculate that this difference in numbers 
reflects a difference in e.g. the capacity to generate long-lived plasma cells, memory B cells, Abs 
or support effector functions of immune cells. What is the trigger to this dysfunction is difficult to 
determine in our cohort, as it seems that viral load is not related to LTI development. Finally, none of 
the immunological markers included in this study was associated with symptoms at birth. 
7.1.2. Neonatal metabolic markers in relation to symptoms, LTI and viral load
In Chapter 3 the metabolism of neonates was assessed by means of quantification of the metabolites 
extracted from dried blood spots (DBS) for the screening of the rare genetic metabolic disorders 
(essential amino acids, hormones, carnitines and enzymes). During infections, there is a general 
increase of metabolic requirements. The virus is a considerable burden on cells because they are 
dependent on the host’s energy and biosynthetic pathways to replicate (7). For example, CMV 
envelope is enriched for longer chain fatty acids, and its infectivity is reduced by the inhibition of 
the host enzyme involved in their biosynthesis. This is why we found a positive correlation between 
palmytoilcarnitine, which reflects the level of palmitate (precursor of longer chain fatty acids) and 
viral load. Additionally, the immune system increases the proteins biosynthesis to allow a broad-
spectrum of anti-microbial functions (7). In our cohort, cCMV influenced the metabolites only in 
premature neonates. If cCMV occurs in premature neonates, they may not be able to cope, or at 
least not as good as term neonates, with the general increased energetic and biosynthetic demand 
during an infection, with a consequent lower level of essential aminoacids reflected in whole blood. 
However, since a certain degree of correlation has been shown between cCMV and prematurity (8), 
we cannot establish which was first, and most likely it is a combination of factors. Although we did 
not find a significant difference in the number of premature between cCMV+ and cCMV-, we found 
more prematurity in the infected group that developed LTI than in the infected group that did not. 
Interestingly, prematurity, both early, moderate and late, has been shown to be associated with LTI 
similar to those reported for cCMV (9). Obviously, prematurity, even if not caused by cCMV, will not 
help to fight the effect of a CMV infection.      
Finally, in past pediatric cohorts more female were reported with neurological impairments 
and cerebral ultrasounds findings, even though the number of infected males was higher than 
the number of  females (10). This bias was explained by assuming that the most severely affected 
fetuses died in utero and that the damage in the survivers was caused by the immune inflammatory 
response to CMV and by direct cytopathic effect (CPE) (10). Since in our cohort neonates were 
not selected based on their abnormal ultrasonographic state, or on the maternal primary infection, 
we did not enrich for severe cases. And this may be the reason why we did not detect differences 
in male/female proportion between symptomatic and asymptomatic. However, we found a higher 
proportion of infected males that developed LTI, whereas this was not observed in the control group 












infections in female, or higher susceptibility to autoimmune diseases when an inadequately high 
immune response occurs, might be involved in the long-term response to CMV as well. The overall 
morbidity rate is higher in males than females (11) and, in absence of immunopathology, the sex-
related differences might lead to a more effective long-term CMV control in female. Interestingly, 
infections as measles, mumps and RSV, other relevant problems in neonates, can cause more 
extensive complications in male (12). Such differences certainly merit more research because sex-
specific data on long-term CMV response in congenitally infected newborns are missing. 
7.1.3. Neonatal transcriptome in relation to LTI and viral load 
In Chapter 4 neonatal trascriptome was assessed my means of sequencing RNA extracted from 
DBS. Overall, the differences in whole blood gene expression profile were too small to be able 
to identify prognostic markers. This happened for a number of reasons extensively discussed in 
the paper. However, since gene expression analysis captures a snapshot of the cellular activity, 
considered to be the result of the response to genetic, environmental and epigenetic factors (13), 
we could make important observations on cCMV immuneregulation. Indeed, DBS mainly reflect 
the neonatal immune system because they are produced by spotting whole blood on filter paper. 
Three main observations characterized this study. First of all, high CMV viral load is the main initiator 
of the transcriptional differences observed in whole blood. Consequently, the differences between 
CMV+ and CMV- are diluted out because of the presence of low viral load individuals in the CMV+ 
group. Second of all, numerous antiviral and NK cells activation genes were positively associated 
with CMV viral load, suggesting the involvement of the innate immune system in response to higher 
CMV viral load in the fetus. This has been shown before in human first-trimester maternal-decidual 
tissues. Here, CMV infection upregulated genes related to antiviral innate immune response 
pathways, with particular emphasis on immune cell activation, proliferation, and trafficking patways 
(14). Therefore, what occurs at the maternal-fetal interface may be reflected at birth. Third of all, 
anti-inflammatory markers, such as the cytokine IL-4, were associated with congenitally infected 
children that did not develop LTI, suggesting that LTI pathogenesis may be partially attributable 
to an uncontrolled inflammation. The molecular mechanisms of LTI development are largely 
unknown. In neonates with neurological impairments and cerebral ultrasounds findings at birth, 
an uncontrolled inflammation together with a direct CPE are believed to be the responsible (10). 
Whereas, the late-onset hearing loss is believed to be the result of a chronic productive infection 
that occurs throughout childhood (15, 16). This suggests that the long-term immune response 
against cCMV is dysfunctional. Therefore, it cannot be excluded that such a dysfunctional 
immune response can lead to an uncontrolled inflammation that additionally contributes to tissue 
damage. Similarly to IL-10, IL-4 has been shown to possess similar capacity of down-regulating 
the production of pro-inflammatory mediators by microglia, both in humans and in mice (17-19), 
and its neuroprotective effect is believed to be based on the inhibition of brain inflammation (20). 
Additionally, in a cohort of healthy CMV infected individuals, the CD4 T-cell response associated with 
a protective immunity included the production of IL-4 (21). Considering that half of the neonates 












inflammatory markers may help in limiting the long-term tissue damage. Finally, what causes this 
immune long-term immune dysfunction is unknown, and T cell exhaustion could be one potential 
mechanimsm. However, in our cohort, T cell exhaustion that characterized the infected group, and 
was more marked with high CMV viral load, did not seem to play a role in the development of LTI, 
further supporting the reversibility of such phenomenon.  
7.1.4. Maternal-child HLA, expressed at the placenta, in realtion to symptoms, LTI 
and viral load
In Chapter 5 the maternal and fetal HLA background was assessed by means of HLA-C, HLA-E and 
HLA-G typing in both mothers and neonates, and the mothers were additionally typed for KIRs. We 
wanted to evaluate whether the maternal-child combination of HLAs expressed at the placenta, as 
well as the individual HLAs, may influence cCMV outcome. cCMV pathogenesis, and consequently 
its clinical outcome, is the result of a complex interplay between viral, maternal, placental, fetal and 
child factors. Within each compartment there are many aspects to be taken contemporarily into 
consideration, and given the complexity of the placental immune cross-talk, a short introduction is 
preparatory to this section’s discussion. 
Maternal-fetal imme cross-talk summary: the mother has a complicated task, she has to 
guarantee the immune tolerance to the fetus, by definition a semi allograft, and at the same time 
has to protect the fetus from infections. These two tasks involve opposite mechanisms of the same 
cellular populations, e.g. CD8+ T cells. Therefore, a proper compromise should be established. T 
cells represent the 5-20% of total decidual lymphocytes in the early phases of gestation, whereas 
this percentage becomes 40-80% at the end of pregnancy (22, 23). The majority of CD8+ T cells are 
activated effector memory T cells with naïve T cells almost absent (24-26), therefore cells that are 
highly Ags experienced/differentiated (27). Maternal fetus-specific T cells, i.e. specific for paternal 
Ags such as HLA-A, HLA-B and HLA-C, have been shown both in the maternal peripheral blood, and 
at the maternal-fetal interface (28, 29). The frequency of B cells in the decidua is very low (30), and 
this allows a certain degree of protection from Abs-mediated effects (31, 32). Monocyte are recruited 
to the decidua through interaction with the trophoblast-derived chemokine receptor ligands, 
they can differentiate into DCs (33), and are approximately <1% of total cells in the first trimester 
(23). Finally, decidual natural killer cells (dNK) cells are the most abundant leucocyte population, 
at least during the first trimester of pregnancy (34), and can also be generated locally (27). NK 
cytotoxicity is controlled by a combination of both activating and inhibitory receptors (35-38). In 
normal conditions, several mechanisms are in place to prevent a detrimental maternal immune 
response against the fetus. However, endogenous and exogenous factors can alter such delicate 
balance. An endogenous factor may be a not so favorable maternal KIR/fetal HLA-C combination 
(27), that skews dNK response towards an inhibitory response, which in turn negatively affects 
trophoblast invasion (39). An exogenous factor may be an infection, such as cCMV, which triggers 
an inflammatory response. This alters normal trophoblast invasion, induces apoptosis and placental 
dysfunction, with a consequent fetal damage, e.g. IUGR (40-42). 
Our findings added to this picture the following: if cCMV occurs at the backdrop of certain 












clinical outcome at birth. In particular, a reduced maternal control over cCMV, due to HLA-G del/
del genotype which leads to higher protein, may induce an increased viral and cellular burden at 
the placenta. Here, a fetal allo-Ags recognition by the maternal immune system may contribute to 
placental inflammation and dysfunction through direct damage. This was suggested by the increased 
percentage of HLA-E mismatches (mm) and HLA-C mm in the group of symptomatic neonates. 
Since in normal healthy pregnancies a shift towards more placental activated T cells in the presence 
of HLA-C mm has been shown (29), our theory seems plausible. Additionally, considering that 
HLA-E and HLA-C can present CMV Ags, a suboptimal viral clearance seems reasonable because 
maternal cells would not efficiently recognize CMV presented in the context of the allo-HLA by fetal 
cells.. This is further supported by the higher percentage of mm in the high viral load group. Finally, 
the absence of maternal HLA-C belonging to the C2 group was associated with symptoms at birth, 
most likely because this skews NK cell activation towards a pro-inflammatory state as the HLA-C1 
has less inhibitory capacity on dNK cells. Indeed, dNK cells do not interact only with fetal ligand, 
but also with maternal ligands as part of the internal immune homeostasis. Taken together, these 
factors may contribute to placental inflammation, dysfunction and a worse outcome at birth. Finally, 
prematurity has been associated to chronic placental inflammation in the absence of infections 
(43), and given the relatively high percentage of prematures in our cohort, the possibility of an 
inflammatory effect independent of CMV needed to be considered as well. Excluding the premature 
from the analysis, the results showed slight changes of p-values, but not of trends in the percentages. 
Removing 11 individuals from the symptomatic group led to lack of statistical power as we are left 
with only 8 individuals, and since we observed the same trends of percentages we could conclude 
that the associations we found were not influenced by prematurity. Although this is logical, from 
a statistical point of view we cannot fully exclude it. However, taking into account the association 
between cCMV and prematurity (8), it is plausible to assume that prematurity is an effect of 
the combination of cCMV and aforementioned HLAs. 
Finally, as previously mentioned, LTI development can be considered the result of a long-term 
immune dysfunction that leads to an uncontrolled viral replication and inflammation. Our 
findings added to this picture the following: HLA-C non-inherited maternal antigens (NIMAs) may 
support a long-term uncontrolled viral replication by means of the tolerance induced in the fetus 
towards NIMAs, which indirectly induce a tolerance to CMV. The NIMA effect has been shown in 
transplantation because it improves the outcome. Despite the exact molecular mechanism is 
largely unknown, several observations led to an hypothetical mechanism, which will be described 
in the paragraph below. Additionaly, as previously mentioned, prematurity has been shown to be 
associated with LTI similar to those reported for cCMV (9). Given the relatively high percentage of 
premature in our cohort, we considered the possibility of an effect independent of CMV. In our 
cohort, the results did not change, suggesting that prematurity does not influence the association 
we found between HLA-C NIMAs and LTI. By removing 6 individuals from the group with LTI, and 5 
in the group without, we are left with 21 vs 64 which does not lead to small numbers, as observed 
for symptoms at birth. 
Hypothetical mechanism of the NIMA effect in cCMV: in order for this effect to occur, the fetal 












cells between mother and fetus that starts during pregnancy and continues with breast feeding, 
leading to microchimerism (44, 45). These allogeneic cells seed in different organs in both mothers 
and children. In the latter, they can reach several fetal tissues such as bone marrow, blood, spleen, 
heart, lungs, pancreas and lymph nodes (46-49). The NIMA “recognition” can occur through 
different mechanisms, direct and indirect pathways. Fetal T cells can recognize NIMAs directly as 
intact antigens expressed on maternal cells or indirectly as peptides presented by the shared HLA. 
Fetal T cells can recognize NIMA derived peptides presented by fetal antigen-presenting cell (APC) 
in HLA Class I and Class II, and fetal APC can “meet” maternal cells in many fetal tissues. However, 
this recognition will not lead to immune activation but to immunomodulation of both T- and B-cells. 
When fetal CD4 T cells, that have already been modulated by NIMA, interact with APC’s expressing 
both NIMA and peptides derived from CMV, this will lead to downregulation of the immune response 
to CMV (linked immune suppression) (50, 51). 
7.1.5. Maternal-child HLA, not expressed at the placenta, in realtion to symptoms, 
LTI and viral load
In Chapter 6 the maternal and fetal HLA background was assessed by means of HLA-A, HLA-B, 
HLA-DR and HLA-DQ typing in both mothers and neonates. We wanted to evaluate whether 
the maternal-child combination of HLAs not expressed at the placenta, as well as the individual 
HLAs, may influence cCMV outcome. We decided to study the HLAs that are not expressed at 
the placenta because an allogeneic response can still occur (28, 52-54). Viral infections can increase 
the levels of pro-inflammatory cytokines and chemokines at the maternal-fetal interface, and 
intensify the decidual T cell influx (22, 55). Therefore, the increased level of allogeneic maternal 
cells specific for fetal Ag that are not expressed by the trophoblast, may contribute to placental 
immunopathology by increasing inflammation. This hypothesis seemed plausible because in 
Chapter 5 placental immunopathology seemed to be responsible for placental dysfunction, and 
a worse outcome at birth. However, mm and NIMAs for those HLAs not expressed at the placenta 
were not associated with a worse short- and long-term outcome in our cohort. However, it is worth 
to mention the trend of higher HLA-A and HLA-B mm percentages in the symptomatic group, which 
therefore are considered to have a small effect in the context of cCMV. Furthermore, HLA-C NIMA 
can have a more important role compared to NIMA of other HLAs. CMV has developed strategies 
to evade host immunity, and to establish latency by down-regulating classical HLA molecules and 
up-regulating non-classical HLA, while maintaining HLA-C expression in order to avoid NK cells 
activation. The important role of HLA-C during CMV infection is further supported by the fact that 
certain HLA-C-restricted CD8 T cells have more efficient antiviral functions than HLA-A or HLA-B 
(56). Thus, if an HLA molecules is not expressed, the NIMA Ag cannot be processed, and the NIMA-
specific regulatory mechanisms do not occur as efficiently as if the Ag is expressed. Additionally, 
the degree of the NIMA effect may also vary according to the percentage of microchimeric cells 
that engrafted fetal tissues. In fetal lymph nodes a predominance of hematopoietic cells was 
observed, with a frequency between 0.0035% to 0.83% (49), and others have reported similar % for 












In this chapter, we additionally evaluated the individual, maternal and child, HLAs in relation to 
neonatal CMV viral load. The main finding is that HLA-DRB1*04 seemed to be protective, or at least 
to better control the infection, as its frequency was increased in the neonates with lower viral load. 
Such an effect did not lie in the maternal-fetal combination, but in the presence of these Ags in 
the child. HLA Class II is involved in the support of CTL and humoral response, which are fundamental 
players in controlling CMV infection. This suggests that a favourable CMV-HLA II combination can 
have an important dual effect.
7. 2 .  CONCLUDING DISCUSSION
Several approaches have been used to explore prognostic markers for long-term outcome, but not 
all of them seemed promising, although all of them were useful to get more insights into cCMV 
pathogenesis. An important aspect should be kept in mind, this is an associative study, and, as such, 
it needs confirmation, both in other associative studies and experimentally. The first would allow us 
to determine whether the findings of this thesis, mainly those genetic, can be reproduced in other 
comparable cohorts. The second would allow the determination of the molecular mechanisms, 
which is fundamental to design any innovative intervention. The neonatal immune markers, 
through DNA quantification of the most common TCR and BCR rearrangements from DBS, together 
with the maternal-child HLA background, through typing DNA from buccal swabs, seemed to be 
quite promising for prognostic markers, and certainly merit further evaluation. Whereas the small 
effect of cCMV on the transcriptome profile from DBS should first be confirmed with fresh material 
before excluding such an approach. Finally, the neonatal metabolism, which was assessed when 
the material was fresh, did not look like an encouraging approach for finding prognostic markers 
in the context of cCMV. In the following paragraphs, an attempt to integrate all the findings in one 
final model is presented in relation to cCMV, symptoms at birth and LTI development (Fig. 1). A final 
paragraph on the role of CMV viral load is included because it was a recurrent topic in all chapters.
7.2.1. Congenital CMV infection
cCMV affected the neonatal immune system by reducing the thymic output of αβ T cells, increasing 
circulating γδ T cells as well as newly formed and circulating B cells (Chapter 2). cCMV did not 
induce extensive proliferation of B cells, rather increased the general production (Chapter 2), and 
induced exhaustion of T cells (Chapter 4). CMV viral load was an important determinant for shaping 
the immune system not only in relation to the number of circulating γδ T cells, newly formed and 
circulating B cells, but also in relation to the whole blood transcriptome of innate immune system and 
NK cell activation (Chapter 4). This raises a central point, i.e. the presence of low viral load neonates 
in the CMV+ group may mask important effects in the immune system. The only immune marker not 
associated with viral load was the thymic output of αβ T cells, however, we cannot conclude that 
the viral load would not influence this compartment because we do not have a marker for circulating 
αβ T cells. And we do not have a marker for the number of newly formed γδ T cells in order to see 
whether, similarly to αβ T cells, cCMV induces a reduced output. Therefore, in future research it 












system, NK cell activation and γδ T cells may be important mechanisms to control CMV in the early 
phase of infection, where the output of αβ T cells is reduced, and the CMV-specific CTL and humoral 
responses are still developing. As both the CTL and the humoral responses are fundamental for 
controlling CMV infection, a favorable HLA Class II-CMV peptide complex would support more 
efficiently both arms of the adaptive immune system with a consequent more efficient viral control 
(Chapter 6). Therefore, in future studies, it would be important to determine which CMV peptide is 
presented in the context of HLA-DRB1*04 as this could be exploited in future vaccine development. 
Moreover, although both the virus and the immune system activation impose an important burden 
on the cellular metabolism, as it has been shown in vitro, overall the effect was not strong enough 
to be reflected in whole blood in the general population but only in premature neonates (Chapter 
3). Premature neonates may not be able to efficiently cope with the general increased metabolic 
requirements, with a consequent lower level of essential aminoacids, fundamental for the correct 
development. Therefore, future studies are needed to evaluate the clinical implications of cCMV in 
this special category of neonates. Finally, similarly to the neonatal immune system, CMV viral load 
appeared to be an important determinant in shaping the neonatal metabolism. Indeed, C16, which 
reflects the level of palmitate, i.e. precursor of longer chain fatty acids for which CMV is enriched 
for, was positively correlated to CMV viral load.
7.2.2. Symptoms at birth
The number of various immune cells was not associated with a worse outcome at birth 
(Chapter 2). One plausible explanation may be the fact that the clinical signs included in the definition 
of symptoms at birth in our cohort are rather general. Indeed, the mechanisms that lead to neonatal 
hepatosplenomegaly, petechiae, purpura, thrombocytopenia, neutropenia or elevated ALAT may 
not be due entirely to a dysfunction of the neonatal immune system per se. Whereas in those 
symptoms that are more specific of cCMV, such as microcephaly, one could assume that the neonatal 
immune system may have a more important role. E.g., in solid organ-transplanted patients, γδ T cell 
expansion was associated with resolution of CMV infection and less symptomatic CMV disease, and 
late γδ T cells expansion was correlated with a more intense and durable CMV infection (58). This 
can potentially be also the case in our cohort if only we could assess all immunological markers 
in relation to the individual clinical signs. In our cohort1, symptoms at birth seemed to be mainly 
caused by a placental dysfunction as a result of a multifactorial process that starts in the mother 
and continues in the placenta (Chapter 5). This seems plausible because a placental dysfunction can 
lead to general fetal harm. The genetic factors involved are: maternal HLA-G del/del genotype that 
increases the cellular and viral burden at the placenta; HLA-E mm and HLA-C mm that induce a fetal 
allo-Ags recognition by the maternal immune system, and a suboptimal viral clereance; absence 
of maternal HLA-C belonging to the C2 group that skews dNK cells activation towards a pro-
inflammatory state (Chapter 5). Here, mm that are specific for HLA not expressed at the placenta, 
such as HLA-A mm and HLA-B mm, may partially contribute to placental inflammation (Chapter 6). 
Evaluating the molecular mechanisms behind the influence of such genetic factors during cCMV 












a prospective study, but to start with maternal blood samples would be useful to compare the CMV-
specific immune system in relation to HLA-G genotype. Additionally, placental specimens would be 
necessary to evaluate the effect of the maternal HLA-G and HLA-C genotypes, as well as maternal-
fetal HLA-C mm and HLA-E mm, in the cellular and structural composition of the placenta. And 
the CMV viral load should always be taken into consideration. 
7.2.3. Long-term impairments
In our cohort, a dysfunctional immune response that leads to an uncontrolled viral replication, 
combined with an uncontrolled inflammatory response, appeared to be responsible for LTI 
development. This most likely involves both the effector and regulatory mechanims. Neonates 
developing LTI had lower numbers of newly formed and circulating B cells at birth, suggesting some 
sort of long-term dysfunction (e.g. in the capacity to generate long-lived plasma cells, memory 
B cells, antibodies (Abs) or support effector functions of immune cells), or reduced capacity to 
control the infection (Chapter 2). As both CTL and humoral response are necessary to control CMV 
infection, it would be extremely interesting in future research to see whether infected neonates 
that developed LTI had lower number of circulating αβ T cells at birth, both total and CMV-specific. 
What is the trigger of this difference in B cells number between infected neonates that develop 
LTI and those who do not is impossible to establish in our cohort. Importantly, the exhaustion that 
we described for T cells (Chapter 6), but that has also been described for B cells in the context of 
other chronic infections such as HIV (59), did not seem to be so permanent to cause a long-term 
dysfunction. The exhaustion temporariness is not surprising because in a murine model of chronic 
infection, the blockade of PD-1 resulted in reversion of the exhaustion (60). A genetic factor 
may contribute to a long-term dysfunction. In our cohort, HLA-C NIMA appeared to be partially 
responsible for LTI development (Chapter 5). The so-called NIMA effect, i.e. immune tolerance to 
NIMA, indirectly can induce a tolerance to the infection with a consequent reduced viral control. 
This effect, that can influence both T and B cells, is due to microchimeric cells that persists at least 
till early adulthood (49, 61). Demonstrating the role of a genetic factor for LTI development is more 
difficult because of the late onset of certain LTI, and of different pathogenetic mechanisms that may 
be responsible for different impairments such as hearing loss and motor impairment. One way to 
start would be to compare the neonatal CMV-specific immune response with and without HLA-C 
NIMA, and repeat this over time, in relation as well to CMV viral load. The immune dysfunction 
that leads to an uncontrolled viral replication may be followed by dysfunctional compensatory 
mechanisms that in turn lead to an uncontrolled inflammatory response. Indeed, in our cohort, 
anti-inflammatory markers characterized infected neonates that did not develop LTI, further 
supporting the role of inflammation as additional determinant for tissue damage (Chapter 4). In 
the context of development of LTI, the sex-related differences in the immune system should be 
taken into consideration as well (Chapter 3). Finally, prematurity has been shown to be associated 
with LTI similar to those reported for cCMV (9), as well as to chronic placental inflammation also 
in the absence of infections (43). However we believe that it is not the prematurity per se that is 












in the definition of “symptoms at birth”, it has been shown that cCMV is frequently accompanied by 
prematurity (8). When focusing on symptomatic groups (with prematurity not used as a criterion) 
the percentage of prematurity is usually around 36% (62). The percentage of symptomatic children 
in the infected group in our cohort, including those that were premature, was 18%, which is similar 
to that found in previous studies. The percentage of prematures in the infected group (10.8%) was 
similar to that found by others (and only slightly higher than in the general population), although 
others have found lower percentages (8, 63). Despite the fact that the percentage of premature 
neonates were relatively high in our cohort, our data showed that the association we found 
between HLAs and cCMV clinical outcome is not confounded by prematurity. However, there is no 
doubt that prematurity will not be beneficial for the undisturbed child development, but cCMV and 
HLAs may have a synergistic effect on prematurity, and these three factors may all contribute to 
LTI development.
7.2.4. CMV viral load and DBS testing
CMV viral load in our cohort was not significantly associated to symptoms at birth nor to LTI. The role 
of CMV viral load in the cCMV clinical outcome still needs to be elucidated as some previous studies 
have related the viral load to a worse outcome (62, 64), whereas others have not (65-67). However, 
there is no standardized way of defining symptoms at birth or LTI, and the CMV viral load in blood 
of infected neonates may vary depending on the timing of infection, whether there was a maternal 
primary or secondary infection, or on the specific compartment impaired. Indeed, it is tempting 
to speculate that between a neonate with cCMV that has hearing loss at birth and a neonate with 
cCMV that has elevated liver transaminases, the peripheral CMV viral load differs. Unfortunately, 
due to lack of statistical power we could not evaluate how whole blood CMV viral load changes in 
relation to the different compartments impaired. For all aforementioned reasons, if any role of viral 
load in blood exists, it may have been diluted in our cohort. In future research, defining the role of 
viral load in relation to individual clinical outcomes, standardizing the definition of symptomatic 
disease and LTI development is absolutely essential in order to be able to draw any conclusion on 
pathogenesis. Indeed, what we concluded in this thesis can very well not be the case in another 
cohort just because different definitions are used. Nevertheless, this cohort study, retrieved 
from a large population screening, does reflect a real population of newborns with cCMV in all 
its diversity, ranging from no symptoms at birth and no LTI to symptoms at birth with severe LTI. 
This would be the situation we will have to deal with in a universal screening setting. Additionally, 
DBS testing for cCMV diagnosis may be seen as a potential limitation. Indeed, the golden standard 
method for cCMV diagnosis is the urine testing because of the high viruria observed in congenitally 
infected infants (65), but saliva is considered equally reliable (68), and CMV viral load is usually lower 
in blood than in urine (65). DBS can be considered a proper and reliable alternative specimen to 
blood, because a positive correlation between CMV viral load measured on DBS and CMV viral load 
measured on whole blood/ plasma, both in the context of cCMV and CMV in transplantation, was 
shown (69, 70). These studies suggested that DBS may be used not only for diagnosis but also for 
monitoring response to therapy. Moreover, DBS testing has a reputation of lower sensitivity, and 
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the relative reduction of CMV viral load on DBS in time (69), the specimens that could be potentially 
more affected from the aforementioned differences between blood and urine/saliva are the ones 
with low viral load. This implies that low-positive neonates may be found in the CMV negative 
group. However, with the high sensitivity of our PCR (estimated > 85%), high specificity (> 99.9%) 
and the cCMV birth prevalence of 0.5%, the chance of a CMV false-negative result is 1/1000 (71). 
Therefore, the influence of the sensitivity of the CMV PCR on DBS on the conclusions in all chapters 
can be considered negligible. Despite the aforementioned potential limitations, the use of DBS, that 
are normally collected at birth for the screening of rare genetic metabolic disorders, has several 
advantages over other specimens. Since the DBS are routinely collected, they are available almost 
worldwide, and allow large-scale retrospective studies for long-term cCMV outcome, which would 
be challenging in a prospective setting. Additionally, CMV detection on DBS does not require special 
facilities, is not expensive and an automation can be performed in order to include many specimens 
at the same time further reducing the price. However, efforts in improving these aspects and 
the standardization of such a method are necessary for the introduction in the screening program.
Figure 1. Final model of cCMV pathogenesis. A) Overall effects of cCMV in relation to the neonatal immune 
system and metabolism. B) Effects of higher CMV viral loads in relation to the neonatal immune system and HLA 
Class II. C) Genetic factors that in presence of a cCMV may lead to placental dysfunction, and consequently to 
symptoms at birth. D) Genetic and immune factors that in presence of a cCMV may lead to reduced viral control 
and increased inflammation throughout childhood, and consequently to LTI development. 












To conclude, any future intervention should focus on supporting both arms of the adaptive 
immune response in order to efficiently control the chronic viral replication, with particular attention 
to regulating the inflammatory response. This seems achievable with a vaccine, though the target 
population may vary depending on the goal of such vaccine. However, as the way to a licensed 
vaccine seems to be long, the tertiary prevention sounds like a good compromise. By means of 
tertiary prevention we would like to prevent, or at least positively affect, the short- and/or long-term 
impairments. How can we efficiently intervene to limit a progressive permanent damage that has 
a late onset manifestable in years after birth? We have to understand the pathogenesis of cCMV, 
and to identify a biomarker that differentiate these groups. The majority of congenitally infected 
neonates are asymptomatic at birth and have a good prognosis for a normal long-term development, 
therefore the comparison of their immunological condition with that of the symptomatic infected 
neonates with a worse long-term outcome, as well as those asymptomatic that develop the same LTI, 
should be the focus in future research. Importantly, the approaches used would need to be powerful 
enough to get subtle differences that are likely to be expected between asymptomatic that develop 
LTI and asymptomatic that do not. In parallel with this, it would be essential to determine whether 
treatments offered to symptomatic neonates, ranging from antivirals to audiological and motor 
follow-up, are beneficial in those asymptomatic neonates that develop LTI. For example, whether 
(val)ganciclovir treatment of asymptomatic neonates with higher probability to develop hearing 
problems actually has a positive effect on the hearing compared to a similar group that did not get 
such treatment. Maybe the side effects of such treatment would exceed the positive effect in a way 
that would be better to somehow boost their immune system. However, an even earlier goal should 
be the standardization of the definitions of symptomatic disease and LTI development, as well as 
the role of viral load in the clinical outcome, without which no reliable conclusion on the actual 
cCMV pathogenesis, and its clinical consequences, can be drawn. Concluding, understanding 
the pathogenesis of cCMV would allow to figure out why certain children develop LTI and others 
do not. In turn, this would provide the necessary biomarkers to predict outcome and stratify 
patients according to the risk. On one hand we could define who benefits most from certain clinical 
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Cytomegalovirus (CMV) infection is a worldwide common infection that in a considerable proportion 
of individuals remains unnoticed. However, when the virus infects the fetus via the placenta during 
pregnancy, it can cause severe disease. The congenital CMV infection (cCMV) can induce a variety 
of clinical manifestations at birth (symptoms at birth), and of permanent long-term impairments 
(LTI). These clinical signs can also vary in severity, e.g. in symptomatic neonates they can range 
from elevated liver enzymes to microcephaly (having a smaller than normal head). The permanent 
long-term disabilities (ranging from neurological to visual impairments) can be progressive 
or reveal themselves later in childhood, for example late onset hearing loss, and in this context 
a retrospective diagnosis may be challenging. Importantly, of the total of infected neonates at birth, 
13% are symptomatic at birth, and half of them will develop LTI. However, 13% of the asymptomatic 
neonates will still develop the same LTI; and since this group is much bigger than the symptomatic 
group, the majority of clinical cases come from the asymptomatic neonates. The latter is where 
the cCMV gets easily unnoticed because you do not see anything suspicious at birth. Summarizing, 
not all infected foetuses will have symptoms at birth or will develop long-term disabilities. At 
this moment, there is no prognostic marker available to anticipate which neonates, and when, 
will develop LTI, nor which type of disability. cCMV can occur at any time during pregnancy, and 
usually when it occurs early in pregnancy it can cause more severe disease because the fetus is 
still developing. cCMV can occur in mothers after their first infection with CMV during pregnancy 
(who were previously seronegative) or who were previously infected with CMV (seropositive). In 
the latter, the vertical transmission rate (i.e. CMV transmission from the mother to the fetus) is 
usually lower than in the seronegative pregnant women, because of the pre-existing immunity to 
CMV, but it is not clear whether this immunity also protects against severe clinical problems. These 
two variables, trimesters of maternal infection and pre-existing immunity, complicate studies on 
cCMV pathogenesis in the general population.
The aim of this thesis was to get new insights into cCMV pathogenesis, and to identify prognostic 
markers for short- and long-term clinical outcome, and correlates of protection for vaccine 
development. For this purpose, a retrospective nation-wide cohort of congenitally infected children 
and controls (i.e. non-infected children) was used. All children were born in The Netherlands in 
2008, and dried blood spots (DBS) were used to diagnose cCMV. DBS are obtained by spotting whole 
blood from the heels of the neonate within one week after birth. These cards are routinely used for 
the screening of the rare genetic metabolic disorders for which a clinical, life-saving, intervention 
is available. DNA was extracted from these cards, and the presence of CMV DNA was evaluated in 
order to diagnose cCMV. Additionally, by quantification of CMV DNA, the viral load (which gives 
an indication on how much virus is present in the body) was determined. Of the children in this 
cohort, clinical data from birth till 6 years of age were available. Another specimen collected from 
this cohort, from both mothers and children, was represented by buccal swabs. DNA was extracted 







were evaluated and related to CMV viral load, symptoms at birth and LTI development at 6 years 
of age:
•	 markers for B cells, αβ and γδ T cells in DBS;
•	 gene expression profiles with specific attention to the immune system and 
inflammation pathways;
•	 data on essential amino acids, hormones, carnitines and enzymes in DBS; 
•	 HLA (human leukocyte antigens) typing on buccal swabs of mothers and children 
with cCMV. 
In the following paragraphs, the main findings of all chapters are presented. First, the above 
mentioned biomarkers in relation to cCMV infection itself and the viral load in DBS are presented. 
Then, the biomarkers in relation to symptoms at birth and LTI development. 
Congenital CMV infection
In order to study the effect of cCMV on different markers, we compared the biomarkers in DBS 
or buccal swabs in children with cCMV to those without cCMV (our control group). In our cohort, 
cCMV resulted in a reduced production of αβ T cells in the thymus, an increased number of γδ 
T cells, and increased production of B cells (Chapter 2). Additionally, cCMV induced exhaustion 
of T cells (i.e. a general state of cellular dysfunction usually induced by chronic infections and 
exposure to high viral loads) (Chapter 4). Of these markers, only the production of αβ T cells was 
not associated with CMV viral load. In Chapter 4, the gene expression profile on the DBS showed 
that gene expression of genes related to the innate immune response and NK cell activation was 
higher in children with a higher CMV viral load. The innate immune system, NK cells and ϒϒ T cells 
may play an important role in controlling CMV in the foetus, where the CMV-specific responses are 
still developing. Furthermore, a specific HLA of Class II in children (i.e. molecule that presents CMV 
components to immune cells), i.e. HLA-DRB1*04, was associated with a better CMV viral control 
(Chapter 6). This positive effect on viral control may rely on the fact that a HLA Class II supports 
both arms of the immune response, cytotoxic and antibody responses. Furthermore, cCMV did not 
affect the neonatal metabolism in DBS, but a reduced level of essential aminoacids (components 
of proteins) was found in  the subgroup of congenitally infected neonates that was premature 
(i.e. birth before the 37 weeks of gestation) compared to the prematurely born children without 
cCMV (Chapter 3). Although cCMV did not affect the neonatal metabolism, a higher CMV viral load 
induced an increase of C16 (Chapter 3). C16 is a fatty acid and  the precursor to longer chain fatty 
acids, for which the outer structure of CMV is enriched. Therefore, the increase of C16 in the high 
viral load group may simply reflect the increased viral burden.
Symptoms at birth
The different markers were also studied in relation to the presence of symptoms at birth, by 







markers related to symptoms at birth were found while studying the HLA-types of both mothers 
and children, with their specific combination. In Chapter 5 and Chapter 6 we assessed the role of 
HLA Class I and Class II, as well as the receptors for NK cells of the mothers, in relation to cCMV 
clinical outcome. We found that mothers with a specific HLA-G deletion/deletion genotype or 
mothers homozygous for HLA-C1, as well as mother-child pairs with HLA-E and HLA-C mismatches 
were associated with symptomatic disease (Chapter 5). The mothers that have the HLA-G deletion/
deletion genotype probably have higher levels of the HLA-G protein that has immunosuppressive 
properties.  The immunosuppression may lead to less viral control upon CMV infection during 
pregnancy and may lead to a higher viral burden  of the placenta. A HLA mismatch exists when 
the mother does not have the same genetic HLA information as the fetus has, because some of 
the genetic HLA information derives from the father, which may be different from that of the mother. 
In  Chapter 5, we demonstrated that in case of  HLA-E or HLA-C mismatch  the chance of a child with 
symptoms at birth was higher. A mismatch of HLA, such as HLA-E and HLA-C that are expressed in 
the placenta, may lead to maternal T cells that are capable of attacking the fetal tissue. Normally, 
this process is suppressed, but in case of a placental CMV infection, this balance may be disturbed 
leading to a T cell reaction towards the placenta and the fetus. Furthermore, HLA matching is 
necessary for an adequate immune response to virus-infected cells. Therefore, a HLA mismatch 
may lead to a worse immune reaction and less control of the viral infection, with higher placental 
and possibly fetal viral loads as a result. Finally, one of the most abundant cells in the placenta is 
the NK cell, which belong to the innate immunity and therefore react rapidly upon activation. These 
cells have the peculiar characteristic of having several activating and inhibitory receptors whose 
combination defines the degree of NK cells activation. The HLA-C molecules  can bind to these 
receptors with different degrees of strength. In our cohort, in the group with symptoms at birth, 
the mothers more frequently missed the inhibitory type of  HLA-C, and therefore the activating 
signals towards NK cells may prevail contributing to the already increased placental inflammation 
(Chapter 5). In Chapter 6 the HLA-types that are not expressed in the placenta were studied. For 
these HLA-types no association with symptoms at birth was found. Summarizing, symptoms at birth 
appear to be related to genetic markers that contribute to high CMV viral load at maternal and 
placental level, due to a lack of viral control, and to a higher level of  placental inflammation.
Long-term impairments
In three chapters biomarkers are described that seem to be associated with LTI at 6 years of age. 
In Chapter 2, infected children that developed LTI had lower numbers of B cells. In addition, we 
found higher percentage of HLA-C non-inherited maternal antigens (NIMA) in those infected 
children that developed LTI (Chapter 5). The fetus is exposed to antigens that he/she did not inherit, 
the so-called NIMA, because during pregnancy and breast-feeding there is a mutual exchange of 
cells between mother and child.  Small numbers of maternal cells seed in several fetal organs and 
persist at least until adulthood. However, instead of the initiation of a fetal immune response against 
these “foreign” maternal antigens, the fetus develops a long-lasting tolerance (NIMA effect). 







However, during infections the NIMA effect may induce an indirect tolerance to the infection as 
well. Consequently an indirect  tolerance to the CMV infection may induce an uncontrolled viral 
replication throughout childhood. Furthermore, in Chapter 4, we show that in children that did not 
develop LTI there was a higher expression of anti-inflammatory markers. This further suggests that 
part of the pathogenesis of LTI development can be attributable to an uncontrolled infection and 
inflammation. 
The aim of this thesis was to identify prognostic markers for short- and long-term clinical 
outcome and correlates of protection for vaccine development. We did find some interesting 
biomarkers that, if confirmed in other cohorts, could be potential candidates for such goals. 
However, sometimes the differences were too small, and a striking biomarker was not found. On 
the other hand, we did find some clues towards a better understanding of cCMV pathogenesis (i.e. 
biological mechanisms that leads to disease). Understanding cCMV pathogenesis is fundamental 
for several reasons. First of all, it would help future research on prognostic markers. Second of all, 
it would support the introduction of innovative clinical strategies to prevent, or at least positively 
affect, the short- and long-term clinical outcome because we would understand the mechanisms 
for the progressive and permanent damage. Indeed, the way to a licensed vaccine is way too long to 
just patiently wait for it. However, in the end, vaccination should be the main goal in cCMV research 
because it could be the ultimate solution for prevention of vertical transmission during pregnancy, 
or disease development in the child. Finally, the identification of the aforementioned biomarker 
could help the future research for vaccine development.  
To conclude, from the research presented in this thesis, several issues have emerged that 
should be taken into account in future research. The majority of congenitally infected neonates 
are asymptomatic at birth and have a good prognosis for a normal development, therefore 
the comparison of their immunological state with that of the symptomatic infected neonates with 
a worse long-term outcome, as well as those asymptomatic that develop the same LTI, is essential 
to determine what is happening in the children who are affected by cCMV. While doing that, we 
should also define new clinical strategies, and also study whether the current clinical strategies are 
beneficial for those asymptomatic neonates that develop the same LTI, and whether for this group 
the benefits of for example antiviral treatment outweigh the side effects. However, an even earlier 
goal should be the standardization of the definitions of symptomatic disease and LTI development 








Cytomegalovirus (CMV) infectie is een wereldwijd voorkomende infectie die bij het merendeel van 
de personen onopgemerkt blijft. Wanneer het virus echter tijdens de zwangerschap het ongeboren 
kind (foetus) via de placenta infecteert, kan het ernstige ziekte veroorzaken. Deze congenitale, of 
aangeboren, CMV infectie (cCMV) kan een verscheidenheid aan klinische manifestaties veroorzaken 
bij de geboorte (symptomen bij de geboorte) en op de lange termijn, de zogenaamde lange termijn 
gevolgen (LTG). De klinische symptomen kunnen ook variëren in ernst, b.v. bij symptomatische 
pasgeborenen kunnen ze variëren van verhoogde leverenzymen tot microcefalie (een te klein 
hoofd). De permanente lange termijn beperkingen (variërend van problemen met het zicht tot 
ernstige neurologische problemen) kunnen deels progressief zijn of zich later in de kindertijd 
openbaren, bijvoorbeeld het later ontstaan van gehoorverlies. In dat geval kan een retrospectieve 
diagnose een uitdaging zijn. Belangrijk is dat van het totaal aantal geïnfecteerde pasgeborenen 13% 
symptomatisch is bij de geboorte en de helft van deze kinderen LTG zal ontwikkelen. Echter, ook 
13% van de asymptomatische pasgeborenen zal dezelfde LTG ontwikkelen; en aangezien deze groep 
veel groter is dan de symptomatische groep, zijn de meeste kinderen met lange termijn problemen 
afkomstig uit de groep die asymptomatisch bij geboorte was. In dit laatste geval wordt cCMV dus 
makkelijk gemist omdat er bij de geboorte geen verdenking ontstaat. Samenvattend, zullen niet 
alle geïnfecteerde kinderen bij de geboorte symptomen vertonen of langdurige beperkingen 
ontwikkelen. Op dit moment is er geen prognostische marker beschikbaar om te voorspellen 
welke neonaten LTG zullen hebben, en wanneer, en welk type beperking ze zullen krijgen. cCMV 
kan op elk moment tijdens de zwangerschap optreden, maar de gevolgen zijn ernstiger wanneer 
de infectie vroeg in de zwangerschap optreedt, omdat de foetus zich dan nog ontwikkelt. cCMV 
kan vóórkomen bij moeders na hun eerste infectie met CMV tijdens de zwangerschap (moeders 
die eerder seronegatief waren) of bij moeders die al eerder geïnfecteerd waren met CMV (dus 
seropositief waren). Bij de laatste groep is de verticale transmissie kans (dat wil zeggen de kans dat er 
CMV-overdracht plaatsvindt van de moeder naar de foetus) meestal lager dan bij de seronegatieve 
zwangere vrouwen, vanwege de reeds bestaande immuniteit tegen CMV, maar het is niet duidelijk 
of deze immuniteit ook beschermt tegen ernstige klinische problemen. Deze twee variabelen, 
trimester van maternale infectie en reeds bestaande immuniteit, bemoeilijken studies over cCMV-
pathogenese in de algemene populatie.
Het doel van dit proefschrift was om nieuwe inzichten te verkrijgen in cCMV-pathogenese 
en om prognostische markers te identificeren voor korte- en lange termijn klinische uitkomsten. 
Hieraan gerelateerd zou de studie een maat voor bescherming tegen CMV kunnen opleveren, 
welke te gebruiken bij vaccinontwikkeling. Voor dit doel werd een retrospectief Nederlands 
cohort van kinderen met cCMV en CMV-negatieve controles (niet-geïnfecteerde kinderen) 
gebruikt. Alle kinderen zijn in 2008 in Nederland geboren en bloed op het hielprikkaartje werd 
gebruikt om cCMV te diagnosticeren. De hielprikkaartjes worden verkregen door binnen een 
week na de geboorte bloed uit de hiel van de pasgeborene op een filterpapier te druppelen. Deze 
hielprikkaarten worden routinematig gebruikt voor het screenen op zeldzame genetische en 








zijn getest op de aanwezigheid van CMV-DNA om cCMV te diagnosticeren. Bovendien werd, door 
het meten van de hoeveelheid CMV-DNA, de “virale load” bepaald (een maat voor hoeveel virus 
in het lichaam aanwezig is). Van de kinderen in dit cohort waren klinische gegevens beschikbaar 
vanaf de geboorte tot de leeftijd van 6 jaar. Verder is van zowel moeders als kinderen een beetje 
wangslijmvlies afgenomen. DNA uit wangslijmvlies is gebruikt voor verschillende genetische 
studies. Voor de studie werden de volgende biomarkers onderzocht in relatie tot cCMV, de CMV-
virale load, symptomen bij de geboorte en LTG tot de leeftijd van 6 jaar:
•	 Markers voor B-cellen, αβ- en γδ-T-cellen in de hielprikkaart
•	 Genexpressie profielen in het bijzonder in relatie tot het immuunsysteem en 
ontstekingsreacties in de hielprikkaart
•	 Gegevens over essentiële aminozuren, hormonen, carnitines en enzymen in de hielprikkaart
•	 HLA (humane leukocyten antigenen) op wangslijmvlies van moeders en kinderen
In de volgende paragrafen worden de belangrijkste bevindingen van alle hoofdstukken weergegeven. 
Eerst worden de bovengenoemde biomarkers met betrekking tot cCMV-infectie zelf en de virale 
load in de hielprikkaart beschreven. Vervolgens, de biomarkers in relatie tot symptomen bij 
de geboorte en LTG-ontwikkeling.
Congenitale CMV infectie
Om het effect van cCMV op de verschillende markers te bestuderen, hebben we de biomarkers in 
de hielprikkaart of wangslijmvlies bij kinderen met cCMV vergeleken met die bij kinderen zonder 
cCMV (onze controlegroep). In ons cohort was in de cCMV groep een verminderde productie van 
αβ T-cellen in de thymus aantoonbaar, een verhoogd aantal γδ T-cellen en verhoogde productie 
van B-cellen (hoofdstuk 2). Bovendien was bij cCMV uitputting van T-cellen te zien (d.w.z. een 
algemene toestand van cellulaire dysfunctie die gewoonlijk wordt gezien bij chronische infecties en 
blootstelling aan hoge virale loads) (hoofdstuk 4). Van deze markers was alleen de productie van αβ 
T-cellen niet geassocieerd met CMV virale load. In hoofdstuk 4 toonde het genexpressieprofiel op 
de hielprikkaart een hogere expressie van genen gerelateerd aan de aangeboren immuunrespons 
en NK-cel activatie bij kinderen met een hogere CMV virale load. Het aangeboren immuunsysteem, 
waaronder NK-cellen en γδ T-cellen, kan een belangrijke rol spelen bij het onder controle 
houden van CMV in het ongeboren kind, waar de CMV-specifieke immuunreactie zich nog moet 
ontwikkelen. Verder was een specifiek HLA van klasse II bij kinderen (d.w.z. een molecuul dat 
CMV-componenten presenteert aan immuun cellen), namelijk HLA-DRB1*04, geassocieerd met 
een betere CMV virus controle (hoofdstuk 6). Dit positieve effect op virus controle kan berusten 
op het feit dat een HLA klasse II beide armen van de specifieke immuunrespons, de cytotoxische 
en antilichaamreacties, ondersteunt. cCMV had geen invloed op het neonatale metabolisme in 
de hielprikkaart, maar een verlaagde hoeveelheid essentiële aminozuren (bestanddelen van 
eiwitten) werd gevonden in de subgroep van te vroeg geboren pasgeborenen met cCMV (geboren 
vóór de 37 weken zwangerschap) in vergelijking met te vroeg geboren kinderen zonder cCMV 







hogere CMV virale load een toename van C16 (hoofdstuk 3). C16 is een vetzuur en de voorloper van 
vetzuren met een langere keten, die ook voorkomen in de envelop van CMV. Daarom kan 
de toename van C16 in de groep met hogere virale load het gevolg zijn van hogere virale replicatie.
Symptomen bij geboorte
De verschillende markers werden ook bestudeerd in relatie tot de aanwezigheid van symptomen 
bij de geboorte, door de markers in de cCMV-groep met symptomen te vergelijken met die in 
de groep zonder symptomen. De enige markers gerelateerd aan symptomen bij de geboorte 
werden gevonden tijdens het bestuderen van de HLA-types van zowel moeders als kinderen, en 
specifieke moeder-kind combinaties. In hoofdstuk 5 en hoofdstuk 6 hebben we de rol van HLA 
Klasse I en Klasse II, als ook van NK-cel receptoren bij de moeder onderzocht in relatie tot de klinische 
uitkomst van cCMV. We vonden dat een specifiek HLA-G-deletie/deletie genotype bij moeder, 
homozygotie voor HLA-C1 bij moeder, en moeder-kind HLA-E en HLA-C mismatches geassocieerd 
waren met symptomatische ziekte (hoofdstuk 5). De moeders met het HLA-G-deletie/deletie 
genotype hebben waarschijnlijk hogere niveaus van het HLA-G-eiwit, dat immunosuppressieve 
eigenschappen heeft. De immunosuppressie kan leiden tot minder controle van het virus na CMV-
infectie tijdens de zwangerschap en kan leiden tot een hogere virale load in de placenta. Er is sprake 
van een HLA-mismatch wanneer de moeder niet dezelfde genetische HLA-informatie heeft als het 
ongeboren kind, omdat een deel van de genetische HLA-informatie afkomstig is van de vader, die 
anders kan zijn dan die van de moeder. In hoofdstuk 5 hebben we aangetoond dat in het geval 
van HLA-E of HLA-C mismatch de kans op een kind met symptomen bij de geboorte hoger was. 
Een mismatch van HLA, zoals van HLA-E en HLA-C die aanwezig zijn in de placenta, kan leiden tot 
maternale T-cellen die gericht zijn tegen foetaal weefsel. Normaal gesproken wordt dit proces 
onderdrukt, maar in het geval van een CMV-infectie van de placenta kan dit evenwicht verstoord 
worden, hetgeen zou kunnen leiden tot een T-celreactie tegen de placenta en de foetus. Verder 
is HLA-matching noodzakelijk voor een adequate immuunrespons op virus geïnfecteerde cellen. 
Daarom kan een HLA-mismatch leiden tot een slechtere immuunreactie en minder controle van 
de virale infectie, met als gevolg een hogere virale load in placenta en mogelijk ook de foetus. Ten 
slotte is één van de meest voorkomende cellen in de placenta de NK-cel, die tot de aangeboren 
immuniteit behoort en daarom snel reageert bij activatie. Deze cellen hebben het bijzondere 
kenmerk dat zij zowel verschillende activerende en remmende receptoren bezitten waarbij 
de combinatie bepaalt in welke mate de NK-cellen geactiveerd worden. De HLA-C-moleculen 
kunnen in verschillende mate aan deze receptoren binden. In de groep met symptomen bij 
de geboorte, misten de moeders vaker het remmende HLA-C type. Daarom zouden de activerende 
signalen bij NK-cellen de overhand kunnen krijgen, hetgeen bijdraagt  aan een (nog verder) 
toegenomen inflammatie van de placenta (hoofdstuk 5). In hoofdstuk 6 werden de HLA-types 
bestudeerd die niet in de placenta tot expressie komen. Voor deze HLA-types werd geen verband 
gevonden met symptomen bij de geboorte. Samenvattend lijken de symptomen bij de geboorte 
verband te houden met genetische markers die bijdragen aan een hoge CMV virale load bij 









In drie hoofdstukken worden biomarkers beschreven die geassocieerd lijken te zijn met LTG op 
6-jarige leeftijd. In hoofdstuk 2 hadden geïnfecteerde kinderen die LTG hadden een lager aantal 
B-cellen. Bovendien vonden we een hoger percentage van HLA-C niet-overerfde maternale 
antigenen (NIMA) in die geïnfecteerde kinderen mét LTG (hoofdstuk 5). Het kind wordt blootgesteld 
aan antigenen die hij niet heeft geërfd, de zogenaamde NIMA, omdat er tijdens de zwangerschap 
en borstvoeding een wederzijdse uitwisseling van cellen tussen moeder en kind plaatsvindt. 
Kleine aantallen maternale cellen nestelen zich in verschillende foetale organen en blijven daar 
tenminste tot de volwassen leeftijd is bereikt. In plaats van een immunologische reactie tegen 
deze “vreemde” maternale antigenen, ontwikkelt de foetus een langdurige tolerantie (NIMA-
effect). Het NIMA-effect is gunstig in de context van transplantatie omdat het de overleving van 
transplantaten kan verbeteren. Tijdens infecties kan het NIMA-effect echter ook een indirecte 
tolerantie voor de verwekker van de infectie veroorzaken. Indirecte tolerantie voor de CMV-infectie 
zou een ongecontroleerde virale replicatie kunnen veroorzaken gedurende de kindertijd. In 
hoofdstuk 4 laten we tenslotte zien dat bij kinderen die geen LTG hebben een hogere expressie van 
anti-inflammatoire markers was. Dit suggereert dat een deel van de pathogenese van lange termijn 
schade kan worden toegeschreven aan een ongecontroleerde infectie en ontsteking.
Het doel van dit proefschrift was om prognostische markers te identificeren voor korte en lange 
termijn klinische uitkomsten en correlaten van bescherming voor de ontwikkeling van vaccins. 
We hebben enkele interessante biomarkers gevonden die, indien bevestigd in andere cohorten, 
potentiële kandidaten voor dergelijke doelen zouden kunnen zijn. Soms waren de verschillen tussen 
de groepen te klein en er was niet één biomarker die eruit sprong. Aan de andere kant hebben 
de bevindingen wel geleid tot een beter begrip van de cCMV-pathogenese (d.w.z. de biologische 
mechanismen die tot ziekte leiden). Het begrijpen van cCMV-pathogenese is om verschillende 
redenen relevant. Allereerst kan dit toekomstig onderzoek naar prognostische markers helpen. 
Ten tweede, als we de mechanismen voor de progressieve en permanente schade beter begrijpen, 
kan dit de toepassing van innovatieve klinische strategieën ondersteunen waarmee de korte- en 
lange termijn klinische uitkomst positief beïnvloed kan worden. Uiteindelijk zou een geregistreerd 
CMV vaccin het ultieme doel van cCMV-onderzoek zijn. Vaccinatie zou verticale transmissie tijdens 
de zwangerschap kunnen voorkomen en cCMV geassocieerde ziekte bij het kind. De identificatie 
van de bovengenoemde biomarker zou ook kunnen helpen bij toekomstig onderzoek naar 
de ontwikkeling van vaccins.
Tot slot, uit het onderzoek zoals beschreven in dit proefschrift, zijn verschillende uitdagingen 
naar voren gekomen waarmee bij toekomstig onderzoek rekening gehouden kan worden. 
De meerderheid van de pasgeborenen met cCMV is asymptomatisch bij de geboorte en heeft een 
goede prognose en een normale ontwikkeling. Daarom is de vergelijking van de immunologische 
kenmerken van deze kinderen met die van symptomatische pasgeborenen mét lange termijn 
schade, als ook met die van asymptomatisch pasgeborenen met dezelfde LTG essentieel om 
te bepalen welke factoren bepalend zijn voor lange termijn schade. Ondertussen moeten we 







nut zijn voor die asymptomatische pasgeborenen. Bij deze groep moet bijvoorbeeld onderzocht 
worden of de voordelen van antivirale behandeling opwegen tegen de bijwerkingen. Daarnaast 
is het van belang om te komen tot standaardisatie van de definities van symptomatische 









ITALIAN SUM M ARY
L’infezione da Citomegalovirus (CMV) e’ un’infezione diffusa in tutto il mondo che, in una notevole 
proporzione di individui, rimane inosservata. Tuttavia, il virus puo’ causare gravi manifestazioni 
quando, durante la gravidanza, infetta il feto passando attraverso la placenta. L’infezione congenita 
da CMV (cCMV) puo’ indurre una varieta’ di manifestazioni cliniche alla nascita (sintomi alla nascita), 
e di danni permanenti a lungo termine (LTI). Tali segni clinici possono anche variare in gravita’, per 
esempio in neonati sintomatici alla nascita possono variare da enzimi epatici elevati a microcefalia 
(testa piu’ piccola del normale). Le disabilita’ permanenti a lungo termine (che vanno da danni 
neurologici a danni visivi) possono essere progressivi o manifestarsi tardi nell’infanzia, come per 
esempio la perdita dell’udito a esordio ritardato, ed in questo contesto una diagnosi retrospettiva 
potrebbe essere difficile. In particolare, del totale di neonati infetti alla nascita, il 13% e’ sintomatico 
alla nascita, e meta’ di loro sviluppa LTI. Tuttavia, il  13% dei neonati asintomatici alla nascita sviluppera’ 
gli stessi LTI; e dal momento che questo gruppo e’ molto piu’ grande del gruppo di neonati 
sintomatici alla nascita, la maggior parte dei casi clinici di LTI deriva dal gruppo degli asintomatici. 
Ed e’ proprio in quest’ultimo gruppo che la cCMV viene facilmente inosservata perche’ non si vede 
nulla alla nascita. Riassumendo, non tutti i feti infetti avranno sintomi alla nascita o svilupperanno 
disabilita’ a lungo termine. In questo momento, non c’e’ nessun marcatore prognostico disponibile 
che possa predire quale neonato sviluppera’ LTI, e quando o quale tipo di disabilita’ avra’. La cCMV 
puo’ avvenire in qualsiasi momento durante la gravidanza, e di solito quando avviene durante le fasi 
iniziali della gravidanza puo’ causare dei danni piu’ severi perche’ il feto si sta ancora sviluppando. 
La  cCMV puo’ avvenire quando le madri si infettano per la prima volta durante la gravidanza (che 
erano sieronegative) oppure che erano gia’ infette con CMV (sieropositive). Nell’ultimo caso, data la 
pre-esistente immunita’ al CMV, la velocita’ di trasmissione verticale (cioe’ la trasmissione del CMV 
dalla madre al feto) e’ di solito piu’ bassa che in donne incinte sieronegative, ma non e’ chiaro se 
tale immunita’ protegga anche da diversi problemi clinici severi. Queste due variabili, il trimestre di 
infezione materna e la pre-esistente immunita’, complicano gli studi sulla patogenesi di cCMV nella 
popolazione generale. 
Lo scopo di questa tesi era di acquisire nuove conoscenze sulla patogenesi di cCMV, di 
identificare marker prognostici per l’esito clinico a breve e lungo termine, e correlati di protezione 
per lo sviluppo del vaccino. A tal proposito, e’ stata usata. una coorte retrospettiva su scala 
nazionale di bambini congenitamente infetti e di controlli (cioe’ bambini non infetti). Tutti questi 
bambini sono nati nei Paesi Bassi nel 2008, e per diagnosticare cCMV sono stati utilizzati campioni di 
sangue essiccato (DBS).  I DBS sono stati ottenuti da sangue intero dal tallone dei neonati entro una 
settimana dalla nascita. Questi campioni sono di solito usati di routine per lo screening delle malattie 
genetiche rare per le quali sono disponibili interventi clinici salva vita.  Il DNA e’ stato estratto da 
questi campioni, e la presenza del DNA virale e’ stata utilizzata per diagnosticare cCMV. Inoltre, 
mediate quantificazione del DNA virale e’ stata determinata la carica virale (che da’ un’indicazione 
della quantita’ di  virus presente nel corpo). Dei bambini di questa coorte, erano disponibili i dati 
clinici dalla nascita fino a 6 anni d’eta’.  Inoltre, sono stati ottenuti ulteriori campioni, sia dalle madri 
che dai bambini, sottoforma di tamponi buccali. Il  DNA e’ stato estratto dai tamponi buccali per 







eseguire diversi studi genetici. Al fine di raggiungere i nostri obiettivi, si sono studiati i seguenti 
biomarkers in relazione alla carica virale, ai sintomi alla nascita e allo sviluppo di LTI a 6 anni d’eta’:
•	 markers per cellule B e cellule T, sia αβ che γδ, nei DBS;
•	 i profili di espressione genica con particolare attenzione ai pathways del sistema immunitario 
e infiammatorio;
•	 dati sugli aminoacidi essenziali, ormoni, carnitine ed enzimi su DBS;
•	 tipizzazione HLA (antigene leucocitario umano) sui tamponi buccali sia delle madri che dei 
bambini con cCMV.
Nei seguenti paragrafi sono presentati i principali risultati di tutti i capitoli. Prima di tutto, sono 
presentati i sopracitati biomarkers in relazione all’infezione cCMV e alla carica virale. Poi, tali 
biomarkers sono stati presentati in relazione ai sintomi alla nascita ed allo sviluppo di LTI. 
Infezione congenita da CMV
Al fine di studiare l’effetto di cCMV sui diversi markers, abbiamo comparato i biomarkers dai DBS o 
dai tamponi buccali in bambini con cCMV a quelli senza cCMV (il nostro gruppo di controllo). Nella 
nostra coorte, cCMV e’ risultato in una riduzione della produzione delle cellule T αβ nel timo, in un 
aumentato numero delle cellule T γδ, e in un’aumentata produzione delle cellule B (Capitolo 2). 
Inoltre, cCMV ha provocato l’esaustione delle cellule T (cioe’ uno stato generale di disfunzione 
cellulare solitamente indotto dalle infezioni croniche e dall’esposizione ad alte cariche virali) 
(Capitolo 4). Di questi markers, solo la produzione delle cellule T αβ non era associata alla carica 
virale. Nel Capitolo 4, il profilo di espressione genica su DBS ha mostrato che l’espressione genica 
relativa alla risposta immunitaria innata e all’attivazione delle cellule NK era piu’ elevata nei bambini 
con una carica virale elevata. Il sistema immunitario innato, le cellule NK e le cellule T γδ potrebbero 
svolgere un ruolo nel controllare CMV nel feto, dove le risposte CMV-specifiche si stanno ancora 
sviluppando. Inoltre, lo specifico HLA di classe II HLA-DRB1*04 (cioe’ una molecola che presenta 
componenti virali alle cellule immunitarie) e’ risultata correlata ad un miglior controllo virale nei 
bambini (Capitolo 6). Tale effetto positivo sul controllo virale potrebbe dipendere dal fatto che le 
molecole HLA di classe II supportano entrambe le braccia della risposta immunitaria, citotossica e 
anticorpale. Inoltre, cCMV non ha influenzato il metabolismo neonatale su DBS, ma un ridotto livello 
di aminoacidi essenziali (componenti delle proteine) e’ stato trovato nel sottogruppo di bambini 
infetti nati prematuri (cioe’ prima delle 37 settimane di gestazione) comparata al sottogruppo 
di bambini senza cCMV nati prematuri (Capitolo 3). Sebbene cCMV non abbia influenzato il 
metabolismo neonatale, una carica virale elevata ha indotto un aumento di C16 (Capitolo 3). C16 e’ 
un acido grasso e precursore di acidi grassi a catena piu’ lunga, per il quale la struttura esterna virale e’ 
arricchita. Pertanto, l’aumento di C16 nel gruppo con carica virale elevata potrebbe semplicemente 








I diversi markers sono stati studiati anche in relazione alla presenza di sintomi alla nascita, 
comparandoli tra il gruppo di bambini infetti con sintomi alla nascita e bambini infetti privi di 
sintomi. Gli unici markers associati a sintomi alla nascita sono stati trovati studiando le molecole 
HLA di entrambe madri e bambini, con la loro specifica combinazione. Nel Capitolo 5 e Capitolo 6 
abbiamo valutato il ruolo delle molecole HLA di Classe I e Classe II, cosi’ come dei recettori delle 
cellule NK materne, in relazione all’esito clinico. E’ emerso che madri con lo specifico genotipo 
HLA-G delezione/delezione, o madri omozigoti per HLA-C1, cosi’ come coppie madre-figlio con 
discordanze per le molecule HLA-E ed HLA-C, fossero associate con sintomi alla nascita (Capitolo 5). 
Le madri con un genotipo HLA-G delezione/delezione probabilmente hanno livelli piu’ elevati della 
proteina HLA-G che ha proprieta’ immunosoppressive. L’immunosoppressione potrebbe indurre 
un ridotto controllo virale sull’infezione durante la gravidanza, e potrebbe indurre un aumentato 
carico virale a livello della placenta. Una discordanza HLA si ha quando la madre non ha la stessa 
informazione genetica del feto, perche’ alcune delle informazioni genetiche derivano dal padre e 
potrebbero essere diverse da quella della madre. Nel Capitolo 5, abbiamo dimostrato che in caso 
di discordanza HLA-E e HLA-C le chance di un bambino con sintomi alla nascita erano piu’ alte. Una 
discordanza di HLA, come HLA-E e HLA-C che sono molecole espresse dalla placenta, potrebbe 
indurre la formazione di cellule T materne capaci di attaccare i tessuti fetali. Normalmente, tale 
processo e’ soppresso, ma in caso di infezione della placenta da CMV, tale equilibrio potrebbe essere 
alterato ed indurre reazioni delle cellule T contro la placenta ed il feto. Inoltre, la concordanza HLA e’ 
necessaria per un’adeguata risposta immunitaria contro le cellule infette. Pertanto, una discordanza 
HLA potrebbe indurre una peggior reazione immunitaria e un minor controllo dell’infezione, con una 
conseguente carica virale placentale e fetale piu’ elevata. Infine, una delle popolazioni cellulari piu’ 
abbondanti a livello placentare e’ rappresentata dalle cellule NK, che appartengono all’immunita’ 
innata, e pertanto possono reagire rapidamente dopo attivazione. Queste cellule hanno la peculiare 
caratteristica di avere diversi recettori attivatori e inibitori la cui combinazione definisce il grado 
di attivazione delle cellule NK. Le molecule HLA-C possono legare tali recettori con diversi gradi 
di forza. Nella nostra coorte, le madri con neonati sintomatici alla nascita piu’ frequentemente 
non avevano il tipo inibitorio di HLA-C, e pertanto i segnali attivatori sulle cellule NK potrebbero 
prevalere contribuendo all’infiammazione placentare gia’ elevata (Capitolo 5). Nel Capitolo 6 sono 
state studiate le molecole HLA non espresse dalla placenta. Per queste molecole non sono state 
trovate associazioni con sintomi alla nascita. Riassumendo, i sintomi alla nascita sembrerebbero 
essere collegati a fattori genetici che contribuirebbero ad aumentare la carica virale materna 
e palcentare, dovuti ad un ridotto controllo dell’infezione, e ad un’aumentata infiammazione 
della placenta.
Disabilita’ a lungo termine
In tre capitoli sono stati descritti biomarkers che sembrerebbero essere associati con LTI a 6 anni 
d’eta’. Nel Capitolo 2, i bambini infetti che hanno sviluppato LTI hanno mostrato un numero ridotto di 







(NIMA) in quei bambini infetti che hanno sviluppato LTI (Capitolo 5). Il feto e’ esposto ad antigeni che 
lui/lei non ha ereditato, il cosiddetto NIMA, perche’ durante la gravidanza e l’allattamento c’e’ uno 
scambio mutuale di cellule tra la madre ed il bambino. Diverse cellule materne si collocano in diversi 
organi fetali e persistono almeno almeno fino all’eta’ adulta. Tuttavia, invece che sviluppare una 
risposta immunitaria fetale contro questi antigeni materni “estranei”, il feto sviluppa una tolleranza 
di lunga durata (effetto NIMA). L’effetto NIMA e’ vantaggioso nel contesto del trapianto perche’ 
puo’ migliorare la sopravvivenza dell’organo. Tuttavia, durante le infezioni l’effetto NIMA potrebbe 
indurre una tolleranza indiretta anche all’infezione. Di conseguenza, durante tutta l’infanzia, una 
tolleranza indiretta all’infezione potrebbe indurre un’incontrollata replicazione virale. Inoltre, nel 
Capitolo 4, nei bambini che non sviluppano LTI c’era una piu’ elevata espressione di markers anti 
infiammatori. Questo suggerisce ulteriormente che parte della patogenesi dello sviluppo di LTI puo’ 
essere attribuibile ad un’incontrollata infezione ed infiammazione. 
Lo scopo di questa tesi era di identificare marker prognostici per l’esito clinico a breve e lungo 
termine, e correlati di protezione per lo sviluppo del vaccino. Abbiamo trovato alcuni biomarkers 
interessanti che, se confermati in altre coorti, potrebbero essere potenziali candidati per tale 
scopo. Tuttavia, talvolta le differenze erano troppo piccole che non e’ stato trovato un marker 
determinante. D’altro canto, abbiamo trovato alcuni indizi per una migliore comprensione della 
patogenesi di cCMV (cioe’ i meccanismi biologici che conducono alla malattia). Comprendere 
la patogenesi di cCMV e’ fondamentale per diverse ragioni,  prima di tutto  aiuterebbe la futura 
ricerca di marker prognostici,  in secondo luogo  supporterebbe l’introduzione di strategie cliniche 
innovative per prevenire, o perlomeno, influenzare positivamente  l’esito clinico a breve e a lungo 
termine, questo  perche’ capiremmo i meccanismi del danno progressivo e permanente.  Infatti, 
la strada verso un vaccino autorizzato e’ troppo lunga per aspettare pazientemente. Tuttavia, alla 
fine, la vaccinazione dovrebbe essere lo scopo ultimo della ricerca su cCMV perche’ eviterebbe 
la trasmissione verticale durante la gravidanza oppure eviterebbe lo sviluppo della malattia nel 
bambino. Infine, l’identificazione dei biomarker sopracitati potrebbe supportare la futura ricerca 
sullo svillupo del vaccino.
Per concludere, dalla ricerca presentata in questa tesi, sono emerse diverse questioni che 
dovrebbero essere tenute in considerazione nella futura ricerca. La maggior parte dei bambini 
infetti con cCMV sono asintomatici alla nascita ed hanno una buona prognosi per uno sviluppo 
normale, pertanto e’ essenziale  la comparazione del loro stato immunologico con quella dei 
bambini sintomatici alla nascita che hanno un esito peggiore a lungo termine, cosi’ come con quelli 
asintomatici che sviluppano gli stessi LTI,  per poter  determinare cosa stia succedendo nei bambini 
con cCMV.  Contemporaneamente  dovremmo anche definire nuove strategie cliniche e studiare se 
le attuali strategie cliniche siano vantaggiose per quei neonati asintomatici che sviluppano gli stessi 
LTI,  e  se per questo gruppo i benefici, per esempio della terapia antivirale, non superino gli effetti 
collaterali. Tuttavia, un traguardo ancora piu’urgente dovrebbe essere la standardizzazione delle 
definizioni di malattia sintomatica e sviluppo di LTI senza la quale non si possono trarre conclusioni 
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